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ABSTRACT  
Background: Although enteral nutrition has been shown to be a viable treatment option for 
the management of active Crohn’s Disease (CD), the evidence regarding its clinical benefits 
compared to standard treatments (e.g., steroids) for maintaining remission in patients with 
CD has been inconsistent.  If enteral nutrition was to be effective, the use of drugs such as 
steroids and immunosuppressive drugs could be reduced, thereby reducing the likelihood of 
adverse events associated with these medications. 
Objectives: This systematic review aimed to assess the effectiveness and cost-effectiveness 
of elemental nutrition (a type of enteral nutrition) for maintenance of remission in patients 
with CD. 
Methods: Electronic searches of major databases (e.g., MEDLINE, EMBASE, CDSR), not 
limited by study design, language, or publication date were carried out.  Websites for relevant 
organisations and references of included studies were checked. Randomised and non-
randomised experimental controlled trials (RCTs and non-RCTs) reporting clinical 
effectiveness and/or cost-effectiveness of elemental nutrition in the maintenance of remission 
in patients with CD were eligible. Study selection, data extraction, and risk of bias 
assessment were performed independently. Risk ratios (RRs) and mean differences (MDs) 
were pooled using a random-effects model.  Heterogeneity was assessed via forest plots, 
Cochran’s Q and the I2 statistics.  Overall quality of evidence for each outcome was rated 
using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE) approach.  
Results: Twelve of 36 potentially relevant papers were included in the review (representing 
three RCTs and five non-RCTs). RCTs indicated a significant benefit of elemental nutrition 
vs. no intervention (an unrestricted diet) in maintaining remission at 24 months (one RCT; 
RR=2.06, 95% CI: 1.00, 4.43; very low grade evidence) and preventing relapse at 12-24 
months post-baseline (two RCTs; pooled RR=0.57, 95% CI: 0.38, 0.84; high grade evidence). 
Similarly, three non-RCTs showed significant benefits of elemental nutrition over no 
intervention in maintaining remission at 12-48 months and preventing relapse at 12 months 
post-baseline (MD=1.20 months, 95% CI: 0.35, 2.04).  Incidence of mucosal healing between 
intervention and control groups was not significantly different (RR=2.70, 95% CI: 0.62, 
11.72).  Adherence was significantly worse for an elemental compared to polymeric nutrition 
(RR=0.68, 95% CI: 0.50, 0.92).  When compared to other active treatments (medications, 
polymeric nutrition, or a combination), elemental nutrition yielded non-significant results 
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with wide 95% CIs, rendering these results inconclusive. Complications and adverse events 
were too sparse to allow meaningful comparisons. None of the studies reported cost-
effectiveness of elemental nutrition. 
Limitations: The findings warrant cautious interpretation given the limitations of the 
evidence in methodological quality (small samples, short follow-up) and the risk of bias in 
individual studies (lack of blinding, confounding).  Due to scarcity of data, no subgroup or 
sensitivity analysis was performed. 
Conclusions: Limited evidence indicates potential benefits of elemental nutrition against no 
intervention in the maintenance of remission and prevention of relapse in adult patients with 
CD.  There was lack or insufficient evidence on adverse events and complications.  Future 
large and long-term randomised trials are warranted to draw more definitive conclusions 
regarding the effects of elemental nutrition in maintaining remission in CD. 
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PLAIN ENGLISH SUMMARY  
We conducted a systematic review of eight prospective controlled experimental trials which 
examined the effectiveness of elemental nutrition for the maintenance of remission in patients 
with Crohn’s disease (CD).  Based on the limited amount of evidence, elemental nutrition 
was more beneficial than an unrestricted diet for the maintenance of remission and prevention 
of relapse in the short-term.  Evidence comparing the benefits of elemental nutrition to other 
treatment options (standard medication, polymeric nutrition) for maintaining remission was 
uncertain, and therefore, inconclusive.  There was insufficient information on adverse events 
and complications.  This review identified methodological shortcomings of individual studies 
(small samples, short follow-up, bias) and gaps in evidence (no cost-effectiveness studies of 
elemental nutrition for maintenance of remission; no studies of elemental nutrition in children 
or young adults in remission).  Future large and long-term randomised trials are warranted to 
draw more definitive conclusions regarding the effects of elemental nutrition in maintaining 
remission in CD.
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GLOSSARY 
 
Enteral nutrition 
A method of delivering nourishment through a tube placed in the nose (nasogastric or nasoenteral 
tube), the stomach (gastrostomy or percutaneous endoscopic gastrostomy tube), or the small intestine 
(jejunostomy or percutaneous endoscopic jejunostomy tube).  Enteral nutrition varies in the protein 
and fat content and can be classified as elemental, semi-elemental, polymeric or specialised.  
 
Elemental nutrition 
Elemental nutrition is a liquid monomeric amino-based formula, which contains individual amino 
acids, glucose polymers, and is low in fat with about 2% to 3% of calories derived from long chain 
triglycerides (LCT).  Elemental nutrition formula does not contain antigens.   
 
Semi-elemental nutrition 
Semi-elemental nutrition is liquid oligopeptide formula that contains peptides of various chain 
lengths, simple sugars, glucose polymers or starch and fat, mainly as medium chain triglycerides 
(MCT). 
 
Polymeric nutrition 
Polymeric nutrition is a liquid whole-protein based formula that contains intact proteins (sources: 
milk, meat, egg, soy), complex carbohydrates and mainly LCTs. 
 
Specialised nutrition 
Specialised nutrition is liquid formula that contains biologically active substances or nutrients such as 
glutamine, arginine, nucleotides or essential fatty acids. 
 
Parenteral nutrition and total parenteral nutrition 
Parenteral nutrition involves feeding via the blood stream intravenously, total parenteral nutrition 
means feeding solely via the intravenous route. 
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EXECUTIVE SUMMARY 
Background 
Crohn's disease (CD) is a relapsing-remitting condition which causes chronic inflammation of the 
gastrointestinal tract.  Frequent symptoms of CD include malnutrition, abdominal pain, diarrhoea, and 
weight loss.  The objective of CD management is to induce and maintain remission of disease by 
controlling inflammation, reducing clinical symptoms, and preventing complications.  The 
management of children with CD involves additional goals to promote normal growth and pubertal 
development.  The choice of therapy depends on the extent of inflammation, the disease severity, and 
complications. 
 
None of the currently available therapeutic options including medical (e.g., corticosteroids, biologics, 
antibiotics), surgical (e.g., bowel resection), and nutritional (e.g., enteral/parenteral feeding, restricted 
diet) leads to complete cure of CD.  Although corticosteroids are the most widely used drugs for the 
treatment of active CD and their use has been shown to be associated with short-term remission, they 
are also associated with steroid dependency, impairment in growth, and risk of infection.  Tumour 
necrosis factor inhibitors are also used but there are safety concerns with their long-term use. 
 
Recently, enteral nutrition has been shown to be a viable treatment option in the management of 
active forms of CD.  But evidence regarding the efficacy of an enteral nutrition relative to standard 
treatment (i.e., steroids) has been inconsistent.  For example, one meta-analysis showed that enteral 
nutrition was at least as effective as steroids in inducing remission in children and young adults with 
active CD.  In contrast, a more recent meta-analysis indicated that enteral nutrition was less beneficial 
compared to steroids in inducing remission in adults with active CD.  In Japan, enteral nutrition is 
recommended as the first-line treatment in the management of active CD.   
 
Evidence for the efficacy of different types of enteral nutrition (i.e., elemental, semi-elemental, 
polymeric) in maintaining remission in CD has been insufficient and is less clear.  Most of the 
comparative evidence on the maintenance of remission rests on a few retrospective observational 
cohort studies and prospective non-randomised controlled trials (non-RCTs).  If enteral nutrition 
proves to be as effective as conventional medications, its use might minimize or replace the use of 
conventional drugs (e.g., steroids).  
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Objectives 
This review aimed to evaluate clinical effectiveness and cost-effectiveness of elemental nutrition (a 
type of enteral nutrition) for the maintenance of remission in CD.  The specific aims of this review 
were to explore: 
 
 The clinical effectiveness and cost-effectiveness of elemental nutrition compared to other 
interventions (e.g., placebo, unrestricted diet, standard drug treatment, or other types of 
enteral nutrition such as polymeric and semi-elemental) for maintaining remission in patients 
with quiescent CD. 
 Whether the treatment effect of elemental nutrition on the maintenance of remission varies 
across groups defined by dose/duration of elemental nutrition, sex (males, females), age 
(adults, adolescents, and children), and type of induction therapy (medically-, nutritionally-, 
surgically-induced). 
 Additional outcomes for patients with CD: adherence to elemental nutrition, CD activity 
index (CDAI), incidence of mucosal healing, quality of life (QOL), adverse events, gain in 
body weight (or body mass index [BMI]), growth, and pubertal development. 
 
Methods  
Search strategy and data sources 
Electronic searches were carried out in MEDLINE, MEDLINE In-Process & Other Non-Indexed 
Citations, EMBASE (via OVID); CDSR, CENTRAL, DARE, NHS EED, HTA database (via the 
Cochrane Library); Science Citation Index and Conference Proceedings (via Web of Knowledge); 
WHO ICTRP; UKCRN Study Portfolio.  The searches were not limited by study design, language, or 
publication date.  Websites for relevant organisations as well as references of included studies were 
checked for relevant studies.  All the retrieved records were collected and then de-duped using a 
specialized database.  
 
Study eligibility criteria  
English publications of RCTs and non-RCTs comparing clinical effectiveness and/or cost-
effectiveness of elemental nutrition to no intervention (restricted/unrestricted diet) or other types of 
treatment (e.g., placebo, semi-elemental/polymeric nutrition, standard drug therapy) in patients with 
CD in remission at baseline were eligible for inclusion.  Reviews, meta-analyses, observational cohort 
studies, case-reports, case-series, editorials, or comments were excluded.  
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Outcomes of interest 
Primary review outcomes were maintenance of remission (% patients maintaining remission, 
cumulative probability of remission, and duration of remission), development of relapse (% patients 
developing relapse, time to relapse), and incidence of mucosal healing (% patients with endoscopic 
mucosal healing).  Secondary outcomes were adherence to elemental nutrition, need for surgery, 
withdrawals from steroids, CDAI score, QOL, gain in body weight or BMI, pubertal development, 
adverse events, and complications.  
 
Study selection and data extraction  
Two independent reviewers used a pre-piloted form to screen the identified records for title/abstract. 
Afterwards, full text reports of all potentially relevant abstracts were retrieved and examined 
independently.  Disagreements were resolved via discussions and consensus agreement.   
 
Two reviewers using a pre-piloted form independently extracted relevant data on study (e.g., author, 
country, design, sample size), participant (e.g., age, sex, type of induction therapy), intervention (e.g., 
type, mode/dose of administration, concomitant diet or medications), and outcome characteristics 
(e.g., scale of measurement, assessment timing, definition of CD relapse).  The extracted data were 
cross-checked by second reviewer and any disagreements were resolved by discussion. 
 
Risk of bias assessment  
Two reviewers independently assessed risk of bias of individual studies.  We used the Cochrane 
Collaboration Risk of Bias (ROB) tool to assess RCTs which rates risk of bias (high, low, and 
unclear) across selection, performance, detection, attrition, and reporting domains.  Non-RCTs were 
assessed using a modified Cochrane ROB tool in which the domain of selection bias was evaluated in 
regards to baseline between-group imbalance for important prognostic factors.  Disagreements on 
extractions were resolved by a third reviewer through discussion. 
 
The quality of economic analyses of the included studies was planned to be assessed using the 
Drummond 10-item checklist. 
 
Data synthesis and overall quality of evidence 
Study, treatment, population, and outcome characteristics were summarised in text and summary 
tables.  The data on effectiveness of elemental nutrition for each outcome of interest were compared 
qualitatively and quantitatively in text and summary tables.  Results for each outcome were stratified 
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by a comparison of elemental nutrition to no intervention (i.e., restricted/unrestricted diet), drug alone, 
combination of elemental nutrition and drug, and other types of enteral nutrition. 
 
The decision to pool data was based on a degree of similarity with respect to methodological and 
clinical characteristics of studies.  Post-treatment mean differences for continuous and risk ratios for 
binary measures were planned to be pooled using a DerSimonian and Laird random-effects model. 
The degree of heterogeneity was determined through inspection of the forest plots, Cochran’s Q and 
the I
2
 statistics.  The heterogeneity was judged according to pre-determined levels of statistical 
significance (Chi
2
-based p<0.10 and/or I
2
>50%).  Study-level clinical and methodological sources of 
heterogeneity was planned to be explored through a priori defined subgroup (i.e. age, sex, induction 
therapy) and sensitivity analysis.  Publication bias was planned to be assessed through visual 
inspection of funnel plots for asymmetry and use of linear regression tests.  
 
Results were rendered inconclusive in cases of missing/partially reported data (undetermined effect 
measures, 95% confidence intervals) or statistically non-significant effect estimates with great 
uncertainty (i.e., sufficiently wide intervals that include moderate to large effect size treatment effects 
in both directions compatible to either benefit or harm of elemental nutrition).   
 
The overall quality of evidence (high, moderate, low, very low grade) for pre-selected gradable 
outcomes (e.g., maintenance of remission, risk of relapse) was assessed using an approach developed 
by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working 
Group (http://www.gradeworkinggroup.org).  
 
Results 
A total of 630 records were identified and screened, of which 594 were excluded at title/abstract level. 
Of the remaining 36 records screened at full-text level, 12 were included in the review (representing 
three RCTs and five non-RCTs). 
 
Out of eight studies, six were conducted in Japan and two in the UK.  The sample size ranged from 33 
to 95 participants.  The mean age ranged from 22 to 44 years and length of follow-up from 12 to 48 
months.  Type of induction therapy in most studies was medical (standard drugs, enteral or parenteral 
nutrition).  Elemental nutrition was given in addition to unrestricted/restricted diet through tube 
infusion and/or oral intake.  Participants in the control groups received either unrestricted diet (no 
intervention), standard drug (e.g., 6-MP, infliximab, prednisolone) or polymeric nutrition.  
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RCTs indicated a significant benefit of elemental nutrition vs. no intervention (unrestricted diet) in 
maintaining remission after 24 months of follow-up (one RCT; RR=2.06, 95% CI: 1.00, 4.43; very 
low grade evidence) and preventing relapse at 12-24 months of follow-up (two RCTs; pooled 
RR=0.57, 95% CI: 0.38, 0.84; high grade evidence).  The 6-12 month maintenance rate was not 
significantly different (RR=1.37, 95% CI: 0.86, 2.17; very low grade evidence; inconclusive result 
due to wide 95% CIs). 
 
Similarly, three non-RCTs showed significant benefits of elemental nutrition over no intervention 
(unrestricted diet) in maintaining remission and preventing the occurrence of relapse at 12 months.  In 
one non-RCT, the use of elemental nutrition was associated with a significantly longer time to relapse 
compared to no intervention (MD=1.20, 95% CI: 0.35, 2.04).  Incidence of mucosal healing between 
elemental nutrition vs. no intervention (unrestricted diet) groups at 12 months was not significantly 
different (inconclusive results; RR=2.70, 95% CI: 0.62, 11.72).  
  
There was a significantly worse adherence rate to elemental nutrition compared to an unrestricted diet 
or polymeric nutrition (RR=0.68, 95% CI: 0.50, 0.92). 
 
In general, effects of elemental nutrition vs. active treatments (medications, polymeric nutrition, or 
combination) yielded statistically non-significant results across outcomes with wide 95% CIs 
including moderate to large treatment effects in both directions and compatible with both benefit or 
harm of elemental nutrition (inconclusive results).  Data on complications and adverse events were 
too sparse (e.g., zero events, low counts) to derive effect estimates and 95% CIs or to permit any 
meaningful comparison between the treatments. 
 
There was no evidence for children with CD.  Likewise, none of the studies reported cost-
effectiveness of elemental nutrition. 
 
Due to scarcity of data, no subgroup or sensitivity analysis could be performed. 
 
Discussion  
Evidence from two RCTs and three non-RCTs demonstrated short-term benefits of elemental nutrition 
for the maintenance of remission and prevention of relapse compared to no treatment (i.e., 
unrestricted diet).  Adherence rates were lower in the elemental vs. no intervention or polymeric 
nutrition groups.  This finding may be explained by the inconvenience of nasogastric feeding, poor 
palatability, and/or higher cost of elemental nutrition compared to an unrestricted diet or polymeric 
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nutrition.  One RCT showed no difference in QOL between elemental nutrition and no intervention 
(unrestricted diet).  
 
Generally, differences across outcomes between elemental nutrition and active treatments (i.e., 
medications, polymeric nutrition, or combination) were not statistically significant.  These results 
should not be interpreted as the treatments being equivalent (or the absence of effect of elemental 
nutrition).  The associated 95% CIs were wide and uninformative suggesting both benefit and harm of 
elemental nutrition.  Therefore, these results are inconclusive. 
 
The data on complications and adverse events was too sparse to permit any meaningful comparison 
between the treatments.  It is unclear whether insufficient evidence on adverse events and 
complications is due to the absence or rarity of these events or it is simply due to underreporting of 
such events. 
 
The review findings warrant cautious interpretation given the limitations of evidence in terms of 
methodological quality (small samples, short follow-up) and risk of bias in individual trials (lack of 
blinding, confounding).  Non-RCTs in particular may have been biased because of the possibility of 
uneven distribution of known (e.g., location of the lesion, disease duration) or unknown prognostic 
factors between groups.  In some non-randomised trials, patients with ‘good compliance’ were 
assigned to elemental nutrition and those with ‘poor compliance’ to the control treatment.  It is hard to 
predict the direction of bias (if any), if good and poor compliers differed systematically. 
 
Future research using long-term large RCTs would fill-in gaps in evidence (e.g., studies in young 
adolescents and children; effects of exclusive elemental nutrition; effects of elemental nutrition in 
subgroups) and improve reporting practices in relation to trial methodology and completeness of 
reported data for better interpretability of evidence.  More research exploring better tasting elemental 
nutritional formulas to maximize the adherence rate to elemental nutrition is also warranted.  
 
Conclusions 
There is limited evidence indicating benefits of elemental nutrition in the maintenance of remission 
and prevention of relapse in adult patients with CD.  There was lack or insufficient evidence on 
adverse events and complications.  Methodological shortcomings of individual studies and gaps in 
evidence have been identified.  Future large and long-term randomised trials are warranted to draw 
more definitive conclusions regarding the effects of elemental nutrition in maintaining remission in 
CD. 
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1 BACKGROUND 
1.1 Description of health problem 
1.1.1 Health problem 
Crohn's disease (CD), a form of inflammatory bowel disease (IBD), is a chronic relapsing-remitting 
condition which causes chronic inflammation of the gastrointestinal tract.  CD can affect any part of 
the digestive tract, from the mouth to the anus.
1
  Usually, CD involves both the superficial and deep 
layers of the intestine.
2
  CD may be characterized by location (terminal ileal, colonic, ileocolic, upper 
gastrointestinal) and/or pattern of disease (inflammatory, perforating, or stricturing).
3
  The most 
frequently reported symptoms of CD include malnutrition, abdominal pain, diarrhoea, weight loss, 
fever, and rectal bleeding.  
 
The disease can occur at any age from early childhood to late adulthood.  However, it is more 
common among age group between 15 and 25 years.  Male and female are affected equally.
4, 5
  
Around one third of people with CD are diagnosed before 21 years of age.   
 
1.1.2 Aetiology of CD 
The aetiology of CD is unknown.  It is hypothesized that CD may result due to interactions amongst 
genetic, immunological and environmental factors.
6
  Smoking and genetic predisposition are the two 
important factors thought to play a key role in the aetiology of CD.
7
 
 
1.1.3 Clinical features of CD 
The clinical course of CD is characterised by exacerbations and remission.
3
  The clinical presentation 
depends on the part of the affected intestine and varies from mild to severe malnutrition, abdominal 
pain, diarrhoea, weight loss, fever, and rectal bleeding.
5, 8
  The symptom pattern in children is 
different to that of adults, and is instead characterized by anaemia, fever, growth failure and/or 
delayed puberty.
8
  
 
1.1.4 Diagnosis of CD 
Initial assessment of patients with suspected CD includes history taking, physical findings and routine 
blood and stool tests.  Further examinations including plain abdominal radiography, colonoscopy, 
flexible sigmoidoscopy, endoscopy or barium x-ray are also performed.  The diagnosis of CD depends 
upon the pathological findings of focal, asymmetric, transmural, or often granulomatous 
inflammation.  Upper or lower gastrointestinal endoscopy should be performed to confirm the 
diagnosis of CD and assess disease location.
8-10
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1.1.5 Prognosis of CD 
CD is considered a serious disease which needs extensive and long-term treatment with continuous 
monitoring.
11
  Quality of life is reduced for CD patients during relapse but patients with few relapses 
or with continuous mild symptoms manage to lead a normal life. 
 
CD patients are affected not only physically, but also mentally (for example with depression) 
impacting on both their personal and professional lives.  Patients with CD take more time off work 
and may change their time schedules at work as a direct result of their disease.
12-14
  
 
As the disease progresses, patients develop complications such as strictures, perforation, and/or fistula 
formation, from 50% to 80% of whom will eventually require surgical interventions.
7
 
 
The mortality rate amongst patients diagnosed with CD has been shown to be greater for those 
diagnosed at an earlier age.  For example, a study by Canavan et al. reported a standardised mortality 
ratio (SMR) among CD patients and showed that younger patient had a worse prognosis compared to 
older patients (overall SMR=1.29, 95% CI: 1.12, 1.45).  The SMR for patients aged 10–19 years was 
16.95 (95% CI: 14.99, 18.91) compared to an SMR of 0.92 (95% CI: 0.65, 1.19) for patients aged 75 
years or older.  Compared to the general population, mortality of patients with CD is also significantly 
higher in the first 3 years after diagnosis or for patients who have had the disease for 13 years or 
more.  Actual cause of death could be anything directly related to the disease or as a consequence of 
the disease such as surgery, malnutrition, colorectal cancer, electrolytes imbalance or massive 
haemorrhage.
13, 14
 
 
1.1.6 Epidemiology of CD 
CD has become an important health threat in the West and industrialised countries.
15
  The areas with 
the highest incidence rate are the United Kingdom (UK), North America, and northern Europe.
16
  The 
annual incidence of CD in Europe and North America has been increasing over time and is estimated 
to be around 2 to 8 per 100,000 population.  Similarly, the prevalence of the disease in the Western 
world has been estimated as approximately 60 per 100,000.
4
 
 
In the UK, CD is one of the most common causes of gastrointestinal morbidity.  In the North of 
England and Scotland, more recent estimates of the prevalence of CD indicate it to be between 145 
and 157 per 100,000.
17
  Scotland has a higher incidence rate compared to London and Wales.  In the 
UK, there are currently at least 115,000 people with CD.
7
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Approximately 80% of CD patients will require surgery over their lifetime.
18
  Between 1990 and 
2000, the rate of hospital admissions rose from 7,648 to 8,834 in England (16% increase).  The age 
standardised admission rate for CD increased from 15.5 to 17.6 per 100,000 (14% increase).  The 
hospital admission rate (in 1999-2000) was higher in females than in males, with a female to male 
ratio of 1.5.  According to age specific admission rates however the hospital admission rate was 
higher for the 25-34 age groups with a more equal distribution between males and females.
19
 
 
1.1.7 Impact of CD 
CD typically affects people during their economically productive adult life and many require life-long 
medical and surgical interventions over several decades.  The financial burden due to the management 
of CD is very large.
20
  Bassi et al (2004) reported a detailed micro-costing analysis of costs of illness 
for IBD in inner city patients for the UK National Health Services.  Using hospital records, the 
authors identified and followed up 479 patients who had received some form of secondary care for 
IBD for up to 6 months.  The mean six-month cost per patient for CD was found to be £1,652.00 
(95% CI: 1,221, 2,239).  Similarly, costs for ambulatory and hospitalisation groups were £516.00 
(95% CI: 452, 618) and £6,923.00 (95% CI: 5415, 8919), respectively.
21
 
 
1.1.8 Measurement of disease 
The most widely used tool for characterising the activity (i.e., severity) of CD is the Crohn’s Disease 
Activity Index (CDAI).
8
  Patients with CDAI score < 150 are often classified as having a quiescent or 
non-active (i.e. in remission) form of disease.  A CDAI score ≥ 150 is indicative of an active form of 
the disease.
22
  CDAI is also used in conjunction with additional parameters/markers such as 
erythrocyte sedimentation rate (ESR) and C Reactive Protein (CRP).
23
 
 
1.1.9 Current service provision 
Management of CD 
According to the current NICE guideline, the management of CD consists of smoking cessation, 
treatment with drugs, nutritional support, and surgery (in severe or chronic cases).  The aim of 
treatment is mainly to reduce symptoms by inducing and maintaining remission so that quality of life 
improves.
7
 
 
The treatment of CD can be categorised as non-surgical and surgical.   
a) Non-surgical interventions include: 
 Smoking cessation 
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 Pharmacological (Corticosteroids, biologics, aminosalicylates, immunosuppressants, tumour 
necrosis factor inhibitors, antibiotics) 
 Nutritional (enteral feeding, restricted diet, parenteral feeding) alone or, as an adjuvant 
therapy  
 
b) Endoscopic/surgical interventions (indicated for complications such as bowel obstruction, 
high grade dysplasia, abscess, internal fistulas, and cancer) 
 
The treatment is chosen after considering a balance between individual response in terms of beneficial 
effects, treatment-related adverse events, and long term complications.
23, 24
  Corticosteroids are most 
widely used for the management of active CD.  However, their use is associated with high risk of 
relapse, low rates of mucosal healing, steroid dependency, and other adverse events (e.g., growth 
impairment in children, increased risk of infection).  There have been safety concerns with long term 
use of other agents such as tumour necrosis factor (TNF) inhibitors.
1
  A summary of the relevant 
national guidelines, including National Service Frameworks are provided in Table 1. 
 
Table 1: Relevant national guidelines, including National Service Frameworks 
NICE Guideline (NICE clinical guideline 152) 2012
7
 
• First line therapy in children and young people to improve growth and development 
 
BSG Guidelines 2011 (British Society of gastroenterology)
25
 
• Usually used as an alternative therapy to corticosteroid for active CD 
• 60 -80% effective on inducing remission for small and large bowel disease 
 
ESPEN guideline 2006 (European Society for Clinical Nutrition and Metabolism)
26
 
• First line induction therapy for children with CD 
• Liquid diet only as sole therapy in adult when treatment with corticosteroid is not possible 
• In case of persistent intestinal inflammation for patient with steroid dependent EN is used in the 
maintenance of remission 
 
Inflammatory Bowel disease (IBD) Working Group of the British Society of Paediatric Gastroenterology, 
Hepatology and Nutrition
3
 
• First line induction therapy for small and large bowel disease 
• To improve nutritional and growth status 
• Both polymeric and elemental nutrition are of similar effect at inducing remission 
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1.2 Description of technology under assessment 
1.2.1 Summary of intervention 
Enteral nutrition has played an important but controversial role in the alleviation of malnutrition and 
control of disease activity in patients with active CD.  Enteral nutrition formulas vary in the protein 
and fat content and are classified as elemental (amino-acid), semi-elemental (oligopeptide), polymeric 
(whole protein) or specialised diet.
27, 28
  Enteral nutrition is a method of delivering nourishment 
through a tube placed in the nose (nasogastric or nasoenteral tube), the stomach (gastrostomy or 
percutaneous endoscopic gastrostomy tube), or the small intestine (jejunostomy or percutaneous 
endoscopic jejunostomy tube). 
 
Elemental nutrition is a liquid formula that contains individual amino acids, glucose polymers, and is 
low in fat with approximately 2% to 3% of calories derived from long chain triglycerides (LCT).  In 
many elemental products, medium chain triglycerides (MCT) are the main fat source, and are 
absorbed directly across the small intestinal mucosa into the portal vein in the absence of lipase or bile 
salts.  Semi-elemental nutrition contains peptides of various chain lengths, simple sugars, glucose 
polymers or starch and fat.  Polymeric nutrition contains intact proteins, complex carbohydrates and 
mainly LCTs.  Specialised nutritional formulas contain biologically active substances or nutrients 
such as glutamine, arginine, nucleotides or essential fatty acids.
28, 29
 
 
The mechanism of action of enteral nutrition on CD is not known.  Several hypothesised mechanisms 
underlying the proposed benefits of enteral nutrition in CD include reduced gut activity, include 
reduction of antigenic load, nutritional effects, anti-inflammatory effects, or modulation of immune 
system and gastrointestinal flora.
30-33
 
 
1.2.2 Types and route of administration  
 As exclusive enteral nutrition (EEN): provided especially as a sole dietary source and a 
primary medical therapy to induce remission 
 As partial enteral nutrition (PEN): given additionally to normal unrestricted/restricted diet, to 
improve nutritional status and /or to maintain remission 
 
Both EEN and PEN may be administered either orally or with nasogastric (NG) tube.
34
 
 
1.2.3 Enteral nutrition as induction therapy 
There is some evidence of clinical benefit and long term safety of enteral nutrition in inducing 
remission in patients, especially children and young adults with active CD
35, 36
 and in maintaining the 
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remission of quiescent CD.
30
  For example, in Japan, enteral nutrition is recommended as the first-line 
treatment in the management of active CD.
33, 37
  It has also been recommended as first line therapy in 
children and young adults with concerns about growth and side effects.  Although enteral nutrition has 
been shown to be an effective and safe intervention for induction of remission in patients with active 
CD, withdrawal from enteral nutrition and resumption of normal diet would often be followed by 
reoccurrence of gastrointestinal symptoms and use of corticosteroids.
38
  Evidence comparing clinical 
effectiveness of enteral nutrition to corticosteroids for the induction of remission has been 
inconsistent, with one meta-analysis showing no difference between the two,
36
 and a more recent 
meta-analysis indicating a superiority of corticosteroids over enteral nutrition.
27
 
 
1.2.4 Enteral nutrition as maintenance therapy 
Evidence of the efficacy of different types of enteral nutrition (i.e., elemental, semi-elemental, 
polymeric) in maintaining remission in CD has been insufficient and less clear.
1, 3, 4, 15
 
 
NICE recommends that enteral nutrition should not be used as maintenance therapy after surgery.
7
  
Moreover, use of enteral nutrition as maintenance therapy is challenging due to compliance issues.
1
  
Most evidence on the comparative clinical effectiveness of enteral nutrition in the maintenance of CD 
remission rests upon retrospective observational cohort studies and prospective non-randomised 
controlled experimental trials.
1, 3, 15
26 
 
2  DEFINITION OF THE DECISION PROBLEM 
2.1 Decision problem 
Crohn’s disease (CD) is a chronic relapsing-remitting inflammatory disease affecting the 
gastrointestinal tract.
1
  Currently, none of the available therapeutic options (e.g., medical, surgical, or 
nutritional) lead to complete cure of CD.  The management of the disease usually involves the 
induction and then maintenance of remission of disease activity by controlling the extent of 
inflammatory process, correcting malnutrition, and reducing symptoms as well as the occurrence of 
complications.
23, 24
  In children, the additional aim of the treatment is to promote healthy growth and 
development. 
 
Enteral nutrition is one of the available treatment options in the management of CD and has been 
shown to be beneficial in inducing remission and improving nutritional status in adults and children 
diagnosed with active CD.
31, 37
  There is less clarity of the role of enteral nutrition in maintaining 
remission in patients with quiescent CD. 
 
If enteral nutrition is at least as effective as standard medical treatments, it could potentially replace or 
minimize the use of steroids and/or other pharmaceutical agents, thereby prevent the occurrence of 
adverse events, complications, steroid dependence, and growth retardation in both adults and children 
with CD.  
 
The objective of this systematic review was to identify, appraise and evaluate the evidence on clinical 
effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in CD.
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2.2 Overall aims and objectives of assessment 
 
 To evaluate the clinical effectiveness and cost-effectiveness of elemental nutrition 
administered alone or in combination with other interventions (e.g., diet, standard drug 
treatment) compared to other intervention(s) (e.g., placebo, diet, standard drug treatment) for 
maintaining remission in patients with CD. 
 
 To compare the clinical effectiveness and cost-effectiveness of elemental nutrition with other 
types of enteral nutrition (semi-elemental, polymeric nutrition), duration, and dose in regards 
to maintaining remission and adherence. 
 
 To explore subgroup effects of elemental nutrition on maintenance of remission (i.e., risk of 
relapse or recurrence).  Specifically, to examine if the treatment effect of elemental nutrition 
varies across groups defined by sex (males, females), age (adults, adolescents, and children), 
and type of induction therapy (medically-, nutritionally-, surgically-induced).  
 
 To evaluate additional outcomes for patients with CD such as adherence to elemental 
nutrition, CD activity index (CDAI), incidence of mucosal healing, quality of life, adverse 
events, gain in body weight (or BMI), growth, and pubertal development.
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3  METHODS 
 
The review protocol is provided in Appendix I  and is registered on PROSPERO International 
prospective register of systematic reviews (CRD42013005134; available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005134). 
3.1 Search strategies 
Using an iterative procedure an experienced librarian developed the search strategy with input from 
clinical advisors and previous systematic reviews.
37-39
 
 
Comprehensive electronic searches were conducted to identify all references relating to elemental 
nutrition, maintenance of remission, and CD.  Searches were undertaken in August 2013 in 
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE (via OVID); CDSR, 
CENTRAL, DARE, NHS EED, HTA database (via the Cochrane Library); Science Citation Index 
and Conference Proceedings (via Web of Knowledge); WHO ICTRP; UKCRN Study Portfolio. The 
databases were searched from 1947 to August 2013; the actual data range for each of the databases 
searched depended on the coverage of the individual database.  The electronic searches were not 
limited by study design, language, or publication date.  
 
Citation searches of included studies were undertaken using the Web of Science citation search 
facility.  
 
Two supplementary database searches using limits were undertaken.  The first, combining CD with 
the concept of nutrition therapy and limited to systematic reviews or cost-effectiveness, aimed to 
capture any articles that included the assessment question as part of a broader systematic review or 
cost study.  The second, combining CD with the concept of elemental nutrition and limited to relevant 
study types aimed to capture any articles that involved the current included population (see section 
3.2) as part of a controlled clinical trial of both active CD and CD in remission. 
 
Websites such as Crohn’s and colitis UK (NACC);5 Crohn’s nutricia;40 and Children with Crohn’s and 
Colitis (CICRA)
41
 were also checked. 
 
In addition, experts in the field were contacted and references of included studies were also checked 
for potentially relevant studies. 
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All the retrieved records were collected in a specialised database.  Duplicate records were identified 
and removed from the database. 
 
Details of the electronic search strategies used for the review of the clinical effectiveness are given in 
Appendix II. 
 
3.2 Study inclusion criteria 
Type/language of publication: 
English full text and abstracts (only if companion publications to full text included studies). 
 
Study design: 
RCTs and non-randomised controlled clinical trials. 
 
Population: 
Adults, young people, or children with CD in remission (inactive, quiescent CD) at the time of study 
baseline.  
 
Main intervention: 
Elemental nutrition alone via oral passage, nasal passage (naso-gastric tube, naso-jejunal tube, naso-
duodenal tube), or direct passage via the abdomen (gastrostomy tube, jejunostomy tube). 
 
Elemental nutrition in combination with other intervention(s) (e.g., standard drug therapy any other 
type of treatment).  
 
Comparator:  
Enteral nutrition (elemental, semi-elemental, or polymeric nutrition) alone, normal 
unrestricted/restricted diet alone (i.e., no intervention), standard drug therapy alone, any other 
intervention, or placebo. 
 
Enteral nutrition (elemental, semi-elemental, or polymeric nutrition) in combination with other 
intervention(s) (e.g., standard drug therapy, any other intervention or placebo). 
 
Standard drug therapy in combination with any other intervention, and/or placebo.   
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3.3 Study exclusion criteria  
 Induction studies (patients with active CD at baseline) with or without follow up of remitted 
patients continuing to receive maintenance therapy 
 Studies of parenteral (intravenous) nutrition 
 Studies of ulcerative colitis 
 Studies employing non-concurrent (e.g., historical) controls 
 Studies with mixed patient populations (< 80% Crohn’s disease) 
 Studies comparing different formula/diets of elemental nutrition 
 Reviews (systematic or non-systematic), meta-analyses, observational cohort studies, case-
reports, case-series, editorials, abstracts, or comments 
 
3.4 Outcomes of interest 
Outcomes – clinical effectiveness:  
Adult populations 
 Maintenance of remission (% patients in remission at end of follow-up, cumulative 
probability of maintaining remission [Kaplan Meier estimate of survival], and duration of 
remission) - primary outcome 
 Development of relapse/recurrence (proportion of patients developing relapse/recurrence 
[n/N], time to relapse/recurrence [mean # of months]) – primary outcome 
 Incidence of mucosal healing (n/N) – primary outcome 
 Need for surgery (n/N) 
 Withdrawal from steroids (n/N) 
 Steroid dose tapering (n/N) 
 CDAI score (mean endpoint or mean change from baseline) 
 Health related quality of life (mean score: endpoint or mean change) 
 Adverse events (n/N) 
 Complications of CD (n/N) 
 Gain in body weight or BMI (mean change in kg or kg/m2) 
 Adherence (n/N) 
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Younger populations (e.g., adolescents, paediatric) 
 Maintenance of remission (% patients in remission at end of follow-up, cumulative 
probability of maintaining remission [Kaplan Meier estimate of survival], and duration of 
remission) – primary outcome 
 Development of relapse/recurrence (proportion of patients developing relapse/recurrence 
[n/N], time to relapse/recurrence [mean # of months]) – primary outcome 
 Incidence of mucosal healing (n/N) – primary outcome 
 Need for surgery (n/N) 
 Withdrawal from steroids (n/N) 
 Steroid dose tapering (n/N) 
 CDAI score (mean endpoint score or mean change score from baseline)  
 Health related quality of life (mean score: endpoint or mean change) 
 Adverse events (n/N) 
 Complications of CD (n/N) 
 Gain in body weight or BMI (mean change in kg or kg/m2) 
 Adherence (n/N) 
 Growth (mean change score/any growth measure from baseline) 
 Pubertal development 
 
Outcomes – cost-effectiveness:  
 Costs (no efficacy measures: cost-minimisation analysis) 
 Costs and efficacy measures - clinical and quality-adjusted life years (QALYs) (full economic 
analysis) 
 Incremental cost-effectiveness ratios (ICERs) (full economic analysis) 
 Results from cost-effectiveness acceptability curves (CEACs) 
 
3.5 Study selection strategy  
Two independent reviewers using a pre-piloted screening form screened all identified bibliographic 
records for title/abstract.  Full text reports of all potentially relevant records were then retrieved and 
examined independently.  Disagreements were resolved via discussions and consensus agreement 
(either between the two reviewers or via a third party). 
 
The study flow and reasons for exclusion of full text papers were documented in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study flow diagram.
42
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3.6 Data extraction strategy 
Two reviewers independently extracted relevant data using a pre-defined pre-piloted extraction sheet 
(Appendix III).  The extracted data included details about study (e.g., author, country, design, sample 
size, follow-up duration, risk of bias items), participant (e.g., age, sex, inclusion/exclusion criteria, 
CD activity index, clinical/endoscopy definitions of CD remission, type of induction therapy), 
intervention/comparator (brand name/manufacturer of elemental nutrition; type, mode, duration, and 
dose of administration of elemental nutrition, any concomitant diet or dietary restriction, and other co-
intervention such as medications), and outcome characteristics (e.g., type and scale of measurement, 
timing of assessment, definition of CD relapse/recurrence).  The extracted data were cross-checked by 
second reviewer and any disagreements were resolved by discussion.  Further discrepancies were 
resolved by a third reviewer, if necessary.  
 
For individual studies, the dichotomous and continuous summary clinical effectiveness outcome 
measures of association were summarized as risk/odds ratio, mean difference, and measures of 
variability (p-value, 95% confidence interval).  We tried to calculate missing statistical parameters 
(e.g., risk ratios, mean differences, standard deviations, standard errors, and 95% confidence intervals 
[CIs]) for clinical outcomes of interest (e.g., maintenance of remission, risk of relapse, time to relapse, 
incidence of mucosal healing, need for surgery, withdrawals, adherence, adverse events, and 
complications).  All calculated parameters were entered into the data extraction sheets and marked as 
‘calculated’. 
 
3.7 Risk of bias assessment strategy 
Two reviewers independently assessed the methodological and reported quality of included individual 
studies.  Any disagreements between the two reviewers were resolved by a third reviewer through 
discussion. 
 
RCTs were quality-assessed using the Cochrane Collaboration Risk of Bias (ROB) tool
43
 which 
covers the following domains of threat to internal validity: selection bias (randomisation sequence 
generation, treatment allocation concealment), performance bias (blinding of participants/personnel), 
detection bias (blinding of outcome assessors), attrition bias (incomplete outcome data primary 
outcome), reporting bias (selective outcome/analysis reporting), and other pre-specified bias (e.g., 
funding source, adequacy of statistical methods used, type of analysis, baseline between-group 
imbalance in important prognostic factors). 
 
The risk of bias assessment falls into three categories of high, low, and unclear risk of bias.  The 
assessments were provided in ROB tables and summary graphs.  Non-randomised controlled clinical 
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trials were assessed using a modified Cochrane ROB tool in which the domain of selection bias was 
evaluated in regards to baseline between-group imbalance for important prognostic factors instead of 
randomisation sequence generation and treatment allocation concealment.  For each study (RCT or 
non-RCT), the risk of performance, detection, and attrition bias domains for subjective (e.g., patient-
administered clinical or quality of life scores) and objective (e.g., additional laboratory criteria used in 
the definition of remission/relapse, weight gain, mucosal healing, growth, adverse events) outcomes 
were assessed separately.  Afterwards, within-study summary ROB ratings across all domains were 
derived for subjective and objective outcome groups separately.  At data synthesis stage, across-study 
average summary ROB ratings were determined and assigned to each outcome of interest (Appendix 
IV). 
 
The quality of economic analyses of the included studies was planned to be assessed using the 
Drummond 10-item checklist.
44
 
 
3.8 Data synthesis 
Study, treatment, population, and outcome characteristics were summarised in text and summary 
tables.  The study results on the relative effectiveness of elemental nutrition for each outcome of 
interest were compared qualitatively and quantitatively in text and summary tables. 
 
In the clinical effectiveness part of the review, results for any given outcome measures were presented 
separately stratified by a comparison category: a) elemental nutrition vs. no intervention (i.e., 
restricted/unrestricted diet alone), b) elemental nutrition vs. drug (standard therapy), c) elemental 
nutrition vs. combination of elemental and drug, d) elemental nutrition combination with drug vs. 
drug alone, and e) elemental nutrition vs. other type of enteral nutrition. 
  
The decision to pool individual study results was based on a degree of similarity with respect to 
methodological and clinical characteristics of studies under consideration (e.g., design population, 
comparator treatment, and outcome).  Estimates of post-treatment mean difference for continuous 
outcomes and RRs for binary outcomes (except for rare events) of individual studies were pooled 
using a DerSimonian and Laird random-effects model.
45
  Dichotomous outcomes with low event rates 
(5.0% - 10.0%) were pooled as RR using a Mantel-Haenszel fixed-effects model. Dichotomous 
outcomes for studies with very low event rates (≤ 5.0%) or zero events in one of the treatment arms 
were pooled as odds ratio (OR) using a Peto fixed-effects model.
46
  Trials were not pooled if the mean 
and/or standard deviation for the continuous outcome of interest could not be ascertained. 
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The degree of statistical heterogeneity across pooled studies was determined through inspection of the 
forest plots, Cochran’s Q and the I2 statistics.  The heterogeneity was judged according to pre-
determined levels of statistical significance (Chi
2
-based p<0.10 and/or I
2
>50%).  If data allowed, 
study-level clinical and methodological sources of heterogeneity of effect estimates across studies was 
explored through a priori defined subgroup analysis (i.e., age, sex, induction therapy) and sensitivity 
analysis (risk of bias item-specific ratings, intention-to-treat vs. per protocol analysis). 
Given a sufficient number of data points, publication bias was planned to be assessed through visual 
inspection of funnel plots with respect to plot asymmetry and use of linear regression tests.
47
 
 
Results for individual studies were rendered inconclusive in cases of missing/partially reported data 
(e.g., missing/undetermined summary effect measures and/or corresponding 95% CIs, only p-value 
reported) or statistically non-significant effect estimates with great uncertainty (i.e., wide intervals 
that include moderate to large effect size treatment effects in both directions compatible to either 
benefit or harm of elemental nutrition).   
 
3.9 Overall quality of evidence (GRADE system) 
The overall quality of evidence for pre-selected gradable outcome (maintenance of remission, risk of 
CD relapse/recurrence, mucosal healing, need for surgery, adherence, and adverse events) across 
studies was assessed using the systematic approach developed by the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) Working Group 
(http://www.gradeworkinggroup.org).  
 
The GRADE approach
48
 indicates level of confidence in the observed treatment effect estimate(s) and 
is based on assessments across five domains: a) summary ROB across studies per gradable outcome 
(internal validity across studies; study limitations), b) consistency of results (heterogeneity), c) 
directness of the evidence (applicability of the results), d) precision of the results (the width of 95% 
CI around the estimate), and e) publication/reporting bias (detection of asymmetry in the funnel plot; 
selective outcome reporting).  The overall quality of evidence was rated as high, moderate, low, or 
very low grade.  Initial grade of RCTs was rated as high and downgraded by one point (e.g. from high 
to moderate) if any of the five criteria was not met.  Initial grade for non-RCTs was to be rated as low 
and upgraded by one point (e.g. from low to moderate) if any of the three criteria for upgrading a 
grade was met (e.g., dose-response gradient, large magnitude of effect, and adjustment for 
confounders).
49
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4 RESULTS 
 
4.1 Literature search  
A total of 1,222 records was identified through electronic searches.  Four additional records were 
identified from other sources.  The removal of duplicates left 630 records to be screened, of which 
594 were excluded at title/abstract level as obviously irrelevant.  The remaining 36 records were 
examined for full-text, of which 12 (representing eight unique studies) were included in the review.
30, 
50-60
 
 
Of the eight included studies, one RCT
52, 53
and one non-RCT
30, 59, 60
 were represented in multiple 
publications.  Throughout this review, these two studies will be cited according to their corresponding 
original publications.
30, 52
 
 
The search of on-going trials in Clinical Trials.gov, Current Controlled Trials, UKCRN Portfolio, and 
WHOICTRP databases (carried out in September 2013) retrieved 26 potentially relevant records, none 
of which was deemed relevant for inclusion in the review.  
 
The study flow diagram outlining the process of identifying relevant literature and eight included 
studies
30, 50-52, 55-58
 along with reasons for exclusion is given in Figure 1.  More details on exclusions 
can be found in Appendix V. 
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Figure 1: Study Flow Diagram  
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Records identified through database 
searching  
(n = 1,222) 
Additional records identified 
through other sources  
(n = 4) 
Records after duplicates removed  
(n = 630) 
Records screened at title/abstract  
(n = 630) 
Records excluded at title/abstract  
(n = 594) 
Full-text articles assessed for 
eligibility  
(n = 36) 
Full text articles (n = 24) 
(Reasons for exclusions) 
< 80% participants in remission (n = 1) 
Abstract (n = 10) 
Case report, comment (n = 3) 
Irrelevant treatment/outcome (n= 3) 
Participants with active CD (n = 2) 
Retrospective (cohort) study (n = 3) 
Unclear population/control group (n = 
2) 
Articles (n = 12) representing 8 
unique studies included in 
qualitative synthesis  
 
Studies included in quantitative 
synthesis (meta-analysis) (n = 2) 
37 
 
4.2 Trial characteristics  
This review included three randomised controlled trials (RCTs)
50, 52, 55
 and five non-randomised 
controlled trials (non-RCTs).
30, 51, 56-58
 
 
4.2.1 Randomised controlled trials (RCTs) 
The study and participant characteristics of the three included randomised controlled trials (RCTs)
50, 
52, 55
 are summarised in Table 2.  Of three RCTs, two were conducted in Japan
50, 52
 and one in the 
UK.
55
  A total of 179 participants was randomised across three RCTs with individual trial sample size 
ranging from 33
55
 to 95
50
 participants.  The mean age of participants across the three trials ranged 
from 29
52
 to 44 years
55
 and the proportion of females from 23%
52
 to 68%.
55
  The length of follow-up 
of the studies ranged from 12
52, 55
 to 24 months.
50
  In most participants CD was located in both the 
small and large intestines.  Induction therapies included parenteral nutrition,
50, 52
 central venous 
feeding,
50
 prednisolone,
50, 55
 infliximab,
50, 52
 6-MP,
50
 enteral nutrition,
52
 or surgery.
52
  Only two 
studies
52, 55
 reported criteria used for the diagnosis of CD.  The diagnosis of CD included clinical, 
endoscopic, radiological, and/or histological criteria. 
 
In all three trials, the elemental nutrition was given in addition to unrestricted diet (i.e., normal/free 
diet) through self-inserted feeding tube
50, 52
 or oral intake.
50, 52, 55
  In one trial,
52
 participants in the 
elemental nutrition group were asked to take half of the daily calories through elemental nutrition 
(i.e., ‘half-elemental diet’) and the other half from unrestricted diet.  Participants in the control groups 
were assigned to receive unrestricted diet (no intervention),
50, 52
 drug (6-MP),
50
 or polymeric 
nutrition.
55
 
 
Remission was defined using CDAI score of ≤150 either alone or with additional clinical criteria (e.g., 
absence of diarrhoea and abdominal pain or, ESR<20 mm/h).
55
  Similarly relapse was defined as 
either a CDAI score ≥200 alone or with additional criteria (e.g., the need for an additional medication 
to suppress worsening symptoms,
50, 52
  CDAI score increase by 100 points from baseline).
55
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Table 2: Study and participant characteristics (randomised controlled trials) 
Author 
year 
Ref ID 
Country 
Study details Inclusion/ 
exclusion 
criteria 
Interventions  Patient characteristics 
 Element
al 
nutritio
n 
Control 
1 
Control 
2 
Hanai 
2012
50
 
Japan 
Aim: To 
evaluate the 
efficacy of 
elemental diet 
and 6-MP vs. 
no intervention 
as maintenance 
therapy in CD 
 
Study setting: 
specialty clinic 
 
Length of 
follow up (# 
months): 24  
 
Funding: NR 
Inclusion 
criteria: age 
≥18 years who 
achieved 
remission 
(CDAI < 150) 
within 30 days 
of entry to this 
trial  
 
Exclusion 
criteria: 
Patients with 
abdominal 
abscess, 
stricture (B1 of 
Vienna and 
Montreal 
classification), 
pregnant 
women, 
patients with 
cardiovascular 
disorders and 
history of 
intolerance to 
6-MP  
 
 
 
 
  
Elemental 
nutrition: 
Elental 
(Ajinomoto, 
Tokyo) at 
≥900 kcal/day, 
taken via self-
inserted 
feeding tube (2 
pts) or by oral 
intake (32 pts).  
Restricted diet: 
patients were 
allowed an 
intake of 3.5–
4.0 kcal/kg/day 
from food as 
recommended 
by a qualified 
dietician 
 
Control 1: 
Drug [6-MP 
20-80 mg/day] 
 
Unrestricted 
normal diet 
 
Control 2: No 
intervention 
 
Unrestricted 
normal diet 
 
Patients randomised (n) 32 30 33 
Age (years) - Mean 
(SD/range)  
30.1 
(7.7)  
32.5 
(8.9) 
29.8 
(10.3) 
Sex - female n/N (%) 10/32 
(31.2) 
7/30 
(23.3) 
8/33 
(24.2) 
Weight (kg) - Mean 
(SD/range) 
NR NR NR 
BMI (kg/m
2
) - Mean 
(SD/range) 
NR NR NR 
Smoking n/N (%) 18/32 
(56.2) 
15/30 
(50.0) 
18/33 
(54.5) 
Duration of CD (mo) - 
Mean (SD/range) 
73.2 
(69.6)  
67.2 
(80.4) 
58.8 
(75.6) 
CDAI score- Mean 
(SD/range) 
103.4 
(21.4)  
93.2 
(27.8) 
89.9 
(30.1) 
Location of CD - n/N (%) 
Ilio-colic type 
Ileal type 
Colic type 
 
19/32 
(59.4)  
8/32 
(25.0) 
3/32 
(9.4)  
 
21/30 
(70.0) 
8/30 
(26.7)  
2/30 
(6.7)  
 
19/33 
(57.6) 
11/33 
(33.3) 
3/33 
(9.1) 
Previous bowel resection 
n/N (%) 
NR NR NR 
Type of induction therapy (n[%]): parenteral nutrition 
(70/95 [73.7]), central venous feeding (25/95 [26.3]), 
prednisolone (9/95 [9.5]), infliximab (4/95 [4.2]), 6-MP (14/95 
[14.7]) 
 
Total N received induction therapy: NR 
Total N achieving remission after induction therapy: 105 
Total N allocated to maintenance treatment: 95 
 
Diagnostic criteria used for CD: NR 
 
Co-interventions: 5-ASA (2250–3000 mg/day), 
Sulphasalazine (3000 mg/day) 
 
Outcome definitions applied: Remission (CDAI < 150), 
Relapse/recurrence (CDAI ≥200 or the need for an additional 
medication to suppress worsening symptoms) 
 
Outcomes reported: Maintenance of remission, risk of 
relapse, adverse events, complications, need of surgery  
 
Takagi 
2006
52-54
 
Japan 
Aim:  To 
compare 
relapse rates in 
patients with 
inactive CD 
receiving half 
elemental 
Inclusion 
criteria: CD 
patients if they 
had just 
undergone 
induction of 
remission  
Elemental 
nutrition:  
Elental 
(AJINOMOTO 
PHARMA 
Co., Tokyo, 
Japan) through 
Patients randomised (n) 26 25 
Age (years) - Mean 
(SD/range)  
30.8 
(11.1)  
28.9 (8.1) 
Sex - female n/N (%) 6/26 
(23.1) 
8/25 (32.0) 
Weight (kg) - Mean 
(SD/range) 
NR NR 
39 
 
nutrition 
(elemental 
nutrition + 
unrestricted 
diet) vs. no 
intervention 
(unrestricted 
diet) 
 
Study setting: 
specialty clinic 
 
Length of 
follow up (# 
months): 12 
 
Funding: no 
external 
funding 
received 
 
Exclusion 
criteria: NR 
a self-inserted 
tube and/or 
oral intake  
 
Patients took 
half the 
amount of their 
daily 
allowance of 
calories by 
elemental 
nutrition and 
the remaining 
half by usual 
unrestricted 
meals  
 
Control: No 
intervention; 
patients took 
all nutrients 
via their usual 
un-restricted 
meals  
BMI (kg/m
2
) - Mean 
(SD/range) 
20.1 
(3.1)  
20.0 (3.6) 
Smoking n/N (%) NR NR 
Duration of CD (mo) - 
Mean (SD/range) 
49.2 
(50.4)  
67.2 (78.0) 
CDAI score- Mean 
(SD/range) 
101.8 
(34.1)  
86.4 (31.3) 
Location of CD - n/N (%) 
Small bowel only 
Colon only  
Both 
 
8/26 
(30.7) 
3/26 
(11.5)  
15/26 
(57.7) 
 
7/25 (28.0) 
6/25 (24.0) 
12/25 (48.0) 
Previous bowel resection 
n/N (%) 
11/26 
(42.3)  
11/25 (44.0) 
Type of induction therapy (n[%]): elemental enteral 
nutrition 22/51 [43.1] (1800–2100 kcal/day) for 6–8 weeks; 
total parenteral nutrition 25/51 [49.0] (1500–2100 kcal/day) 
for 6–8 weeks; oral/IV prednisolone 1/51 [2.0] (40 mg/day, 
then tapered down every 2 weeks by 5–10 mg); 5 mg/kg IV 
infliximab 3/51 [5.9], and/or surgery (5/51 [7.9]) 
 
Total N received induction therapy: 82 
Total N achieving remission after induction therapy: 56 
Total N allocated to maintenance treatment: 51 
 
Diagnostic criteria used for CD: clinically, endoscopically, 
radiologically and/or histologically (diagnostic criteria as 
defined by the Ministry of Health, Labour and Welfare of 
Japan) 
 
Co-interventions: Mesalazine (2250–3000 mg/day), 
Azathioprine (50 mg/day) 
 
Outcome definitions applied: remission (CDAI<150), 
relapse/recurrence (CDAI > 200, or the need for therapy to 
induce remission) 
 
Outcomes reported: risk of relapse, HQOL, adherence 
 
Verma 
2001
55
 
UK 
Aim: To 
compare safety 
and efficacy of 
elemental and 
polymeric 
nutrition for 
the 
maintenance of 
remission, risk 
of relapse, and 
intolerance 
 
Study setting: 
specialty clinic 
 
Inclusion 
criteria: 
inactive CD 
and steroid 
dependency for 
maintaining 
clinical 
remission and 
two previous 
unsuccessful 
attempts to 
withdraw 
steroid that 
prompted 
recurrence 
Elemental 
nutrition: 
Orally taken 
(EO28, 
Scientific 
Hospital 
Supplies Ltd, 
Liverpool, 
UK); sachets 
containing 
powdered feed 
mixed with tap 
water (20 
g/100 ml); the 
mean daily 
Patients randomised (n) 19 14 
Age (years) - Mean 
(SD/range)  
41.7 
(5.4)  
44.1 (3.2) 
Sex - female n/N (%) 13/19 
(68.4) 
9/14 (64.3) 
Weight (kg) - Mean 
(SD/range) 
62.4 
(3.4) 
71.4 (7.7) 
BMI (kg/m
2
) - Mean 
(SD/range) 
21.8 
(1.2) 
24.4 (1.6) 
Smoking n/N (%) NR NR 
Duration of CD (mo) - 
Mean (SD/range) 
154.4 
(37.2) 
123.6 (26.4) 
CDAI score- Mean 
(SD/range) 
106.4 
(14.9) 
90.4 (17.8) 
40 
 
  
Length of 
follow up (# 
months): 12  
 
Funding: NR 
 
during or after 
30 d of 
withdrawal 
 
Exclusion 
criteria: 
recurrent 
small-bowel 
obstruction due 
to Crohn’s 
strictures, 
significant 
sepsis 
including 
perianal 
disease, 
previous 
intolerance to 
enteral feeding 
or unwilling to 
give formal 
written consent 
 
intake 730 
(range 600–
1017) Kcal 
Unrestricted 
normal diet 
 
Control: 
Orally taken 
Polymeric 
nutrition 
(Fortisip, 
Nutricia, UK); 
ready-to-drink 
cartons (200 
ml); the mean 
daily intake 
730 (range 
600–1017) 
Kcal 
Unrestricted 
normal diet 
Location of CD - n/N (%) 
Small bowel 
Large bowel 
Mixed anastamotic 
 
7/19 
(36.8) 
4/19 
(21.0) 
2/19 
(10.5) 
 
6/14 (42.8) 
4/14 (28.6) 
0/14 (0.0) 
Previous bowel resection 
n/N (%) 
NR NR 
Type of induction therapy (n[%]): prednisolone (33 [100%]) 
 
Total N received induction therapy: NR 
Total N achieving remission after induction therapy: NR 
Total N allocated to maintenance treatment: 33 
 
Diagnostic criteria used for CD: standard clinical, 
radiological, endoscopic and histological criteria 
 
Co-interventions: Steroids/prednisolone (6.5-7.1 mg), 
Azathioprine (dose: NR), 5-ASA (dose: NR)  
  
Outcome definitions applied: remission (absence of 
diarrhoea and abdominal pain, CDAI≤150 in the 2 weeks 
preceding the study, and ESR<20 mm/h); relapse/recurrence 
(CDAI ≥200 or increased by 100 points from baseline) 
 
Outcomes reported: Maintenance of remission, risk of 
relapse, adherence, withdrawal from steroids 
ASA=aminosalicylic acid; BMI=body mass index; CD=Crohn’s Disease; mo=month(s); CDAI=Crohn’s Disease Activity Index; 
HQOL=health related quality of life; MP=mercaptopurine; N=number; NR=not reported; pts=patients; SD=standard deviation 
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4.2.2 Non-randomised controlled trials (non-RCTs) 
The study and participant characteristics of the five included non-randomised controlled trials (non-
RCTs)
30, 51, 56-58
 are summarised in Table 3.  Of five studies, four were conducted in Japan
30, 51, 57, 58
 and 
one in the UK.
56
  A total of 236 participants were assigned to the study treatments.  The number of 
participants across the studies ranged from 39
56
 to 61.
51
  The mean age in the studies ranged from 22
51
 
to 42 years
56
 and the proportion of females from 13%
51
 to 72%.
56
  The length of follow up ranged 
from 12
30, 57
 to 48 months.
51
  One trial included exclusively those participants who had earlier 
undergone bowel resection surgery for CD.
30
  The majority of participants had both small and large 
bowel involvement of CD.  Only one study reported the diagnostic criteria of CD.
51
  Induction 
therapies were prednisolone,
56, 57
 azathioprine,
56
 5-ASA,
30, 56, 57
 infliximab,
57, 58
 corticosteroid,
30
 bowel 
resection,
30
 parenteral nutrition,
57
 and elemental nutrition.
51, 57
 
 
In all five trials, the elemental nutrition was given in addition to either restricted
30, 51, 57, 58
 or 
unrestricted diet (i.e., normal/free diet)
56
 through feeding tube infusion
30, 51, 57, 58
 or oral intake.
56
 
Participants in the elemental nutrition groups were asked to take half of the daily calories through 
elemental nutrition.
30, 57, 58
  The elemental nutrition groups received either elemental nutrition alone
30, 
51, 56, 57
 or elemental nutrition with drug (sulfasalazine/prednisolone
51
 or infliximab
58
).  Participants in 
the control groups were assigned to receive unrestricted/restricted diet (no intervention),
30, 51, 56, 57
 drug 
only (sulfasalazine/prednisolone
51
 or infliximab
58
).  
 
Remission was defined clinically using CDAI score<150 alone
30, 56-58
 or with additional 
clinical/endoscopic criteria such as normal values of IOIBD, erythrocyte sedimentation rate (ESR) 
and CRP scores
51
 or Rutgeerts score<2.
30, 57
  Relapse/recurrence was defined by subjective/objective 
symptoms (increase of the IOIBD score by ≥2, enhanced ESR/CRP;51 increase in CDAI by >100 
points after baseline, or final CDAI score >150, need of surgery, or increased doses of steroids;
56
 or 
CDAI scores ≥ 150).30, 57, 58  
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Table 3: Study and participant characteristics (non-randomised controlled trials)  
Author 
year 
Ref ID 
Countr
y 
Study 
details 
Inclusion/ 
exclusion 
criteria 
Interventio
ns  
Patient characteristics 
 Eleme
ntal 
nutriti
on 
Contr
ol 1 
Contr
ol 2 
Contr
ol 3 
Hiraka
wa 
1993
51
 
Japan 
Aim: To 
compare the 
effects of 
elemental 
nutrition 
alone, 
combinatio
n of 
elemental 
nutrition 
and drugs, 
drugs alone, 
and no 
intervention 
on 
maintenanc
e of 
remission in 
CD patients 
 
Study 
setting:  
primary 
care  
 
Length of 
follow up 
(# months): 
48  
 
Funding: 
NR 
Inclusion 
criteria:   
patients 
with CD in 
remission 
 
Exclusion 
criteria:  
patients 
with active 
CD 
 
Elemental 
nutrition: 
Elemental 
nutrition 
(Brand: NR) 
via 
nasoenteral 
tube (with 
restricted 
diet) 
 
Control 1: 
Elemental 
nutrition + 
Drug 
[sulfasalazin
e 3g/d or 
prednisolon
e 10mg/d] 
(with 
restricted 
diet) 
 
Control 2:  
Drug 
[sulfasalazin
e 3g/d or 
prednisolon
e 10mg/d] 
(with 
restricted 
diet) 
 
Control 3: 
No 
intervention 
(with 
restricted 
diet) 
Patients assigned (n) 25 22 8 6 
Patients analysed  (n) 22 17 8 6 
Age (years) - Mean 
(SD/range)  
27.0 
(7.4) 
26.6 
(2.4) 
21.9 
(2.6) 
25.7 
(5.0) 
Sex - female n/N (%) 3/22 
(13.6) 
6/17 
(35.3) 
3/8 
(37.5) 
2/6 
(33.3) 
Weight (kg) - Mean 
(SD/range) 
NR NR NR NR 
BMI (kg/m
2
) - Mean 
(SD/range) 
NR NR NR NR 
Smoking n/N (%) NR NR NR NR 
Duration of CD (mo) - 
Mean (SD/range) 
NR NR NR NR 
CDAI score- Mean 
(SD/range) 
61.6 
(29.2) 
56.0 
(26.6) 
68.5 
(30.2) 
69.3 
(52.1) 
Location of CD - n/N (%) 
Small bowel 
Large bowel 
Small and large bowel 
 
5/22 
(22.7) 
1/22 
(4.5) 
16/22 
(72.7) 
 
0/17 
(0.0) 
3/17 
(17.6) 
14/17 
(82.3) 
 
0/8 
(0.0) 
2/8 
(25.0) 
6/8 
(75.0) 
 
0/6 
(0.0) 
0/6 
(0.0) 
6/6 
(100.0
) 
Previous bowel resection 
n/N (%) 
NR NR NR NR 
Type of induction therapy (n[%]): elemental nutrition (25/53 
[47.1]), elemental nutrition and drugs (23/53 [43.4]), drugs alone 
(5/53 [9.4]) 
  
Total N received induction therapy: 84 
Total N achieving remission after induction therapy: 67  
Total N allocated to maintenance treatment: 61 
 
Diagnostic criteria used for CD: Criteria of the Japanese Society 
Gastroenterology 
Co-interventions: NR 
 
Outcome definitions applied: remission IOIBD score (value: 
NR) and normal values of ESR and CRP,  relapse/recurrence of 
subjective/objective symptoms (increase of the IOIBD score by 
≥2, enhanced ESR, and positive CRP) 
 
Outcomes reported: cumulative continuous remission rate 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
Verma 
2000
56
 
UK 
Aim: To 
evaluate 
clinical 
effectiveness 
of adding 
elemental 
nutrition 
taken orally 
to normal 
food for 
maintaining 
remission in 
patients with 
quiescent CD 
over 12 
months 
 
Study 
setting:  
specialty 
clinic 
 
Length of 
follow up (# 
months):  
24  
 
Funding:  
NR 
Inclusion criteria:  
Patients with quiescent 
disease defined by the 
absence of bowel 
symptoms and 
CDAI<150 who had 
been treated with either 
elemental nutrition or 
prednisolone as an 
induction therapy 
within preceding 12 
months 
 
Exclusion criteria:  
CDAI>150, sepsis, 
bowel strictures 
leading to recurrent 
attacks of small bowel 
obstruction or previous 
intolerance to enteral 
feeding 
 
 
 
  
Elemental 
nutrition:   
Elemental 
nutrition 
“EO28 Extra” 
powder taken 
orally in three 
separate 
portions daily 
(with normal 
unrestricted 
diet) 
 
Control 1:  
No 
intervention 
(i.e., normal 
unrestricted 
diet) 
 
Control 2: NA 
Patients 
assigned (n) 
21 18 NA 
Patients 
analysed  
(n) 
17  18 NA 
Age (years) 
- Mean 
(SD/range)  
39.2 (3.9) 42.0 
(3.3)  
NA 
Sex - female 
n/N (%) 
14/21 
(66.6) 
13/18 
(72.2) 
NA 
Weight (kg) 
- Mean 
(SD/range) 
59.4 (2.9) 62.7 
(2.8) 
NA 
BMI 
(kg/m
2
) - 
Mean 
(SD/range) 
20.0 (2.2) 22.9 
(0.9) 
NA 
Smoking 
n/N (%) 
NR NR NA 
Duration of 
CD (mo) - 
Mean 
(SD/range) 
60.3 
(18.4) 
91.0 
(14.8) 
NA 
CDAI 
score- 
Mean 
(SD/range) 
112.8 
(11.5) 
94.6 
(7.1) 
NA 
Location of 
CD - n/N 
(%) 
Small bowel 
Large bowel 
Mixed 
bowel 
Anastomotic  
 
10/17 
(58.8) 
5/17 
(29.4) 
6/17 
(35.3) 
0/17 (0.0) 
 
7/18 
(38.8) 
5/18 
(27.7) 
3/18 
(16.6) 
3/18 
(16.6) 
NA 
Previous 
bowel 
resection 
n/N (%) 
NR NR NA 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
    Type of induction therapy (n[%]): medical 
(prednisolone, azathioprine, 5-ASA)  
Total N received induction therapy: 46 
Total N achieving remission after induction 
therapy: 39 
Total N allocated to maintenance treatment: 
39 
 
Diagnostic criteria used for CD: standard 
clinical, endoscopic, radiological, and when 
possible, histological criteria  
 
Co-interventions: Prednisolone (mean range: 
10.5-17.5 mg/d) azathioprine (dose: NR)  
5-ASA (dose: NR) 
 
Outcome definitions applied: remission 
CDAI<150, relapse/recurrence increase in 
CDAI by >100 points since baseline or final 
CDAI >150 points; need of surgery; increased 
doses of steroids 
 
Outcomes reported: maintenance of clinical 
remission at 12 mo, withdrawal from steroids, 
and duration of remission at 24 mo 
 
Yamamoto 
2010
58
 
Japan 
Aim: to 
assess the 
efficacy of 
EN on the 
maintenance 
rate of 
clinical 
remission in 
patients with 
quiescent CD 
receiving 
infliximab as 
maintenance 
therapy 
 
Study 
setting: 
specialty 
clinic 
 
Length of 
follow up (# 
months): 14  
 
Funding: NR 
Inclusion criteria:  
patients diagnosed with 
CD who had achieved 
clinical remission 
(CDAI<150 after 
infliximab induction 
therapy) with time 
from the induction of 
remission to entry ≤2 
weeks; patients who 
had experienced EN 
therapy including 
elemental nutrition 
infusion at least one 
time before entry; and 
patients who agreed to 
continue with the 
assigned treatment 
(with or without 
concomitant enteral 
nutrition) for 56 weeks 
 
Exclusion criteria:  
patients who had 
severe anorectal 
involvement; patients 
Elemental 
nutrition: 
Elemental 
nutrition via 
nasogastric 
tube infusion 
during night-
time (Elental 
(Ajinomoto, 
Tokyo )) + 
Drug 
[infliximab 5 
mg/kg] (with 
restricted low 
fat diet) 
 
Control 1: 
Drug 
[Infliximab 5 
mg/kg] (with 
unrestricted 
low fat diet) 
 
Control 2: NA 
Patients 
assigned (n) 
32 24 NA 
Patients 
analysed (n) 
32 24 NA 
Age (years) 
- Mean 
(SD/range)  
31.0 (9.0) 33.0 
(7.8) 
NA 
Sex - female 
n/N (%) 
12/32 
(37.5) 
8/24 
(33.3) 
NA 
Weight (kg) 
- Mean 
(SD/range) 
NR NR NA 
BMI 
(kg/m
2
) - 
Mean 
(SD/range) 
NR NR NA 
Smoking 
n/N (%) 
4/32 
(12.5) 
4/24 
(16.6) 
NA 
Duration of 
CD (mo) - 
Mean 
(SD/range) 
33.0 
(24.8) 
35.0 
(19.6) 
NA 
CDAI 
score- 
Mean 
(SD/range) 
102.1 
(18.1) 
102.3 
(22.5) 
NA 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
who had tight bowel 
strictures or enteric 
fistulae even if clinical 
symptoms were 
quiescent  
Location of 
CD - n/N 
(%) 
Small bowel 
Small bowel 
and colon  
 
11/32 
(34.4) 
21/32 
(65.6) 
 
11/24 
(45.8) 
13/24 
(54.1) 
NA 
Previous 
bowel 
resection 
n/N (%) 
11/32 
(34.4) 
8/24 
(33.3) 
NA 
Type of induction therapy (n[%]): medical 
(infliximab 5 mg/kg) 
 
Total N received induction therapy: NR 
Total N achieving remission after induction 
therapy: 56 
Total N allocated to maintenance treatment: 
56 
 
Diagnostic criteria used for CD: NR 
 
Co-interventions: Mesalazine (Pentasa 3 
g/day), Azathioprine (Imuran 50–100 mg/day) 
 
Outcome definitions applied: remission CDAI 
< 150,  relapse/recurrence score CDAI > 150 
 
Outcomes reported: remission maintenance 
rate, time to relapse 
 
Yamamoto 
30, 59, 60
 
Japan 
Aim:  
to examine if 
long-term 
elemental 
nutrition 
infusion 
along with 
low fat diet is 
useful in 
reducing 
clinical and 
endoscopic 
recurrence 
rates after 
resection for 
CD 
 
Study 
setting:  
specialty 
clinic 
 
Length of 
Inclusion criteria:  
patients with 
endoscopic and 
histological diagnosis 
of CD, aged 15-75 yrs 
who had resection for 
ileal and ileocolonic 
(including ileocaecal) 
CD; received EN 
therapy including 
elemental nutrition 
infusion at least once 
before operation; 
agreed to continue 
assigned treatment 
(with or without enteral 
nutrition) for more than 
1 year after operation 
 
Exclusion criteria:  
patients with colonic 
CD alone or with 
diffuse small bowel CD  
Elemental 
nutrition: 
Elental 
(Ajinomoto, 
Tokyo, Japan) 
infused at 
home 
nasogastrically 
via self-
intubated tube 
in the night-
time 1 week 
after operation 
(with restricted 
food diet) 
 
Control 1:  
No 
intervention 
(i.e., normal 
unrestricted 
Patients 
assigned (n) 
20 20 NA 
Patients 
analysed  
(n) 
20 20 NA 
Age (years) 
- Mean 
(SD/range)  
31.0 
(16.5) 
33.0 
(17.4) 
NA 
Sex - female 
n/N (%) 
8/20 
(40.0) 
6/20 
(30.0) 
NA 
Weight (kg) 
- Mean 
(SD/range) 
NR NR NA 
BMI 
(kg/m
2
) - 
Mean 
(SD/range) 
NR NR NA 
Smoking 
n/N (%) 
2/20 
(10.0) 
2/20 
(10.0) 
NA 
Duration of 
CD (mo) - 
Mean 
(SD/range) 
37.0 
(31.7) 
39.0 
(36.7) 
NA 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
follow up (# 
months): 12  
 
Funding: no 
external 
funding 
received 
diet) 
 
Control 2: NA 
CDAI 
score- 
Mean 
(SD/range) 
NR NR NA 
Location of 
CD - n/N 
(%) 
Terminal 
ileum 
Terminal 
ileum and 
colon  
Ileocolonic 
anastomosis 
 
 
5/20 (25.0)  
11/20 
(55.0) 
4/20 (20.0) 
 
7/20 
(35.0) 
9/20 
(45.0) 
4/20 
(20.0) 
NA 
Previous 
bowel 
resection 
n/N (%) 
20/20 
(100.0) 
20/20 
(100.0) 
NA 
Type of induction therapy (n[%]): bowel 
resection (40/40 [100.0]), corticosteroids (37/40 
[92.5]), pentasa (32/40 [77.5]) 
 
Total N received induction therapy: NR 
Total N achieving remission after induction 
therapy: NR 
Total N allocated to maintenance treatment: 
40 
 
Diagnostic criteria used for CD: endoscopic 
and histological (no specific criteria reported) 
 
Co-interventions: Pentasa 3000 mg/day as a 
prophylactic medication.  
No corticosteroid, immunosuppressive drugs, or 
infliximab except patients who relapsed  
 
Outcome definitions applied: remission 
CDAI<150 (clinical), Rutgeerts score<2 
(endoscopic), relapse/recurrence clinical (at 6, 
12 mo: CDAI≥150; at 60 mo: CDAI≥200), 
endoscopic (Rutgeerts score≥2) 
 
Outcomes reported: clinical and endoscopic 
recurrence  
 
Yamamoto 
2007b
57
 
Japan 
Aim: To 
investigate if 
long-term 
enteral 
nutrition (vs. 
no 
intervention) 
is effective in 
reducing 
Inclusion criteria:  
patient with 
endoscopic/histological 
diagnosis of CD in the 
terminal ileum and/or 
the colon; age: 15-75 
years; clinical 
remission (CDAI<150) 
after medical 
Elemental 
nutrition: 
Elemental 
nutrition: 
Elental 
(Ajinomoto, 
Tokyo)(with 
restricted food 
Patients 
assigned (n) 
20 20 NA 
Patients 
analysed (n) 
20 20 NA 
Age (years) 
- Mean 
(SD/range)  
29.0 
(17.4) 
31.0 
(20.1) 
NA 
Sex - female 
n/N (%) 
6/20 
(30.0) 
7/20 
(35.0) 
NA 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
clinical and 
endoscopic 
relapse rates 
and inhibiting 
mucosal 
cytokine 
production in 
patients with 
quiescent CD 
 
Study 
setting: NR 
 
Length of 
follow up (# 
months): 12  
 
Funding: NR 
treatment; the duration 
from the induction of 
remission to 
entry<8 weeks; patients 
had experienced enteral 
nutrition therapy 
including elemental 
nutrition infusion at 
least 1 time before 
entry; patient agreed to 
continue with assigned 
treatment (with or 
without enteral 
nutrition) for >1 year; 
and patient agreed to 
have ileocolonoscopy 
with multiple mucosal 
biopsies even if they 
did not have any 
clinical symptoms  
 
Exclusion criteria:  
diffuse jejunoileal or 
gastroduodenal; severe 
anorectal stricture or 
sepsis; tight bowel 
strictures or enteric 
fistulae even though 
clinical symptoms were 
quiescent; patient had 
diet) 
 
Control 1: no 
intervention 
(i.e., normal 
unrestricted 
diet  
Control 2: NA 
Weight (kg) 
- Mean 
(SD/range) 
51.1 (8.5) 48.9 
(7.6) 
NA 
BMI 
(kg/m
2
) - 
Mean 
(SD/range) 
19.2 (1.3) 19.1 
(1.8) 
NA 
Smoking 
n/N (%) 
2/20 
(10.0) 
4/20 
(20.0) 
NA 
Duration of 
CD (mo) - 
Mean 
(SD/range) 
32.0 
(35.3) 
36.0 
(38.9) 
NA 
CDAI 
score- 
Mean 
(SD/range) 
101.0 
(28.2) 
92.0 
(21.5) 
NA 
Location of 
CD - n/N 
(%) 
Terminal 
ileum 
Colon  
Terminal 
ileum and 
colon  
 
7/20 
(35.0) 
2/20 
(10.0) 
11/20 
(55.0) 
 
8/20 
(40.0) 
2/20 
(10.0) 
10/20 
(50.0) 
NA 
Previous 
bowel 
resection 
n/N (%) 
4/20 
(20.0) 
4/20 
(20.0) 
NA 
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Author 
year 
Ref ID 
Country 
Study details Inclusion/ exclusion 
criteria 
Interventions  Patient characteristics 
 Elemental 
nutrition 
Control 
1 
Control 
2 
received 
corticosteroids, 
immunosuppressive 
drugs, or infliximab at 
entry 
Type of induction therapy (n[%]): 4 pts (5 
mg/kg x 1 or x 3 prednisolone, infliximab), 6 
pts (prednisolone with enteral nutrition), 10 pts 
(prednisolone alone), 20 pts (enteral nutrition 
alone), 36 pts (Pentasa 750–3000 mg/day), and 
the majority of patients required parenteral 
nutrition at the start of the treatment 
 
Total N received induction therapy: NR 
Total N achieving remission after induction 
therapy: NR 
Total N allocated to maintenance treatment: 
40 
 
Diagnostic criteria used for CD: endoscopic 
and histological (not specified) 
 
Co-interventions: Pentasa 3000 mg/day as a 
prophylactic medication.  No corticosteroid, 
immunosuppressive drugs, or infliximab except 
patients who relapsed  
 
Outcome definitions applied: remission 
CDAI<150 (clinical), NR (endoscopic; specific 
threshold for the mucosal inflammation grade 
NR), relapse/recurrence CDAI≥150 (clinical), 
NR (endoscopic; specific threshold for the 
mucosal inflammation grade NR) 
 
Outcomes reported: CDAI score, cumulative 
proportion of patients maintaining clinical 
remission (CDAI<150), endoscopic severity of 
disease activity/mucosal inflammation, mucosal 
cytokine assays 
ASA=aminosalicylic acid; BMI=body mass index; CD=Crohn’s Disease; mo=month(s); CDAI=Crohn’s Disease Activity 
Index; CRP=C-reactive protein; EN=Enteral nutrition; ESR=erythrocyte sedimentation rate; HQOL=health related quality of 
life; IOBD=International Organization for the Study of Inflammatory Bowel Disease; N=number; NR=not reported; 
pts=patients; SD=standard deviation 
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4.3 Risk of bias assessment  
Risk of bias assessment for the eight included studies (three RCTs
50, 52, 55
 and five non-RCTs
30, 51, 56-58
) 
are presented in risk of bias tables and graphs separately for RCTs (Table 4; Figure 2) and non-RCTs 
(Table 5; Figure 3). 
 
4.3.1 Randomised controlled trials (RCTs) 
Overall, two
50, 52
 of the three RCTs reported an adequate method for random sequence generation and 
only one
52
 reported adequate treatment allocation concealment (low risk of bias).  All three RCTs 
were rated as having low risk of performance and detection bias for objective (e.g., radiography, 
endoscopy) vs. subjective (e.g., patient-administered functional scores, CDAI) outcomes.  The RCTs 
failed to report blinding status of the patients and study personnel.  But based on the nature of the 
administered intervention, it is unlikely that study personnel and participants in these studies were 
blinded.  In two RCTs,
50, 55
 it was not clear if outcome assessors were blinded.  Outcome assessors in 
one RCT
52
 were reported to be blinded.  For the three RCTs, the influence of attrition bias was judged 
at low risk.  All three RCTs were judged as being at high risk for selective outcome and/or analysis 
bias.  Risk of other bias (e.g., funding source, balance imbalance in important characteristics, 
inappropriate analysis) for two RCTs
50, 52
 was judged to be low. 
 
4.3.2 Non-randomised controlled trials (non-RCTs) 
The presence of imbalance in important baseline factors was suspected for two non-RCTs (high risk 
of bias)
51, 56
 and was unclear for the remaining three non-RCTs.
30, 57, 58
  In the first trial,
51
 there was 
some between-group imbalance in induction therapy and distribution of the lesion.  In the second 
trial,
56
 the elemental nutrition group had a shorter disease duration (60.3 vs. 91.0 months), greater 
ESR, and a longer steroid use compared to the no intervention group. Four non-RCTs
30, 56-58
 were 
rated as having low risk of performance and detection bias for objective (e.g., radiography, 
endoscopy) vs. subjective (e.g., patient-administered functional scores, CDAI) outcomes.  Three 
RCTs
51, 56, 58
 failed to report blinding status of the patients, study personnel, as well as outcome 
assessors.  Based on the nature of the administered intervention in these studies, it is unlikely that 
study personnel and participants were blinded.  The remaining two non-RCTs
30, 57
 explicitly reported 
that patients and study personnel were not blinded, but outcome assessors were blinded.  For four 
non-RCTs,
30, 56-58
 the influence of attrition bias was judged at low risk.  Three of the five non-RCTs
30, 
57, 58
 were judged as being at low risk for selective outcome and/or analysis bias. Risk of other bias 
(e.g., funding source, balance imbalance in important characteristics, inappropriate analysis) for four 
non-RCTs
30, 56-58
 was judged to be low.
50 
 
Table 4: Risk of bias for randomised controlled trials: review author’s judgments about each risk of bias item 
First author, year, 
study ID 
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Table 5: Risk of bias for non-randomised controlled trials: review author’s judgments about each risk of bias item 
First author, year, 
study ID 
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Figure 2: Overall risk of bias assessment: randomised controlled trials 
 
 
0% 20% 40% 60% 80% 100%
Other bias: Funding source, adequacy of statistical methods used, type of
analysis [ITT/PP], baseline imbalance in important characteristics
Reporting bias: Selective reporting of the outcome, subgroups, or analysis
Attrition bias: Objective (e.g., radiography, endoscopy)
Attrition bias: Subjective (e.g., patient-reported)
Detection bias: Objective (e.g., radiography, endoscopy)
Detection bias: Subjective (e.g., patient-reported)
Performance bias: Objective (e.g., radiography, endoscopy))
Performance bias: Subjective (e.g., patient-reported)
Selection bias: Allocation concealment
Selection bias: Random sequence generation
Low risk of bias
Unclear risk of bias
High risk of bias
NA
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Figure 3: Overall risk of bias assessment: non-randomised controlled trials 
 
0% 20% 40% 60% 80% 100%
Other bias: Funding source, adequacy of statistical methods used, type of
analysis [ITT/PP]
Reporting bias: Selective reporting of the outcome, subgroups, or analysis
Attrition bias: Objective (e.g., radiography, endoscopy)
Attrition bias: Subjective (e.g., patient-reported)
Detection bias: Objective (e.g., radiography, endoscopy)
Detection bias: Subjective (e.g., patient-reported)
Performance bias: Objective (e.g., radiography, endoscopy)
Performance bias: Subjective (e.g., patient-reported)
The presence/absence of baseline between-group imbalance in important
prognostic factors (e.g., age, sex, CDAI, duration of CD, location of CD,
complications during induction therapy, type of induction therapy, pre-study
compliance, co-intervention, and/o
Low risk of bias
Unclear risk of bias
High risk of bias
NA
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4.4 Clinical effectiveness of elemental nutrition 
Results of included trials are provided in Table 6 to Table 24.  Results reported partially (e.g., missing 
effect measures, 95% CIs) or statistically non-significant effect measures with wide 95% CIs were 
considered inconclusive. 
 
4.4.1 Maintenance of Remission  
In seven of the eight included trials, the maintenance of remission was reported as the proportion of 
patients maintaining remission
30, 50, 55-58
 and/or cumulative probability of maintaining remission 
(Kaplan Meier estimates of survival).
50, 51, 57, 58
  This outcome was not reported for one trial.
52
  None of 
the trials reported duration of remission.  See Table 6 to Table 9. 
 
Elemental nutrition vs. No intervention (i.e., unrestricted/free or restricted diet) 
Randomised controlled trials 
In one trial,
50
 the post-treatment differences for the maintenance of remission at 6 and 12 months were 
not statistically significant between the elemental nutrition and no intervention groups [review 
conclusion: inconclusive].  However, at 24 months of follow-up, elemental nutrition was significantly 
more beneficial in maintaining remission compared to no intervention (RR=2.06, 95% CI: 1.00, 4.43). 
The same trial reported statistically significantly greater cumulative probability for being in remission 
for the participants who received elemental nutrition vs. no intervention at 18 (p=0.04) and 24 months 
of follow-up (p=0.03) [review conclusion: inconclusive].  See Table 6 and Table 7. 
 
Non-randomised controlled trials  
Two of the three trials,
30, 56, 57
 reporting maintenance of remission (i.e., proportion of patients 
maintaining remission), indicated significantly greater rates of maintenance in favour of elemental 
nutrition at 12 months post-baseline.
30, 57
  For example, in one of these trials,
57
 significantly more 
participants receiving elemental nutrition maintained their remission at 12 months of follow-up 
(RR=2.14, 95% CI: 1.12, 4.10).  The results regarding maintenance of remission reported in one trial
56
 
and cumulative probability of maintaining remission at 48 months reported in one trial (no 
intervention: restricted diet)
51
 were rendered inconclusive due to wide statistically non-significant 
95% CIs
56
 and partially reported data (missing effect estimates and 95% CIs), respectively.
51
  See 
Table 8 and Table 9. 
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Elemental nutrition vs. Drug 
Randomised controlled trials 
In one trial,
50
 the maintenance rate of remission (i.e., proportion of patients maintaining remission and 
cumulative probability of maintaining remission) at 6 to 24 months of follow-up was not significantly 
different between the participants receiving elemental nutrition and 6-mercaptopurine (6-MP).  Due to 
missing effect estimates (for the cumulative probability of maintaining remission) and wide 95% CIs 
(for the proportion of patients maintaining remission), this result was deemed inconclusive.  See Table 
6 and Table 7. 
 
Non-randomised controlled trials  
One trial
51
 showed significantly greater cumulative probability of maintaining remission in 
participants receiving elemental nutrition vs. those on sulfasalazine/prednisolone at 48 months of 
follow-up (63% vs. 0%, p<0.05).  However, due to partially reported data (i.e., missing 95% CIs), this 
result was deemed inconclusive.  See Table 8 and Table 9. 
 
Elemental nutrition vs. Elemental nutrition plus drug 
Randomised controlled trials 
No trial with these comparisons 
 
Non-randomised controlled trials  
In one trial,
51
 the cumulative probability of maintaining remission was not significantly different for 
the participants receiving elemental nutrition vs. elemental nutrition plus sulfasalazine or prednisolone 
at 48 months of follow-up (63% vs. 66%, p>0.05).  Due to partially reported data (i.e., missing 95% 
CIs), this result was deemed inconclusive.  See Table 8 and Table 9. 
 
Elemental nutrition plus drug vs. Drug 
Randomised controlled trials 
No trial with these comparisons. 
 
Non-randomised controlled trials  
In one trial,
58
 the proportion of patients maintaining remission (RR=1.17, 95% CI: 0.83, 1.64) and 
cumulative probability of maintaining remission (p=0.32) were not significantly different in the 
elemental nutrition plus infliximab vs. infliximab alone group at 14 months of follow-up [review 
conclusion: inconclusive].  In contrast, another trial
51
 showed a significant effect of adding elemental 
nutrition to sulfasalazine/prednisolone compared to sulfasalazine/prednisolone alone on the 
cumulative probability of maintaining remission at 48 months post-baseline (66% vs. 0%, p<0.05) 
[review conclusion: inconclusive].  See Table 8 and Table 9. 
56 
 
Elemental nutrition vs. Polymeric nutrition 
Randomised controlled trials 
In one trial,
55
 the proportion of participants maintaining remission was not significantly different 
between the groups receiving elemental and polymeric nutrition at 12 months of follow-up (RR=0.98, 
95% CI: 0.44, 2.19) [review conclusion: inconclusive].  See Table 6. 
 
Non-randomised controlled trials  
No trial with these comparisons. 
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Table 6: Proportion of patients maintaining remission¥ (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
52
 NR 1 [NA] No evidence 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
 
6 mo 
12 mo 
24 mo 
 
 
6 mo 
12 mo 
24 mo 
Elemental nutrition vs. 6-MP 
27/32 (84.4) vs. 24/30 (80.0)
50
 
20/32 (62.5) vs. 20/30 (66.7)
50
 
14/32 (46.9) vs. 17/30 (56.7)
50
 
 
Elemental nutrition vs. NI  
27/32 (84.4) vs. 23/33 (69.6)
50
 
20/32 (62.5) vs. 15/33 (45.5)
50
 
14/32 (46.9) vs. 7/33 (21.2)
50
 
Elemental nutrition vs. 
6-MP 
RR=1.05 (0.83, 1.33)
£
 
RR=0.93 (0.64, 1.35)
£
 
RR=0.77 (0.46, 1.27)
£
 
 
Elemental nutrition vs. 
NI  
RR=1.21 (0.92, 1.58)
£
  
RR=1.37 (0.86, 2.17)
£
 
RR=2.06 (1.00, 4.43)
£
 
1 [high ROB]  Inconclusive 
(elemental 
nutrition vs. 6-
MP)  
 
Inconclusive 
(elemental 
nutrition vs. NI at 
6-12 mo)  
 
In favour of 
elemental 
nutrition (vs. NI) 
at 24 mo 
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo 8/19 (42.1) vs. 6/14 (42.8)
55
 
(remission: CDAI plus other 
criteria) 
p=NR [NS]  
RR=0.98 (0.44, 2.19)
£
  
1 [unclear ROB] Inconclusive  
95% CI=95 percent confidence interval; CDAI=crohn’s disease activity index; MP=mercaptopurine; NA=not applicable;  
NI=no intervention; NR=not reported; NS=statistically not significant; mo=month(s); RCT=randomised controlled trial; 
RR=risk ratio (relative risk); SD=standard deviation; SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
¥ Remission defined using CDAI only unless specified otherwise (e.g., endoscopic, blood parameter, other criteria in 
addition) 
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Table 7: Cumulative survival rate for being in remission (%) – Randomised controlled trials 
 
Follow-up 
Arm-specific Kaplan-Meier 
survival rate estimates  
Difference  
(p value or 95% CI) 
# of RCTs  
[SROB across studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
52
 NR 1 [NA] No evidence 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
 
6 mo 
12 mo 
18 mo 
24 mo 
 
 
6 mo 
12 mo 
18 mo 
24 mo 
Elemental nutrition vs. 6-MP 
NR
50
 
NR
50
 
NR
50
 
NR
50
 
 
Elemental nutrition vs. NI 
NR
50
 
NR
50
 
NR
50
 
NR
50
 
Elemental nutrition vs. 
6-MP 
p=0.83 [NS]  
p=0.54 [NS]  
p=0.41 [NS]  
p=0.31 [NS]  
 
Elemental nutrition vs. 
NI  
p=0.19 [NS]  
p=0.17 [NS]  
p=0.04 [SS]  
p=0.03 [SS]  
 
1 [high ROB] 
 
Inconclusive  
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo NR
55
 NR 1 [NA] Inconclusive  
95% CI=95 percent confidence interval; mo=month(s); MP=mercaptopurine; NA=not applicable; NI=no intervention; NR=not 
reported; NS=statistically not significant; RCT=randomised controlled trial; RR=risk ratio (relative risk); SROB=summary risk 
of bias; SS=statistically significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated
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Table 8: Proportion of patients maintaining remission¥ (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
# of non-RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 10/21 (47.6) vs. 4/18 (22.2)
56
 p=0.0003 [SS] 
RR=2.14 (0.81, 5.67), 
p=0.18 [NS]
£
 
1 [high ROB] Inconclusive  
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
12 mo 
 
19/20 (95.0) vs. 13/20 (65.0)
30
 
 
p=NR 
RR=1.46 (1.04, 2.05)
£
  
 
2 [high ROB] 
 
In favour of 
elemental nutrition  12 mo 15/20 (75.0) vs. 7/20 (35.0)
57
 p=0.01 [SS] 
RR=2.14 (1.12, 4.10)
£
 
 
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence 
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo 25/32 (78.1) vs. 16/24 (66.6)
58
 p=0.51 [NS]  
RR=1.17 (0.83, 1.64)
£
  
1 [high ROB] Inconclusive  
95% CI=95 percent confidence interval; CDAI=crohn’s disease activity index; mo=month(s); NA=not applicable; NI=no 
intervention; NR=not reported; NS=statistically not significant; RCT=randomised controlled trial; RR=risk ratio (relative risk); 
SROB=summary risk of bias; SS=statistically significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg) 
¥ Remission defined using CDAI only unless specified otherwise (e.g., endoscopic, blood parameter, other criteria 
additionally) 
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Table 9: Cumulative survival rate for being in remission (%) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific Kaplan-Meier 
survival rate estimates  
Difference  
(p value or 95% CI) 
# of non-RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
56
 NR 1 [NA] No evidence  
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo NR
30
 NR 1 [NA] No evidence  
12 mo NR
57
 p=0.01 [SS] in favour of 
elemental nutrition as 
reported 
1 [high ROB] Inconclusive  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12 mo 
 
 
24 mo 
 
 
48 mo 
94% (NR) vs. 75% (NR) vs. 
63% (NR) vs. 50% (NR)
51
 
 
63% (NR) vs. 66% (NR) vs. 
42% (NR) vs. 33% (NR)
51
 
 
63% (NR) vs. 66% (NR) vs. 0% 
(NR) vs. 0% (NR)
51
 
At 48 mo 
p<0.05 [1 vs. 3] SS 
p<0.01 [1 vs. 4] SS 
p<0.05 [2 vs. 3] SS 
p<0.05 [2 vs. 4] SS 
 
p≥0.05 [1 vs. 2] NS 
1 [high ROB] Inconclusive  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 p=0.32 [NS] 1 [high ROB] Inconclusive 
95% CI=95 percent confidence interval; mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; NS=statistically 
not significant; RCT=randomised controlled trial; RR=risk ratio (relative risk); SROB=summary risk of bias; SS=statistically 
significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)
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4.4.2 Development of Relapse/Recurrence 
In seven of the eight included trials, the development of relapse/recurrence was reported as the 
proportion of patients developing relapse
30, 50, 52, 55-58
 and/or mean time to relapse.
56
  All seven studies 
reported clinical relapse (defined using CDAI alone or with other criteria) and one study
30
 additionally 
reported endoscopic relapse (Rutgeerts score≥2).  See Table 10 and Table 11. 
 
Elemental nutrition vs. No intervention (i.e., unrestricted/free diet) 
Randomised controlled trials 
Our meta-analysis of two RCTs
50, 52
 indicated a significantly reduced risk of relapse amongst 
participants receiving elemental nutrition vs. no intervention at 12 to 24 months of follow-up (pooled 
RR=0.57, 95% CI: 0.38, 0.84; Chi
2
=0.04, p=0.83, I
2
=0%).  See Figure 4 and Table 10. 
 
Figure 4: Patients developing relapse/recurrence at 12 to 24 months: elemental nutrition vs. no 
intervention (unrestricted diet) 
 
 
Non-randomised controlled trials  
Findings from three trials consistently showed a significant benefit of elemental nutrition vs. no 
intervention in reducing risk of clinical (RR=0.50, 95% CI: 0.25, 0.98;
56
 RR=0.14, 95% CI: 0.02, 
1.00;
30
 and RR=0.38, 95% CI: 0.16, 0.87
57
) as well as endoscopic relapse (RR=0.42, 95% CI: 0.20, 
0.88)
30
 at 12 months post-baseline.  In one of the trials,
30
 the between-group difference in the risk of 
endoscopic relapse at 60 months follow-up was not statistically significant (RR=0.68, 95% CI: 0.42, 
1.11) [review conclusion: inconclusive].  See Table 11. 
 
In one trial,
56
 at 12 months post-baseline, the mean time (in months) to relapse in the elemental 
nutrition group was significantly longer compared to no intervention group (7.4 vs. 6.2, mean 
difference: 1.20, 95% CI: 0.35, 2.04).  See Table 12. 
 
Elemental nutrition vs. Drug 
Randomised controlled trials 
In one trial,
50
 the difference in the occurrence of relapse between participants receiving elemental 
nutrition and 6-MP after 24 months of follow-up was not statistically significant (RR=1.61, 95% CI: 
0.73, 3.53) [review conclusion: inconclusive].  See Table 10. 
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Non-randomised controlled trials  
Evidence not reported.
51
  See Table 11. 
 
Elemental nutrition vs. Elemental nutrition plus drug 
Randomised controlled trials 
No trial with these comparisons. 
 
Non-randomised controlled trials  
Evidence not reported.
51
  See Table 11. 
 
Elemental nutrition plus drug vs. Drug 
Randomised controlled trials 
No trial with these comparisons. 
 
Non-randomised controlled trials  
Of the two available trials with the above-mentioned comparisons,
51, 58
 only one reported this 
outcome.
58
 In this trial, the difference in the occurrence of relapse between participants receiving 
elemental nutrition plus infliximab vs. infliximab alone was not statistically significant (RR=0.65, 
95% CI: 0.27, 1.56) [review conclusion: inconclusive].  See Table 11. 
 
Elemental nutrition vs. Polymeric nutrition 
Randomised controlled trials 
In one trial,
55
 at 12 months of follow-up, the difference in the occurrence of relapse between 
participants receiving elemental and polymeric nutrition was not statistically significant (RR=1.18, 
95% CI: 0.48, 2.83) [review conclusion: inconclusive].  See Table 10. 
 
Non-randomised controlled trials  
No trial with these comparisons. 
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Table 10: Proportion of patients developing relapse/recurrence¥ (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo 9/26 (34.6) vs. 16/25 (64.0)
52
 
(relapse: CDAI plus other criteria) 
 
HR=0.40 (0.16, 0.98) 
adjusted estimate 
 
RR=0.54 (0.29, 0.99)
£
 
1 [low ROB] In favour of 
elemental 
nutrition group 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
 
24 mo 
 
 
 
24 mo 
Elemental nutrition vs. 6-MP 
12/32 (37.5) vs. 7/30 (23.3)
50
 
(relapse: CDAI plus other criteria) 
 
 
Elemental nutrition vs. NI 
12/32 (37.5) vs. 21/33 (63.6)
50
 
(relapse: CDAI plus other criteria) 
Elemental nutrition vs. 
6-MP 
RR=1.61 (0.73, 3.53)
£
 
 
 
Elemental nutrition vs. 
NI 
RR=0.58 (0.35, 0.98)
£
  
 
1 [low ROB] Inconclusive 
(elemental 
nutrition vs. 6-
MP) 
 
In favour of 
elemental 
nutrition group 
(vs. NI) 
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo 8/19 (42.1) vs. 5/14 (35.7)
55
  p=NR [NS]  
RR=1.18 (0.48, 2.83)
£
  
1 [high ROB] Inconclusive  
95% CI=95 percent confidence interval; CDAI=crohn’s disease activity index; HR=hazard ratio; mo=month(s); 
MP=mercaptopurine; NI=no intervention; NR=not reported; NS=statistically not significant; RCT=randomised controlled trial; 
RR=risk ratio (relative risk); SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
¥ Relapse defined using CDAI only unless specified otherwise (e.g., endoscopic, blood parameter, other criteria in addition
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Table 11: Proportion of patients developing relapse/recurrence¥ (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of non-RCTs  
[SROB across 
studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 7/21 (33.3) vs. 14/18 (77.7)
56
 
(relapse: CDAI plus other criteria) 
p<0.00001 [SS] 
RR=0.50 (0.25, 0.98)
£
 
1 [unclear 
ROB] 
In favour of 
elemental nutrition 
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
 
12 mo 
60 mo 
 
 
 
 
 
 
6 mo 
12 mo 
60 mo 
 
Clinical relapse (CDAI≥150/200) 
1/20 (5.0) vs. 7/20 (35.0)
30
 
6/20 (30.0) vs. 12/20 (60.0)
30
 
 
 
 
 
 
Endoscopic relapse (Rutgeerts score≥2)  
5/20 (25.0) vs. 8/20 (40.0)
30
 
6/20 (30.0) vs. 14/20 (70.0)
30
 
9/16 (56.2) vs. 14/17 (82.3)
30
 
 
 
 
 
 
 
 
Clinical relapse (12 mo) 
p=0.048 [SS] 
RR=0.14 (0.02, 1.00)
£
  
 
Clinical relapse (60 mo) 
p=0.11 [NS]  
RR=0.50 (0.23, 1.07)
£
 
 
Endoscopic relapse (6 mo)  
p=0.50 [NS]  
RR=0.62 (0.24, 1.58)
£
  
 
Endoscopic relapse (12 mo)  
p=0.027 [SS]  
RR=0.42 (0.20, 0.88)
£
  
 
Endoscopic relapse (60 mo)  
p=0.21 [NS]  
RR=0.68 (0.42, 1.11)
£
  
1 [high ROB] 
 
 
 
 
 
 
 
1 [low ROB] 
 
Clinical relapse 
In favour of 
elemental nutrition 
(at 12 mo) 
 
Inconclusive (at 60 
mo) 
 
Endoscopic relapse 
In favour of 
elemental nutrition 
(12 mo) 
 
Inconclusive (at 6 mo 
and 60 mo) 
12 mo 5/20 (25.0) vs. 13/20 (65.0)
57
 OR=0.20 (0.04, 0.70), 
p=0.03
£
 
RR=0.38 (0.16, 0.87)
£
  
1 [high ROB] 
  
In favour of 
elemental nutrition  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI (restricted 
diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] Inconclusive  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo 7/32 (21.8) vs. 8/24 (33.3)
58
 p=0.51 [NS] 
RR=0.65 (0.27, 1.56)
£
  
1 [high ROB] Inconclusive 
95% CI=95 percent confidence interval; CDAI=crohn’s disease activity index; mo=month(s); NA=not applicable; NI=no intervention; 
NR=not reported; NS=statistically not significant; RCT=randomised controlled trial; RR=risk ratio (relative risk); SROB=summary risk 
of bias; SS=statistically significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive; ** Decision was consensus-based 
£ Calculated; β Sulfasalazine (3g/d) or prednisolone (10mg/d) µ Infliximab (5 mg/kg) 
¥ Relapse defined using CDAI only unless specified otherwise (e.g., endoscopic, blood parameter, other criteria additionally)  
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Table 12: Time to relapse/recurrence (mean # of months) – Non-randomised controlled trials 
 
Follow-up 
 Arm-specific estimates  
Mean (SD or 95% CI)  
 
Difference  
(p value or 95% CI) 
 
# of non-RCTs  
[SROB across 
studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 7.4 (0.9) vs. 6.2 (0.4)
56
 p=NR  
MD=1.20 (0.35, 2.04), 
p=0.012
£
  
1 [unclear 
ROB] 
In favour of 
elemental nutrition 
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo NR
30
 NR 1 [NA] No evidence  
12 mo NR
57
 NR 1 [NA] No evidence  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 NR 1 [NA] No evidence  
95% CI=95 percent confidence interval; mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; 
RCT=randomised controlled trial; RR=risk ratio (relative risk); SD=standard deviation; SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)  
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4.4.3 Incidence of Mucosal Healing (Endoscopic Remission) 
Only one of the eight included trials (non-randomised study)
57
 reported this outcome, which was 
based on mucosal inflammation grade categorized as follows: 0=macroscopically normal, 1= granular 
mucosa and contact bleeding, 2= erythematous and oedematous mucosa, aphtoid or superficial ulcers, 
and 3=deep ulcers with slough and inflammatory pseudo polyps.  In this non-randomised study, at 12 
months of follow-up, the proportion of participants achieving grade 0 between elemental nutrition and 
no intervention (unrestricted diet) groups was not significantly different (RR=2.70, 95% CI: 0.62, 
11.72) [review conclusion: inconclusive].  See Table 13. 
 
Table 13: Proportion of patients with mucosal healing (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of non-RCTs  
[SROB across 
studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
56
 NR 1 [NA] No evidence 
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo  NR
30
 NR 1 [NA] No evidence 
12 mo 6/20 (30.0) vs. 2/18 (11.1)
57
  
(Grade 0: macroscopically normal) 
p=NR 
RR=2.70 (0.62, 11.72)
£
  
1 [low ROB] Inconclusive 
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI (restricted 
diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence 
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 NR 1 [NA] No evidence 
95% CI=95 percent confidence interval; mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; RCT=randomised 
controlled trial; RR=risk ratio (relative risk); SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)  
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4.4.4 Need for Surgery 
Three of the eight included trials reported this outcome: one RCT
50
 and two non-RCTs.
30, 57
  See Table 
14 and Table 15. 
 
Elemental nutrition vs. No intervention (i.e., unrestricted/free diet) 
Randomised controlled trials 
At 24 months follow-up,
50
 the proportion of participants in need of surgery was not statistically 
significantly different between the elemental nutrition and no intervention groups (RR=1.03, 95% CI: 
0.06, 15.79; Fisher’s exact test p>0.99) [review conclusion: inconclusive].  See Table 14. 
 
Non-randomised controlled trials  
In two trials,
30, 57
 at 12 to 60 months of follow-up, the difference in proportion of participants in need 
of surgery between the elemental nutrition and no intervention groups was not statistically significant 
(RR=0.20, 95% CI: 0.02, 1.56) [review conclusion: inconclusive].  See Table 15. 
 
Elemental nutrition vs. Drug 
Randomised controlled trials 
At 24 months follow-up,
50
 the difference in proportion of participants in need of surgery between the 
elemental nutrition and 6-MP groups was not statistically significant (RR=0.93, 95% CI: 0.06, 14.32; 
Fisher’s exact test p>0.99) [review conclusion: inconclusive].  See Table 14. 
 
Non-randomised controlled trials  
Evidence not reported.
51
  See Table 15. 
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Table 14: Proportion of patients in need of surgery (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
52
 NR 1 [NA] No evidence 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
 
24 mo 
 
 
 
 
24 mo 
Elemental nutrition vs. 6-MP 
1/32 (3.1) vs. 1/30 (3.1)
50
 
 
 
 
 
Elemental nutrition vs. NI  
1/32 (3.1) vs. 1/33 (3.0)
50
 
Elemental nutrition vs. 
6-MP 
p>0.99 [NS] Fisher’s 
exact test
£
 
RR=0.93 (0.06, 14.32)
£
 
 
Elemental nutrition vs. 
NI  
p>0.99 [NS] Fisher’s 
exact test
£
 
RR=1.03 (0.06, 15.79)
£
 
1 [low ROB]  
Inconclusive  
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo NR
55
  NR 1 [NA] No evidence 
95% CI=95 percent confidence interval; mo=month(s); MP=Mercaptopurine; NA=not applicable; NI=no intervention; NR=not 
reported; NS=statistically not significant; RCT=randomised controlled trial; RR=risk ratio (relative risk); ROB=summary risk 
of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
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Table 15: Proportion of patients in need of surgery (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
# of non-RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
56
 NR 1 [NA] Inconclusive  
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
60 mo 
 
1/20 (5.0) vs. 5/20 (25.0)
30
 p=0.18 [NS]  
RR=0.20 (0.02, 1.56)
£
 
 
2 [low ROB] 
 
Inconclusive 
 12 mo 0/20 (0.0) vs. 2/20 (10.0)
57
 p=NR 
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] Inconclusive  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 NR 1 [NA] No evidence 
RR=risk ratio (relative risk); SROB=summary risk of bias; SD=standard deviation; 95% CI=95 percent confidence interval; 
NR=not reported; mo=month(s); NA=not applicable; NI=no intervention 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg) 
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4.4.5 Adherence  
Seven of the eight included trials reported any information on adherence: two RCTs
52, 55
 and five non-
RCTs.
30, 51, 56-58
  See Table 16 and Table 17. 
 
Elemental nutrition vs. No intervention (i.e., unrestricted/free or restricted diet)  
Randomised controlled trials 
In one RCT,
52
 the difference in the rates of adherence at 12 months of follow-up between the groups 
of elemental nutrition and no intervention (unrestricted diet) was not statistically significant (77% vs. 
80%; RR=0.96, 95% CI: 0.72, 1.28) [review conclusion: inconclusive].  See Table 16. 
 
Non-randomised controlled trials  
The rate of adherence reported for two trials
30, 56
 was significantly lower in the elemental nutrition vs. 
no intervention group at 12 months (RR=0.81, 95% CI: 0.65, 0.99)
56
 and 60 months (RR=0.80, 95% 
CI: 0.64, 0.99)
30
 after the baseline.  For the remaining two trials comparing elemental nutrition to no 
intervention (unrestricted diet
57
 or restricted diet,
51
) the between group differences in adherence were 
not statistically significant at 12 months (90% vs. 100%, Fisher’s exact test p=0.48)57 and 48 months 
post-baseline (88% vs. 100%, Fisher’s exact test p>0.99)51 [review conclusion: inconclusive].  See 
Table 17. 
 
Elemental nutrition vs. Drug 
Randomised controlled trials 
No evidence reported.
50
 
 
Non-randomised controlled trials  
In one trial comparing elemental nutrition to sulfasalazine/prednisolone,
51
 the between group 
differences in adherence at 48 months post-baseline were not statistically significant (88% vs. 100%, 
Fisher’s exact test p=0.84) [review conclusion: inconclusive].  See Table 17. 
 
Elemental nutrition vs. Elemental nutrition plus drug 
Randomised controlled trials 
No trial with these comparisons 
 
Non-randomised controlled trials  
In one trial comparing the elemental nutrition to the combination of elemental nutrition and 
sulfasalazine/prednisolone,
51
 the between group differences in adherence at 48 months post-baseline 
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were not statistically significant (88% vs. 77.3%, Fisher’s exact test p=0.55) [review conclusion: 
inconclusive].  See Table 17. 
 
Elemental nutrition plus drug vs. Drug 
Randomised controlled trials 
No trial with these comparisons 
 
Non-randomised controlled trials  
In one trial comparing the combination of elemental nutrition and sulfasalazine/prednisolone to 
sulfasalazine/prednisolone alone,
51
 the between group differences in adherence at 48 months post-
baseline were not statistically significant (77.3% vs. 100%, Fisher’s exact test p=0.37).  Another trial 
comparing the combination of elemental nutrition and infliximab vs. infliximab alone
58
 reported 78% 
of adherence for the elemental nutrition group.  No data was reported for the infliximab group [review 
conclusion: inconclusive].  See Table 17. 
 
Elemental nutrition vs. Polymeric nutrition  
Randomised controlled trials 
The rate of adherence reported in one trial
55
 was significantly lower in the elemental nutrition vs. 
polymeric nutrition group at 12 months after the baseline (68.4% vs. 100%, RR=0.68, 95% CI: 0.50, 
0.92).  See Table 16. 
 
Non-randomised controlled trials  
No trial with these comparisons.
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Table 16: Proportion of patients with adherence (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo 20/26 (77.0) vs. 20/25 (80.0)
52
 RR=0.96 (0.72, 1.28)
£
  1 [low ROB] Inconclusive  
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
24 mo NR
50
 NR 1 [NA] No evidence 
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo 13/19 (68.4) vs. 14/14 (100.0)
55
 RR=0.68 (0.50, 0.92)
£
 1 [unclear ROB] In favour of 
polymeric 
nutrition group 
95% CI=95 percent confidence interval; MP=Mercaptopurine; NI=no intervention; NR=not reported; RCT=randomised 
controlled trial; RR=risk ratio (relative risk); SD=standard deviation; SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
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Table 17: Proportion of patients with adherence (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of non-RCTs  
[SROB across 
studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 17/21 (80.9) vs. 18/18 (100.0)
56
 p=NR  
RR=0.81 (0.65, 0.99)
£
 
1 [unclear 
ROB] 
In favour of NI group 
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
12 mo 
60 mo 
20/20 (100.0) vs. 20/20 (100.0)
30
 
16/20 (80.0) vs. 20/20 (100.0)
30
 
p=NR  
RR=0.80 (0.64, 0.99)
£ 
 
 
2 [low ROB]  
In favour of the NI (60 
mo) 
12 mo 18/20 (90.0) vs. 20/20 (100.0)
57
 p=0.48 Fisher’s exact test£ NS Inconclusive  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
48 mo 22/25 (88.0) vs. 17/22 (77.3) vs. 8/8 
(100.0) vs. 6/6 (100.0)
51
  
Fisher’s exact test£ 
p=0.55 [1 vs. 2] NS 
p=0.84 [1 vs. 3] NS 
p>0.99 [1 vs. 4] NS 
p=0.37 [2 vs. 3] NS 
p=0.53 [2 vs. 4] NS 
1 [low ROB] Inconclusive  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo 25/32 (78.1) vs. NR (NR)
58
 NR 1 [NA] No evidence  
95% CI=95 percent confidence interval; NA=not applicable; NI=no intervention; NR=not reported; NS=statistically not significant; 
RCT=randomised controlled trial; RR=risk ratio (relative risk); SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg) 
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4.4.6 Withdrawal from Steroids 
Two of the eight included trials (one RCT
55
 and one non-RCT
56
) reported the proportion of 
participants who withdrew from taking steroids.  Results from both trials showed statistically non-
significant differences in the withdrawals from steroids at 12 months post-baseline between the 
groups of elemental nutrition vs. polymeric nutrition (42.1% vs. 42.8%, RR=0.98, 95% CI: 0.44, 
2.19)
55
 or no intervention – unrestricted diet (23.8% vs. 22.2%, RR=1.07, 95% CI: 0.33, 3.39)56 
[review conclusion: inconclusive].  See Table 18 and Table 19. 
 
Table 18: Proportion of patients who withdrew from taking steroids (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
52
 NR 1 [NA] No evidence 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
24 mo NR
50
 NR 1 [NA] No evidence 
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo 8/19 (42.1) vs. 6/14 (42.8)
55
 p=NR [NS]  
RR=0.98 (0.44, 2.19)
£
 
1 [unclear ROB] Inconclusive  
95% CI=95 percent confidence interval; mo=month(s); MP=Mercaptopurine; NA=not applicable; NI=no intervention; NR=not 
reported; NS=statistically not significant; RR=risk ratio (relative risk); SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
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Table 19: Proportion of patients who withdrew from taking steroids (n/N) – Non-randomised controlled 
trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of non-RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 5/21 (23.8) vs. 4/18 (22.2)
56
 p=NR  
RR=1.07 (0.33, 3.39)
£
 
1 [unclear ROB] Inconclusive  
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo  NR
30
 NR 1 [NA] No evidence  
12 mo NR
57
 NR 1 [NA] No evidence  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 NR 1 [NA] No evidence  
95% CI=95 percent confidence interval;  mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; 
RCT=randomised controlled trial; SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)  
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4.4.7 Steroid Dose Tapering  
Only one trial (non-RCT) reported this outcome.
56
  At 12 months of follow-up, the difference in the 
proportion of participants whose steroid dose was tapered in those receiving elemental nutrition vs. no 
intervention (unrestricted diet) was not statistically significant (47.6% vs. 22.2%, RR=2.14, 95% CI: 
0.80, 5.67) [review conclusion: inconclusive].  See Table 20. 
 
Table 20: Proportion of patients whose steroid dose was tapered (n/N) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
# of non-RCTs  
[SROB across studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo 10/21 (47.6) vs. 4/18 (22.2)
56
 p=NR  
RR=2.14 (0.80, 5.67)
£
 
1 [unclear ROB] Inconclusive  
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo  NR
30
 NR 1 [NA] No evidence  
12 mo NR
57
 NR 1 [NA] No evidence  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence  
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 NR 1 [NA] No evidence  
95% CI=95 percent confidence interval;  mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; 
RCT=randomised controlled trial; SROB=summary risk of bias 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)
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4.4.8 Crohn’s Disease Activity Index 
Two non-RCTs
57, 58
 reported incomplete data on 12-14 month post-treatment mean CDAI score 
(missing study group-specific means and variability parameters) showing significantly lower mean 
disease activity in favour of the elemental nutrition vs. no intervention (unrestricted diet) group 
(p=0.04)
57
 and non-significant difference between the groups of elemental nutrition plus infliximab 
vs. infliximab alone (p>0.05)
58
 [review conclusion: inconclusive].  See Table 21. 
 
Table 21: Crohn’s Disease Activity Index (score: 0-600) – Non-randomised controlled trials 
 
Follow-up 
Arm-specific estimates 
Mean (SD or 95% CI) 
 
Difference 
(p value or 95% CI) 
 
# of non-RCTs 
[SROB across 
studies]** 
Treatment effect 
Conclusion* 
Elemental nutrition (unrestricted diet) vs. NI (unrestricted diet) 
12 mo NR
56
 NR 1 [NA] No evidence 
Elemental nutrition (restricted diet) vs. NI (unrestricted diet) 
6, 12, 60 mo NR
30
 NR 1 [NA] No evidence 
12 mo NR
57
 p=0.04 [SS] in favour 
of elemental nutrition 
group 
1 [high ROB] Inconclusive  
Elemental nutrition (restricted diet) vs. Elemental nutrition/Drug
β
 (restricted diet) vs. Drug (restricted diet) vs. NI 
(restricted diet) 
12, 24, 48 mo NR
51
 NR 1 [NA] No evidence 
Elemental nutrition/Drug
µ
 (restricted diet) vs. Drug
µ
 (unrestricted diet)   
14 mo NR
58
 p>0.05 [NS] 1 [high ROB] Inconclusive  
95% CI=95 percent confidence interval;  mo=month(s); NA=not applicable; NI=no intervention; NR=not reported; 
NS=statistically not significant; RCT=randomised controlled trial; SD=standard deviation; SROB=summary risk of bias; 
SS=statistically significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated   
β Sulfasalazine (3g/d) or prednisolone (10mg/d) 
µ Infliximab (5 mg/kg)
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4.4.9 Health Related Quality of Life 
Only one trial (RCT)
52
 reported any information on health related quality of life.  At 12 month of 
follow-up, the adjusted mean Inflammatory Bowel Disease Questionnaire (IBDQ) score did not differ 
between the participants receiving elemental nutrition vs. no intervention unrestricted diet (171.9 vs. 
176.7, p>0.05).  See Table 22. 
 
Table 22: Health-related quality of life (mean IBDQ score; score range: 32-224) – Randomised controlled 
trials 
 
Follow-up 
Arm-specific estimates  
Mean (SD or 95% CI) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB 
across 
studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo 171.9 (126.4, 217.3) vs. 176.7 (142.5, 211.0)
52
 Adjusted mean IBDQ 
score difference 
p>0.05 [NS]  
1 [high ROB] No difference 
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
24 mo NR
50
 NR 1 [NA] No evidence 
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo NR
55
 NR 1 [NA] No evidence 
95% CI=95 percent confidence interval;  mo=month(s); MP=mercaptopurine; NA=not applicable; NI=no intervention; NR=not 
reported; NS=statistically not significant; RCT=randomised controlled trial; SD=standard deviation; SROB=summary risk of 
bias; IBDQ= Inflammatory Bowel Disease Questionnaire 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
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4.4.10 Adverse Events and Complications 
For two RCTs reporting adverse events,
50, 52
 no meaningful comparison was possible, since the effect 
estimates could not be generated due to zero counts in the nominators [review conclusion: 
inconclusive].  For example, one trial reported the absence of adverse events.
52
  In the other trial,
50
 
none of the 32 participants in the elemental nutrition group experienced any adverse event or 
complication.  Of the 30 participants in the 6-MP group, two experienced elevated aspartate 
transaminase (AST), one participant- hair loss, and one participant – abscess (complication).  Of the 
33 participants in the no intervention group (unrestricted diet), one experienced elevated amylase. 
None of the participants in this group experienced any complication.  See Table 23 and Table 24. 
 
Table 23: Proportion of patients with adverse event(s) (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across 
studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo 0/26 (0.0) vs. 0/25 (0.0)
52
  1 [low ROB] Inconclusive  
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
24 mo Elemental nutrition vs. 6-MP 
0/32 (0.0) vs. 2/30 (6.6) [elevated 
AST] and 1/30 (3.1) [hair loss]
50
 
 
Elemental nutrition vs. NI 
0/32 (0.0) vs. 1/33 (3.0) [elevated 
amylase]
50
 
Elemental nutrition vs. 6-MP 
- 
 
 
Elemental nutrition vs. NI 
 
1 [low ROB] Inconclusive  
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo NR
55
 NR 1 [NA] No evidence 
95% CI=95 percent confidence interval; AST=aspartate transaminase;  mo=month(s); MP=mercaptopurine; NA=not applicable; 
NI=no intervention; NR=not reported; NS=statistically not significant; RCT=randomised controlled trial; SROB=summary risk 
of bias; SS=statistically significant  
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated  
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Table 24: Proportion of patients with complication(s) (n/N) – Randomised controlled trials 
 
Follow-up 
Arm-specific estimates  
n/N (%) 
Difference  
(p value or 95% CI) 
 
# of RCTs  
[SROB across 
studies]** 
Treatment 
effect 
Conclusion* 
Elemental nutrition (with unrestricted diet) vs. NI (unrestricted diet) 
12 mo 0/26 (0.0) vs. 0/25 (0.0)
52
  1 [low ROB] Inconclusive  
Elemental nutrition (with restricted diet) vs. 6-MP (with unrestricted diet) vs. NI (unrestricted diet) 
24 mo Elemental nutrition vs. 6-MP 
0/32 (0.0) vs. 1/30 (3.1) [abscess] 
50
 
 
Elemental nutrition vs. NI 
0/32 (0.0) vs. 0/33 (3.0)
50
 
Elemental nutrition vs. 6-MP 
 
 
Elemental nutrition vs. NI 
 
1 [low ROB] Inconclusive  
Elemental nutrition (with unrestricted diet) vs. Polymeric nutrition (with unrestricted diet) 
12 mo NR
55
  NR 1 [NA] No evidence 
95% CI=95 percent confidence interval; mo=month(s); MP=mercaptopurine; NA=not applicable; NI=no intervention; NR=not 
reported; NS=statistically not significant; RCT=randomised controlled trial; SROB=summary risk of bias; SS=statistically 
significant 
* Favours elemental nutrition (or comparator treatment), no difference, or inconclusive 
** Decision was consensus-based 
£ Calculated 
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4.4.11 Unreported Outcomes of Interest 
None of the eight included trials reported changes in anthropometric measures (e.g., weight, BMI, 
height, linear growth) and pubertal development.  
 
4.5 Cost-effectiveness of elemental diet 
This review did not identify any study assessing cost-effectiveness of elemental nutrition.  One RCT
52, 
54
 reported monthly costs for the two study groups of elemental nutrition and no intervention (i.e., free 
diet).  This study was not an economic evaluation; therefore no formal assessment of methodological 
quality of economic assessment was undertaken.  In addition there was not sufficient information on 
the cost data collection and analysis.  According to this study report,
54
 the adjusted one year monthly 
cost treatments were not significantly different between the elemental nutrition and free diet groups 
(US$ 880.00 vs. US$ 600.00, p>0.05).  See Cost Table in Appendix IV. 
 
4.6 Rating the overall quality of evidence (GRADE System) 
The overall quality ratings for each gradable outcome (i.e., maintenance of remission, risk of relapse, 
mucosal healing, need of surgery, withdrawal from steroids, steroid dose tapering, adherence, and 
adverse events) are presented in the Evidence Profile (EP) Table (see Table 25). 
 
The overall quality of evidence for each gradable outcome was rated for the comparison between 
elemental nutrition and no intervention, given that two RCTs
50, 52
 comparing elemental nutrition to no 
intervention (unrestricted diet) were judged to be the only potentially combinable evidence. 
 
The overall quality ratings across the gradable outcomes for the above-mentioned comparison were as 
follows: maintenance of remission (Grade: Very Low), risk of relapse (Grade: High), need of surgery 
(Grade: Very Low), adherence (Grade: Very Low), and adverse events (Grade: Moderate).  Mucosal 
healing, withdrawal from steroids, and steroid dose tapering were not rated due to the absence of 
evidence.
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Table 25: GRADE evidence profile for gradable outcomes reported in RCTs of Crohn’s disease 
 (adapted from Guyatt et al., 2011)
49
 
 
Outcome  
[follow-up timing]  
N of studies 
reporting 
outcome 
(participants) 
Pooled effect estimate 
(95% CI) and conclusion  
SROB 
across 
studies 
Consistency Directness Precision Outcome 
reporting 
bias 
Quality of the 
evidence 
(GRADE)* 
Elemental nutrition vs. NI (i.e., unrestricted/free diet) – 2 RCTs50, 52 
Maintenance of remission  
[12 mo] 
1 (65)
50
 No pooled estimate 
RR=1.37 (0.86, 2.17) 
Inconclusive 
High 
SROB 
NA Direct Imprecise Likely  Very low 
Maintenance of remission  
[24 mo] 
1 (65)
50
  No pooled estimate 
RR=2.06 (1.00, 4.43) 
In favour of elemental 
nutrition 
High 
SROB 
NA Direct Precise  Likely  Very low  
Development of 
relapse/recurrence 
[12 mo-24 mo] 
2 (116)
50, 52
 Pooled estimate 
RR=0.57 (0.38, 0.84) 
In favour of elemental 
nutrition  
Low 
SROB  
Consistent  Direct  Precise  Unlikely  High  
Mucosal healing  
[NA] 
0 (0) NA NA NA NA NA NA NA (no evidence) 
Need of surgery  
[24 mo] 
1 (65)
50
  No pooled estimate 
RR=1.03 (0.06, 15.79) 
Inconclusive  
Low 
SROB  
NA Direct Imprecise Likely  Very low  
Withdrawal from steroids  
[NA] 
0 (0) NA NA NA NA NA NA NA (no evidence) 
Steroid dose tapering  
[NA] 
0 (0) NA NA NA NA NA NA NA (no evidence) 
Adherence  
[12 mo] 
1 (51)
52
 No pooled estimate 
RR=0.96 (0.72, 1.28) 
Inconclusive 
Low 
SROB 
NA Direct Imprecise Likely  Very low  
Adverse events  
[12 mo-24 mo] 
2 (116)
50, 52
  No pooled estimate 
Parameters not estimable 
Inconclusive 
Low 
SROB 
Consistent  Direct  Imprecise Unlikely Moderate  
GRADE= Grading of Recommendations, Assessment, Development, and Evaluation; RCT=randomised controlled trial; CI=confidence interval; SROB=summary risk of bias; 
RCT=randomised controlled trial; NA=not applicable; mo(s)=month(s); NI=no intervention 
*GRADE categories: high, moderate, low, very low, NA (no evidence) 
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4.7 Summary of Findings  
Limited evidence from two RCTs in patients with CD in remission
50, 52
 has indicated a significant 
beneficial effect of elemental nutrition vs. no intervention (unrestricted diet) in maintaining remission 
after 24 months of follow-up (RR=2.06, 95% CI: 1.00, 4.43; very low grade evidence
50
) and 
preventing the occurrence of relapse at 12-24 months of follow-up (pooled RR=0.57, 95% CI: 0.38, 
0.84; high grade evidence
50, 52
).  The shorter-term maintenance rate of remission (at 6 and 12 months) 
between the two randomised groups was not significantly different (12 month RR=1.37, 95% CI: 
0.86, 2.17; very low grade evidence; inconclusive result due to wide 95% CIs).
50
 
 
Similarly, three non-RCTs also showed significant benefits of elemental nutrition over no intervention 
(unrestricted diet) in maintaining remission at 12-48 months
30, 57
 and preventing the occurrence of 
relapse at 12 months.
30, 56, 57
  Evidence on the maintenance of remission from two non-RCTs was 
rendered inconclusive due to wide non-significant 95% CIs (RR=2.14, 95% CI: 0.81, 5.67)
56
 and 
missing data (i.e., effect estimates and/or 95% CIs).
51
  In one non-RCT,
56
 the use of elemental 
nutrition was associated with a significantly longer time to relapse compared to no intervention after 
12 months of follow-up (MD=1.20, 95% CI: 0.35, 2.04). 
 
According to one non-RCT,
57
 the incidence of mucosal healing (endoscopic remission) at 12 months 
between patients receiving elemental nutrition vs. no intervention (unrestricted diet) was not 
significantly different (inconclusive results; RR=2.70, 95% CI: 0.62, 11.72).  
 
Based on evidence from two non-RCTs,
30, 56
 and one RCT,
55
 there was a significantly worse 
adherence rate in the elemental nutrition groups compared to either no intervention (unrestricted 
diet)
30, 56
 or polymeric nutrition group (RR=0.68, 95% CI: 0.50, 0.92).
55
 
 
In general, evidence comparing the effects of elemental nutrition and active treatment(s) 
(sulfasalazine/prednisolone, infliximab, elemental nutrition, polymeric nutrition, or combination) 
across the outcomes of interest yielded statistically non-significant results with wide 95% CIs 
implying possible moderate to large effect size treatment effects in both directions compatible both 
with benefit and harm from elemental nutrition (inconclusive results).  
 
Evidence on complications and adverse events was too sparse (e.g., zero events, low counts) to derive 
effect estimates and 95% CIs and permit any meaningful comparison between the treatments. 
 
There was no reported evidence on changes in anthropometric measures (e.g., body weight, height, 
BMI, linear growth rate) and pubertal development.  See Table 26. 
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Table 26: Summary of findings and overall quality ratings of evidence regarding the differences between 
elemental nutrition and other interventions for each reported outcome 
 
Conclusive evidence suggesting difference Conclusive evidence 
suggesting no 
difference 
Inconclusive evidence 
Maintenance of Remission (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
At 24 months  
1 RCT
50
 
[very low grade] 
In favour of elemental nutrition  
 
At 12-48 months  
2 non-RCTs
30, 57
 
In favour of elemental nutrition  
None  
 
 
At 6 and 12 months (NS)  
1 RCT
50
 
[very low grade]  
 
 
At 12 months (NS) 
1 non-RCT
56
 
 
At 48 months (SS=favoured elemental nutrition) 
1 non-RCT
51
 
Elemental Nutrition vs. Drug
50, 51
 
None  
 
 
None  
 
At 6, 12, 24 months (NS) 
1 RCT
50
 
 
At 48 months (SS=favoured elemental nutrition) 
1 non-RCT
51
 
Elemental Nutrition vs. Elemental Nutrition plus Drug
51
 
None  
 
None  At 48 months (NS) 
1 non-RCT
51
 
Elemental Nutrition plus Drug vs. Drug
51, 58
 
None  
 
None  At 14 months (NS) 
1 non-RCT
58
 
 
At 48 months (SS=favoured elemental nutrition 
plus drug) 
1 non-RCT
51
 
Elemental Nutrition vs. Polymeric Nutrition
55
 
None  
 
None  At 12 months (NS) 
1 RCT
55
 
Risk of Relapse/Recurrence (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
At 12-24 months None  At 60 months (NS) 
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2 RCTs
50, 52
 
[high grade] – pooled estimate 
In favour of elemental nutrition  
 
At 12 months 
3 non-RCTs
30, 56, 57
 
In favour of elemental nutrition  
1 non-RCT
30
 
Elemental Nutrition vs. Drug
50, 51
 
None None At 24 months (NS) 
1 RCT
50
 
Elemental Nutrition plus Drug vs. Drug
51, 58
 
None None At 14 months (NS) 
1 non-RCT
58
 
Elemental Nutrition vs. Polymeric Nutrition
55
 
None None At 12 months (NS) 
1 RCT
55
  
Time To Relapse (# of months) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
At 12 months  
1 non-RCT
56
 
In favour of elemental nutrition 
None None 
Mucosal Healing (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None None At 12 months (NS) 
1 non-RCT
57
 
Need for Surgery (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None None At 24 months (NS) 
1 RCT
50
 
[very low grade]  
 
At 12 and 60 months (NS) 
2 non-RCTs
30, 57
 
Elemental Nutrition vs. Drug
50, 51
 
None None At 24 months (NS) 
1 RCT
50
 
Adherence (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
At 12 and 60 months  None At 12 months (NS) 
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2 non-RCTs
30, 56
 
In favour of no intervention 
1 RCT
52
 
[very low grade]  
 
At 12 and 48 months (NS) 
2 non-RCTs
51, 57
 
Elemental Nutrition vs. Drug
50, 51
 
None None  At 48 months (NS) 
1 non-RCT
51
 
Elemental Nutrition vs. Elemental Nutrition plus Drug
51
 
None None  At 48 months (NS) 
1 non-RCT
51
 
Elemental Nutrition plus Drug vs. Drug
51, 58
 
None None  At 48 months (NS) 
1 non-RCT
51
 
Elemental Nutrition vs. Polymeric Nutrition
55
 
At 12 months  
1 RCT
55
 
In favour of polymeric nutrition 
None None  
Withdrawal from Steroids (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None None  At 12 months (NS) 
1 non-RCT
56
 
Elemental Nutrition vs. Polymeric Nutrition
55
 
None None  At 12 months (NS) 
1 RCT
55
 
Steroid Dose Tapering (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None None  At 12 months (NS) 
1 non-RCT
56
 
Health Related Quality of Life (mean IBDQ score) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None At 12 months (NS) 
1 RCT
52
  
In no favour of either 
intervention 
None 
Adverse Events and Complications (n/N) 
Elemental Nutrition vs. No Intervention
30, 50-52, 56, 57
 
None None  At 12 and 24 months (estimates could not be 
generated) 
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2 RCTs
50, 52
  
[moderate grade] 
Elemental Nutrition vs. Drug
50, 51
 
None None  At 24 months (estimate could not be generated) 
1 RCT
50
  
NS=statistically not significant; RCT=randomised controlled trial; SS=statistically significant 
 
4.8 Other Analyses  
4.8.1 Publication bias 
The impact of publication bias on the pooled treatment effect estimates (i.e., degree of funnel plot 
asymmetry) could not be explored due to an insufficient number of data points in the forest/funnel 
plots. 
 
4.8.2 Subgroup effects 
The reviewed evidence was too sparse and heterogeneous to allow exploration of whether or not the 
relative effect of elemental nutrition differed by study-level methodological (i.e., risk of bias, type of 
data analysis) or patient-related characteristics (i.e., age, sex, or induction therapy). 
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5 DISCUSSION  
CD is a chronic relapsing-remitting condition that causes chronic inflammation of the gastrointestinal 
tract.  The clinical presentation of CD is often characterised by malnutrition, abdominal pain, diarrhoea, 
and weight loss.
33
  Despite the availability of a variety of therapeutic options used in the management of 
CD (medications, surgical, or nutritional), none of these options lead to complete cure of this condition. 
32
  
The main objective of any given management option is to induce and then maintain remission of disease 
activity by controlling the extent of inflammation, reducing clinical symptoms, and preventing 
complications.  Although corticosteroids are the most widely used drugs for the treatment of active CD, 
their use has been shown to be associated with short-term remission, steroid dependency, impairment in 
growth, and risk of infections.
33
  
 
For the past two decades, nutritional therapy/enteral nutrition has been suggested as an effective treatment 
option in the management of CD in adults and children in terms of controlling CD activity.
31, 37
  For 
example, one meta-analysis indicated that enteral nutrition was at least as effective as steroids in inducing 
remission in children and young adults with active CD.
36
  In contrast, a more recent review demonstrated 
that enteral nutrition given to adults was in general beneficial but less effective in inducing remission 
compared to steroids.
27
  There has been little clarity as regards to the role of enteral nutrition for 
maintaining remission in patients with quiescent CD.  The relevant evidence has been scarce, mostly of 
observational nature, and inconsistent in terms of findings.
33, 37
  Owing to its good safety profile, and if 
proved at least as effective as standard medical treatments, enteral nutrition would potentially replace or 
minimise the use of steroids, biologics, immunosuppressants.  This in turn would lead to improved 
clinical outcomes, fewer adverse events, in general, and better growth rates and pubertal development in 
younger patients with CD.
35, 37
 
 
The mechanism of action of elemental nutrition on CD is not known. Several hypothesised mechanisms 
underlying the proposed benefits of enteral nutrition in CD include reduced gut activity, reduction of 
antigenic load, nutritional effects, anti-inflammatory effects, or modulation of immune system and 
gastrointestinal flora.
30-33
  
 
5.1 Main findings 
This review systematically identified, appraised, and synthesised relevant evidence on the comparative 
clinical effectiveness of elemental nutrition for maintaining remission in patients with CD.  Limited 
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evidence from two RCTs
50, 52
 and three non-RCTs
30, 56, 57
 has suggested that elemental nutrition (given 
orally or via feeding tube) was more effective for the maintenance of remission (at 12-48 months; very 
low grade evidence based on RCTs) and prevention of relapse (at 12-24 months; high grade evidence 
based on RCTs) compared to no treatment (i.e., unrestricted diet).  Evidence from one non-RCT also 
indicated that patients receiving elemental nutrition experienced longer mean time to relapse compared to 
patients in the no intervention group on unrestricted diet only.
56
  The 12-month rates of adherence were 
lower in the elemental nutrition vs. no intervention (i.e., unrestricted diet)
30, 56
 or polymeric nutrition 
group.
55
  This finding may be explained by the inconvenience of nasogastric feeding, poor palatability, 
and/or higher cost of elemental nutrition compared to unrestricted diet and polymeric nutrition.
31, 61
  
Limited evidence from one RCT
52
 demonstrated no difference in health related quality of life between 
elemental nutrition and no intervention (unrestricted diet). 
 
In general, comparisons of elemental nutrition to active treatments (sulfasalazine/prednisolone, 
infliximab, elemental nutrition, polymeric nutrition, or combination) across the outcomes of interest were 
not statistically significant.  These results should not be interpreted to mean that the treatments being 
compared are equivalent (or that there is an absence of effect of elemental nutrition).  The associated 95% 
CIs tended to be so wide and uninformative as to include potential moderate to large treatment effects 
compatible with both benefit and harm of elemental nutrition.  Therefore, these results are inconclusive.  
 
The data on complications and adverse events was too sparse (e.g., zero events, low counts) to derive 
effect estimates and 95% CIs or to permit any meaningful comparison between the treatments.  It is 
unclear whether insufficient evidence on adverse events and complications is due to the absence or rarity 
of these events or it is simply due to underreporting of such events. 
 
For some reported evidence (e.g., cumulative probability of survival for being in remission) adequate 
interpretation was not possible due to poor reporting or missing data (no summary effect measures, 95% 
CIs, standard deviations), and therefore was considered inconclusive. 
 
5.2 Limitations of evidence 
The review findings warrant cautious interpretation given the limitations of the evidence in terms of small 
trial size, methodological quality, and risk of bias in individual trials (lack of blinding, short duration of 
follow-up, confounding). 
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For example, the lack of blinding of participants, study personnel, and/or outcome assessors may have led 
to systematic differences in care giving, administration of co-interventions, and outcome assessments 
across the compared treatment groups.  Generally, subjective measures such as those based on patient-
reported outcomes including clinical symptoms (e.g., abdominal pain, number of soft stools), quality of 
life, or clinically defined remission/relapse) are more prone to bias than objective outcomes (e.g., 
endoscopic or biologically defined remission using serum/faecal biomarkers and radiography additional 
to CDAI, adverse events, and complications). 
 
Some of the results, especially in non-RCTs, may have been biased since some known or unknown 
prognostic factors may have been distributed unevenly between the treatment groups.  As for the known 
confounders, there was some between-group imbalance in two non-RCTs with regards to induction 
therapy, location of the lesion, and disease duration.
51, 56
  Moreover, in three non-RCTs
30, 57, 58
 patients 
with ‘good compliance’ were assigned to elemental nutrition and those with ‘poor compliance’ to the 
control groups.  Given that ‘good compliers’ may be inherently different from ‘poor compliers’ in clinical 
characteristics, this selective assignment could have distorted the group balance in some of these 
prognostic covariates (unclear risk of bias).  Additional concern for confounding effects is justified since 
in some of the studies the use of concomitant drugs given for prophylaxis (e.g., 5-ASA, sulphasalazine, 
azathioprine, prednisolone) differed across the treatment groups in frequency/dose.
30, 50, 52, 55, 56, 58
 
 
In general, more or less consistent results for primary outcomes observed between RCTs and non-RCTs 
give more credence to the validity of findings in this review. 
 
Additional limitations of the relevant evidence are worth mentioning.  There was a lack of evidence of 
effects of elemental nutrition in young adolescents and children with CD in remission.  The data reported 
on health related quality of life, adverse events, and complications were insufficient to allow any adequate 
conclusion.  There was no relevant evidence for changes in anthropometric measures (weight, BMI, 
height, linear growth) and pubertal development.  Given that all of the included studies evaluated 
elemental nutrition in addition to restricted or unrestricted diet, this review was unable to assess the 
effectiveness of an exclusive elemental nutrition in the maintenance of remission in patients with CD. 
 
5.3 Comparison of current findings to previous systematic reviews 
We identified two SRs evaluating comparative effectiveness of elemental nutrition in maintaining 
remission for patients with CD.
32, 37
  The Cochrane review’s eligibility criterion for design was set to 
91 
 
RCTs (included two RCTs).
32
  The study eligibility for the other SR was wider and encompassed RCTs, 
prospective non-randomised controlled trials, and retrospective observational cohort studies (included one 
RCT, three non-RCTs, and six retrospective cohort studies).
37
  All potentially eligible trials included in 
the two SRs, were also included in the present review.  In general, findings of this review are in 
agreement with those from other two SRs in showing benefits of elemental nutrition compared to no 
intervention (i.e., unrestricted diet) in maintaining remission amongst patients with CD.  In agreement 
with our review, findings in relation to the comparison between elemental and polymeric nutrition were 
inconclusive.
32
 
 
5.4 Strengths and limitations of current review 
One of the strengths of this review is that we used systematic, comprehensive, and independent strategies 
to minimise bias in searching, identifying, selecting, extracting, and appraising the primary studies.  The 
search strategy was applied to multiple electronic sources, relevant websites, as well as reference lists of 
potentially eligible publications were searched.  Moreover, this review included a higher hierarchy of 
evidence (i.e., randomised and non-randomised controlled trials). 
 
This review has its own limitations.  The presence of clinical heterogeneity (e.g., population 
characteristics, induction therapy), potential for confounding (especially in non-RCTs), and poor 
reporting (missing data on outcomes) led to limitations for pooling the results across studies.  Since this 
review included only English language full text publications, the effects of publication bias cannot be 
ruled out.  Given the insufficient number of pooled studies (data points), this effect could not be 
investigated via funnel plots.  Likewise, the paucity of data did not allow exploration of whether there 
was any variation in treatment effect across the pre-defined subgroups of patients or methodological 
features of studies. 
 
5.5 Applicability of findings and implications for clinical practice and policy 
making 
It is not usually easy to determine the extent to which studies are applicable to a broader context of 
routine clinical practice in a given geographical place and this is true in this case for extrapolating to the 
UK for a number of reasons.  This process of ascertaining applicability is hindered by poor reporting, 
selective eligibility criteria and enrolment, non-participation and differences between treatments and 
outcomes used in research versus those used in routine clinical practice.  Specifically, the extent of 
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applicability of this review’s findings to clinical practice in the UK may be limited, since six of the eight 
included studies were conducted in Japan,
30, 50-52, 57, 58
 and only two in the UK.
55, 56
  The trials reviewed 
may have been overly selective in enrolling and assigning patients to treatments, thereby leading to 
samples that are not representative of patients with CD in remission encountered in daily clinical practice. 
Patient adherence is important for successful treatment with elemental nutrition.  However, if studies have 
reported the effects of elemental nutrition in only good compliers, this will also limit the applicability of 
findings to a broader group of patients.  Since all included studies investigated adult patients, the 
conclusions regarding the benefits of elemental nutrition in maintaining remission of CD may not be 
readily applicable to younger patients (< 18 years old).  Most results were based on outcomes ascertained 
at 12-24 months of follow-up.  The conclusions of the review regarding longer-term benefits 
indeterminate and cannot be extrapolated.  Finally, our findings may not be readily applicable to patients 
receiving exclusive elemental nutrition, since the evidence available to us and which we reviewed 
presented only those scenarios where elemental nutrition was given in addition to diet.  In summary we 
would counsel caution in attempting to extrapolate the findings of this review to practice in the UK and 
would recommend that further research is required – please see research recommendations.  
 
5.6 Implications for future research 
Large well-powered and long-term randomised trials are needed to either refute or corroborate our 
findings.  Future research needs to address gaps in the reviewed evidence (e.g., studies in young 
adolescents and children with CD in remission; effects of exclusive elemental nutrition; effects of 
elemental nutrition in subgroups defined by age, sex, duration/location of CD, and type of induction 
therapy) and improve reporting practices in relation to trial methodology (e.g., methods of treatment 
assignment, blinding, power analysis, statistical analysis) as well as completeness of reported data 
(missing effect estimates, 95% CIs, adverse events, complications) for better interpretability of evidence. 
More research exploring better tasting elemental nutritional to maximise the adherence rate to elemental 
nutrition feeding is also warranted.  
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6 CONCLUSIONS 
This systematic review assessed comparative clinical effectiveness of elemental nutrition for the 
maintenance of remission in patients with CD based on evidence from eight prospective controlled 
studies.  Overall, the findings warrant cautious interpretation given the limited amount of evidence (small 
number of studies), methodological shortcomings (short-term follow-up, small studies), poor reporting 
(missing data, partial reporting of data), and role of bias which cannot be ruled out (adherence to 
elemental nutrition, confounding, lack of blinding).  Given these caveats, the results from five studies 
indicated significant benefits of elemental nutrition (given orally or via feeding tube) in maintaining 
remission and preventing relapse compared to no intervention (i.e., unrestricted diet) at 12 to 48 months 
of follow-up.  A limited amount of evidence showed greater patient adherence rates for unrestricted or 
polymeric nutrition groups compared to an elemental nutrition group at 12 months follow-up.  According 
to evidence from one trial, there was no difference in health related quality of life between patients 
receiving an elemental vs. an unrestricted diet after 12 months of follow-up.  In general, effect estimates 
for most outcomes across comparisons between elemental nutrition and active treatments (e.g., 
prednisolone) were statistically non-significant accompanied by a great degree of uncertainty (very wide 
95% CIs) and therefore were rendered inconclusive.  There was a lack or insufficient evidence on adverse 
events and complications and no evidence on cost effectiveness.  There was no similar evidence reported 
for children or younger patients with CD in remission.  Future large and long-term randomised trials are 
warranted to draw more definitive conclusions regarding the effects of elemental nutrition in maintaining 
remission in CD.  
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3. Plain English Summary 
 
Crohn's disease (CD) is a chronic relapsing-remitting condition that causes inflammation of the intestines. 
Frequent symptoms of CD include malnutrition, abdominal pain, and diarrhoea.  None of the currently 
available therapeutic options (e.g., medical, surgical, nutritional) lead to a complete cure of CD.  The 
management involves induction and maintenance of remission of disease activity through alleviating 
inflammatory process and correcting malnutrition.  In children, a major additional goal is to promote 
normal growth and pubertal development.  Although there is some evidence indicating beneficial effects 
of elemental diet for induction of remission in patients with active CD, clinical evidence regarding the 
role of elemental diet in maintaining remission in CD has not been well studied or clarified.  This 
systematic review aims to evaluate recent comparative evidence on clinical effectiveness and cost-
effectiveness of elemental diet for the maintenance of remission in patients with CD.  
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4.  Decision problem 
Objectives 
The general objective of this systematic review is to identify, appraise, and evaluate the evidence on 
clinical effectiveness and cost-effectiveness of elemental diet, a type of enteral nutrition (EN), for the 
maintenance of remission in Crohn’s disease (CD).  
 To evaluate the clinical effectiveness and cost-effectiveness of elemental nutrition administered 
alone or in combination with other interventions (e.g., diet, standard drug treatment) compared to 
other intervention(s) (e.g., placebo, diet, standard drug treatment) for maintaining remission in 
patients with CD. 
 To compare the clinical effectiveness and cost-effectiveness of elemental nutrition with other 
types of EN (semi-elemental, polymeric nutrition), duration, and dose in regards to maintaining 
remission and adherence. 
 To explore subgroup effects of elemental nutrition on maintenance of remission (i.e., risk of 
relapse or recurrence).  Specifically, to examine if the treatment effect of elemental nutrition 
varies across groups defined by sex (males, females), age (adults, adolescents, and children), and 
type of induction therapy (medically-, nutritionally-, surgically-induced).  
 To evaluate additional outcomes for patients with CD such as adherence to EN, CD activity index 
(CDAI), incidence of mucosal healing, quality of life, adverse events, gain in body weight (or 
body mass index), growth, and pubertal development.  
 
4.1 Background 
Crohn's disease (CD), a form of inflammatory bowel disease (IBD), is a chronic relapsing-remitting 
condition which causes chronic inflammation of the intestines. CD can affect any part of the digestive 
tract, from the mouth to the anus.
1
  The most frequent symptoms of CD include malnutrition, abdominal 
pain, diarrhoea, weight loss, fever, and rectal bleeding.  Although currently there are medical (e.g., 
corticosteroids, biologics, aminosalicylates, immunosuppressants, tumor necrosis factor inhibitors, 
antibiotics), endoscopic/surgical (indicated for complications such as bowel obstruction, high grade 
dysplasia, abscess, internal fistulas, and cancer), and nutritional (e.g., enteral feeding, restricted diet, 
parenteral feeding) therapeutic options available to patients with CD, none of them leads to complete cure 
of this condition.
1,2
  Therefore, the management of the disease usually involves the induction and 
maintenance of remission of disease activity by controlling the extent of inflammatory process, correcting 
malnutrition, as well as reducing symptom presentation and occurrence of complications.
2,3
  In children, a 
major additional goal is to facilitate normal growth and pubertal development which are frequently 
impeded.  
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The choice of therapeutic options depends largely on the extent of inflammation, the disease severity, and 
complications.  Any therapeutic recommendation needs to consider a balance between individual 
response in terms of beneficial effects, treatment-related adverse events, and long term complications.
2,3
 
Corticosteroids are most widely used agents for the management of active CD.  However, their use is 
associated with high risk of relapse, low rates of mucosal healing, steroid dependency, and other adverse 
events (e.g., growth impairment, infections).  There have been safety concerns with long term use of other 
agents such as tumor necrosis factor (TNF) inhibitors.
1
 
 
Nutritional therapy has played an important but controversial role in the alleviation of malnutrition and 
control of disease activity in patients with active CD.  There is some evidence on clinical benefits and 
long term safety of EN in inducing remission in patients, especially children and young adults with active 
CD.
4,5
  For example, in Japan, EN is recommended as the first-line treatment in the management of active 
CD.
1,6
 Although EN has been shown to be an effective and safe intervention for induction of remission in 
patients with active CD, withdrawal of EN and resumption of normal diet would often be followed by 
reoccurrence of gastrointestinal symptoms and use of corticosteroids.
7
  Evidence comparing clinical 
effectiveness of EN to corticosteroids for the induction of remission has been inconsistent, with one meta-
analysis showing no difference between the two,
5
 and more recent meta-analysis indicating a superiority 
of corticosteroids over EN.
8
  
 
Equally important evidence on the efficacy of different types of EN (i.e., elemental, semi-elemental, 
polymeric) in maintaining remission in CD has been insufficient and less clear.
1,6,7,9
  If EN proves to be at 
least as effective as conventional medications, its use might minimize or replace the use of steroids, 
biologics, and immunosuppresants.
1,6,7
 
 
Most evidence on the comparative clinical effectiveness of EN in the maintenance of CD remission rests 
upon retrospective observational cohort studies and prospective non-randomised controlled experimental 
trials.
1,6,9
  The similar evidence from RCTs is insufficient due to difficulties with consent and adherence 
of patients assigned to EN.
7,10-12
  In general, retrospective observational cohort studies pose difficulties in 
establishing causality due to their methodological limitations.
6
  For example, given the retrospective 
nature of such studies, temporality between the occurrence of exposure and outcome is unclear or 
indeterminate.  Furthermore, since retrospective studies utilize the patient data that had been collected for 
other purposes than the question of interest, these studies may not be able to adjust the effect estimates of 
elemental nutrition for many important confounders (e.g., disease activity, smoking, age, adherence, co-
morbidities, nutritional status) since such data had not been collected. 
104 
 
In order to bring more clarity to this area, this review aimed to evaluate evidence on clinical effectiveness 
and cost-effectiveness of elemental diet (a type of enteral nutrition) for the maintenance of remission in 
CD.  Given the above-mentioned limitations of retrospective observational cohort studies in establishing 
causality, this review will focus on higher hierarchy of evidence by including only prospective studies, 
i.e., randomised and non-randomised controlled clinical trials. 
 
4.2 Report methods for synthesis of evidence 
Search strategy 
Scoping searches have been undertaken to inform the development of the search strategy and assess the 
volume and type of literature relating to the assessment question.  We used an iterative procedure with 
input from clinical advisors and previous systematic reviews.
6,7,13
  The yield of 324 records from the 
search developed for MEDLINE, before any limits were applied or any sifting was undertaken, 
demonstrated that there is limited evidence in this area (see Appendix 1). 
 
A copy of the main database search strategy that is likely to be used in the major databases is provided in 
the Appendix 1.  This draft search strategy, developed for MEDLINE, will be adapted as appropriate for 
other databases and will include the concepts of CD, remission and elemental nutrition.  This strategy will 
not include limits for study design, language or publication date, as the number of articles to sift identified 
in the scoping search is not anticipated to be high. 
 
The overall search strategy will comprise the following main elements: 
 Searching of electronic bibliographic databases and trial registries 
 Supplementary searching (including scrutiny of references of included studies, citation searching, 
searching relevant websites) 
 Contact with clinical advisors in the field 
 
Databases will include: 
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE (via OVID); CDSR, 
CENTRAL, DARE, NHS EED, HTA database (via the Cochrane Library); Science Citation Index and 
Conference Proceedings (via Web of Knowledge); WHO ICTRP; UKCRN Study Portfolio. 
 
Citation searches of included studies will be undertaken using the Web of Science citation search facility. 
The reference lists of included studies and relevant review articles will also be checked.  Clinical advisors 
in the field will be consulted and websites of relevant organisations checked. 
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Two supplementary database searches using limits will be undertaken.  The first, combining CD with the 
concept of nutrition therapy and limited to systematic reviews or cost-effectiveness, will aim to capture 
any articles that include the assessment question as part of a broader systematic review or cost study.  The 
second, combining CD with the concept of elemental nutrition and limited to relevant study types, will 
aim to capture any articles that include our population as part of a controlled clinical trial of both active 
CD and CD in remission. 
 
All retrieved records will be collected in a specialised database.  All duplicate records will be identified 
and removed.   
 
Study eligibility criteria 
Inclusion criteria: 
Type/language of publication 
English full text and abstracts (only if companion publications to full text included studies) 
 
Study design  
RCTs and prospective non-randomised controlled clinical trials  
 
Population  
Adults, young people, or children with CD in remission (inactive, quiescent CD) at the time of study 
baseline 
 
Intervention 
 Elemental nutrition via oral passage, nasal passage (naso-gastric tube, naso-jejunal tube, naso-
duodenal tube), or direct passage via the abdomen (gastrostomy tube, jejunostomy tube) alone  
 Elemental nutrition in combination with other intervention(s) (e.g., standard drug therapy, 
restricted diet) 
 
Comparator  
 Enteral nutrition (elemental, semi-elemental or polymeric nutrition) alone, normal unrestricted 
diet alone (i.e., no intervention), restricted diet alone, standard drug therapy alone, any other 
intervention or placebo.  
 Enteral nutrition (elemental, semi-elemental or polymeric nutrition) in combination with other 
intervention(s) (e.g., standard drug therapy, restricted diet, any other intervention or placebo ) 
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 Any combination of standard drug therapy, restricted diet, any other intervention, and/or placebo 
 
Exclusion criteria:  
a) Induction studies (patients with active CD at baseline) with or without follow up of remitted 
patients receiving maintenance therapy 
b) Studies of parenteral (intravenous) nutrition 
c) Studies of ulcerative colitis 
d) Reviews, meta-analyses, case-reports, case-series, retrospective observational studies, editorials, 
comments 
e) Studies employing non-concurrent (e.g., historical) controls 
f) Studies with mixed patient population (< 80% Crohn’s disease) 
g) Studies comparing different nutrition/diets of elemental nutrition  
 
Outcomes – clinical effectiveness  
Adult populations 
a) Maintenance of remission (% patients in remission at end of follow-up, cumulative probability of 
maintaining remission [Kaplan Meier estimate of survival], duration of remission) – primary 
outcome 
b) Development of relapse/recurrence (proportion of patients developing relapse/recurrence [n/N], 
time to relapse/recurrence [mean # of months]) – primary outcome 
c) Incidence of mucosal healing – primary outcome 
d) Need for surgery (n/N) 
e) Withdrawal from steroids (n/N) 
f) Steroid dose tapering (n/N) 
g) CDAI (measured as continuous or categorical outcome)  
h) Quality of life (QOL) 
i) Adverse events (treatment-related) 
j) Complications of CD 
k) Gain in body weight or body mass index 
l) Adherence 
 
Younger populations (e.g., adolescents, paediatric) 
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a) Maintenance of remission (% patients in remission at end of follow-up, cumulative probability of 
maintaining remission [Kaplan Meier estimate of survival], duration of remission) – primary 
outcome 
b) Development of relapse/recurrence (proportion of patients developing relapse/recurrence [n/N], 
time to relapse/recurrence [mean # of months]) – primary outcome 
c) Incidence of mucosal healing – primary outcome 
d) Need for surgery (n/N) 
e) Withdrawal from steroids (n/N) 
f) Steroid dose tapering (n/N) 
g) CDAI (measured as continuous or categorical outcome)  
h) Quality of life (QOL) 
i) Adverse events (treatment-related) 
j) Complications of CD 
k) Gain in body weight or body mass index 
l) Adherence 
m) Growth  
n) Pubertal development  
 
Outcomes – cost-effectiveness  
a) Costs (no efficacy measures: cost-minimization analysis) 
b) Costs and efficacy measures - clinical and quality-adjusted life years (full economic analysis) 
c) Incremental cost-effectiveness ratios (full economic analysis) 
d) Results from cost-effectiveness acceptability curves 
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Study selection strategy 
Two independent reviewers will screen all identified bibliographic records for title/abstract and then for 
full text using a pre-specified and piloted questionnaire form.  The study flow and reasons for exclusion 
of full text papers will be documented in the PRISMA study flow diagram (Appendix 2).
14
  
 
Data extraction strategy 
Two reviewers will independently extract relevant data using an a priori defined pre-piloted extraction 
sheet (Appendix 3).  The extracted data will be cross-checked and any disagreements will be resolved by 
discussion or by recourse to a third party reviewer.  The extracted data will include study (e.g., author, 
country, design, sample size, follow-up duration, risk of bias items), participant (e.g., age, sex, 
inclusion/exclusion criteria, CD activity index, clinical/endoscopy definitions of CD remission, type of 
induction therapy), intervention/comparator (brand name/manufacturer of EN; type, mode, duration, and 
dose of administration of EN, any concomitant diet or dietary restriction, and other co-intervention such 
as medications), and outcome characteristics (e.g., scale of measurement, timing of assessment, definition 
of CD relapse/recurrence).  
 
For individual studies, the dichotomous and continuous summary clinical effectiveness outcome measures 
of association will be summarized as risk/odds ratio, mean difference, and measures of variability (p-
value, 95% confidence interval).  If needed and data allows, we will attempt to calculate missing 
statistical parameters (e.g., risk ratios, mean differences, standard deviations, standard errors, and 95% 
confidence intervals) for primary clinical outcomes of interest (e.g., risk of relapse, time to relapse, 
quality of life, weight gain, CD activity index).  All calculated parameters will be entered into the data 
extraction sheets and will be marked as ‘calculated’. 
 
Individual study quality assessment strategy 
Two reviewers will independently assess the methodological and reporting quality of included individual 
studies.  Any disagreements between the two reviewers will be resolved by a third reviewer through a 
discussion. 
 
RCTs will be assessed using the Cochrane Collaboration Risk of Bias (ROB) tool
15
 which covers the 
following domains of threat to internal validity: selection bias (randomisation sequence generation, 
treatment allocation concealment), performance bias (blinding of participants/personnel), detection bias 
(blinding of outcome assessors), attrition bias (incomplete outcome data – primary outcome), reporting 
bias (selective outcome/analysis reporting), and other pre-specified bias (e.g., funding source, adequacy 
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of statistical methods used, type of analysis, baseline between-group imbalance in important prognostic 
factors).  The risk of bias assessment falls into three categories of high, low, and unclear risk of bias.  The 
assessments will be provided in ROB tables and summary graph (Appendix 4).  Prospective non-
randomised controlled clinical trials (CCTs) will be assessed using a modified Cochrane ROB tool in 
which the domain of selection bias will be evaluated in regards to baseline between-group imbalance for 
important prognostic factors instead of randomisation sequence generation and treatment allocation 
concealment (Appendix 5).  For each study (RCT or non-RCT), the risk of performance, detection, and 
attrition bias domains for subjective (e.g., patient-administered clinical or quality of life scores) and 
objective (e.g., presence of remission, relapse/recurrence, time to relapse, weight gain, mucosal healing, 
growth, adverse events) outcomes will be assessed separately.  Afterwards, within-study summary ROB 
rating across all domains will be derived for subjective and objective outcome groups separately 
(Appendix 6).  At data synthesis stage, across-study average summary ROB will be determined and 
assigned to each outcome of interest. 
 
The quality of economic analyses of the included studies will be assessed using the Drummond 10-item 
checklist (Appendix 7).
16
 
 
Data analysis and synthesis 
Study, treatment, population, and outcome characteristics will be summarised in text, evidence, and 
summary tables.  The study results on the relative effectiveness of EN for each outcome of interest and 
cost-effectiveness will be compared qualitatively and quantitatively in text and summary tables. 
 
In the clinical effectiveness part of the review, results for any given outcome measures will be presented 
separately stratified by a) induction therapy (medically-, nutritionally-, surgically-induced remission), b) 
age (adult vs. paediatric), and c) regimen (elemental, semi-elemental, polymeric nutrition, dose, mode of 
administration).  
 
The decision to pool individual study results will be based on a degree of similarity with respect to 
methodological and clinical characteristics of studies under consideration (e.g., design, population, 
comparator treatment, and outcome).  Estimates of post-treatment mean difference for continuous 
outcomes and RRs for binary outcomes (except for rare events) of individual studies will be pooled using 
a DerSimonian and Laird random-effects model.
17
  Dichotomous outcomes with low event rates (5.0%-
10.0%) will be pooled as RR using a Mantel-Haenszel fixed-effects model.  Dichotomous outcomes for 
studies with very low event rates (≤ 5.0%) or zero events in one of the treatment arms were pooled as 
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odds ratio (OR) using a Peto fixed-effects model.
18
  Trials will not be pooled if the mean and/or standard 
deviation for the continuous outcome of interest cannot not be ascertained. 
 
The degree of statistical heterogeneity across pooled studies will be determined through inspection of the 
forest plots, Cochran’s Q and the I2 statistics.  The heterogeneity will be judged according to pre-
determined levels of statistical significance (Chi-square p < 0.10 and/or I
2
> 50%).  If data allows, study-
level clinical and methodological sources of heterogeneity of effect estimates across studies will be 
explored through a priori defined subgroup analysis (i.e., age, sex, induction therapy) and sensitivity 
analysis (risk of bias item-specific ratings, intention-to-treat vs. per protocol analysis). 
 
Given a sufficient number of data points, publication bias will be assessed through visual inspection of 
funnel plots with respect to plot asymmetry and use of linear regression tests.
19
 
 
Overall quality of evidence (GRADE system) 
The overall quality of evidence for pre-selected gradable outcome (risk of CD relapse/recurrence) across 
studies will be assessed using the systematic approach developed by the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) Working Group 
(http://www.gradeworkinggroup.org).  
 
The GRADE approach
20
 indicates level of confidence in the observed treatment effect estimate(s) and is 
based on assessments across five domains: a) summary ROB across studies per gradable outcome 
(internal validity across studies; study limitations), b) consistency of results (heterogeneity), c) directness 
of the evidence (applicability of the results), d) precision of the results (the width of 95% CI around the 
estimate), and e) publication/reporting bias (detection of asymmetry in the funnel plot; selective outcome 
reporting).  The overall quality of evidence is categorized as high, moderate, low, or very low grade. 
Initial grade of RCTs will be rated as high and will be downgraded by one point (e.g., from high to 
moderate) if any of the five criteria is not met. Initial grade for non-RCTs will be rated as low and will be 
upgraded by one point (e.g., from low to moderate) if any of the three criteria for upgrading a grade is met 
(e.g., dose-response gradient, large magnitude of effect, and adjustment for confounders).
21
  The process 
of assessment of overall quality of evidence grading will be provided in Appendix 8.  
 
4.3 Results section  
The review results will be organised in text and tables (evidence and summary tables).  The summary 
tables will tabulate characteristics, methodological quality, and results for included primary studies. 
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Tables for primary studies will present summary data on participants (age, gender, number/range of 
participants), interventions (enteral diet, comparator), outcomes (e.g., type, summary effect measures, 
95% CIs, timing), and settings (e.g., primary care, specialty clinic).  Meta-analyses of primary studies will 
be presented in forest plots accompanied by measures of heterogeneity.  If pooling is not feasible, due to 
the lack of sufficient data or important clinical/statistical heterogeneity across studies, the findings from 
individual studies will be summarised narratively.  Evidence for each outcome of remission maintenance 
from one or more studies (either un-pooled or pooled) will be summarised and graded accordingly, and 
presented in a tabular form. 
 
4.4 Discussion section 
This section will cover the interpretation and validity of the findings of the review in light of available 
evidence and the review methodology.  We will highlight and discuss strengths and limitations of the 
review and their likely influence on the effect estimates.  The stability of treatment effect measures will 
be explored and discussed. Future research implications of the review findings will also be discussed. 
Identified gaps/inconsistencies in the current knowledge (e.g., heterogeneity, lack or insufficiency of 
evidence) and methodological limitations of the reviewed evidence (e.g., study design, risk of bias in 
primary studies, short term follow-up, inadequate sample size, outcome measurement methods) will be 
highlighted and corresponding recommendations for future research directed at mitigation of these 
limitations will be outlined.  Where possible, the recommendations will be of sufficient detail and clarity 
to form the basis of a future commissioning brief (e.g., PICO and suggested study type). 
 
Unlike most of the previously published reviews, this review will employ a systematic approach by 
focusing only on higher level hierarchy of evidence (randomised and non-randomised controlled clinical 
trials) with the purpose of elucidating the role of enteral diet in the maintenance of CD compared to other 
treatments.  Moreover, it will provide an updated evidence base on this topic and will be better equipped 
in determining comparative clinical and cost-effectiveness of enteral diet for the maintenance of 
remission in CD.  
 
We anticipate that this review will better inform researchers, clinicians, and policy makers in deriving 
more robust recommendations for appropriate treatment choices in the maintenance of CD, and serve as 
an impetus towards improved conduct, methodology, and reporting of future studies in this area. 
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5. Expertise in this TAR team 
Warwick Evidence is a technology assessment group located within Warwick Medical School. Warwick 
Evidence brings together experts in clinical and cost effectiveness reviewing, medical statistics, health 
economics and modelling. The team planned for the work includes: Dr Paul Sutcliffe, Dr Alexander 
Tsertsvadze and Dr Tara Gurung, who are experienced systematic reviewers; Mrs Rachel Court, 
information specialist; Ruth Pulikottil-Jacob, provides modelling and health economic expertise; 
Professor Aileen Clarke, Dr Ngianga-Bakwin Kandala provide epidemiological and statistical expertise; 
Dr Ramesh Arasaradnam, University Hospital, Coventry, and Professor Simon Murch, University of 
Warwick, will provide clinical advice. 
 
6. Competing interests of authors and advisors 
None of the authors have any competing interests. 
 
7. Timetable/milestones 
Draft protocol finalised    TBC 
Commissioning decision   TBC 
Anticipated start date    1 October 2013 
Progress report     15 November 2013 
Final assessment report    11 January 2014 
 
8. Team members’ contributions 
Research team:  Warwick Evidence 
Lead:   Dr Paul Sutcliffe 
Title:  Associate Professor 
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 574505 
Email:  p.a.sutcliffe@warwick.ac.uk 
Contribution: Co-ordinate review process, protocol development, assessment for eligibility,   
  quality assessment of trials, data extraction, data entry, data analysis, and report   
  writing 
 
Name:  Dr Alexander Tsertsvadze 
Title:  Senior Research Fellow 
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Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 574505 
Email:  a_tsertsvadze@hotmail.com 
Contribution: Co-ordinate review process, protocol development, assessment for eligibility,   
  quality assessment of trials, data extraction, data entry, data analysis, and report   
  writing  
 
Name:  Ms Rachel Court 
Title:  Information Specialist 
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 522427 
Email:  R.A.Court@warwick.ac.uk 
Contribution: Protocol development, develop search strategy and undertake the electronic literature  
  searches 
 
Name:  Ms Ruth Pulikottil-Jacobs 
Title:  Research Fellow Health Economics  
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 151902 
Email:  R.Jacob@warwick.ac.uk 
Contribution: Health economics modeller, assessment for eligibility and data extraction  
 
Name:  Dr Tara Gurung 
Title:  Research Fellow 
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health 
Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 150711 
Email:  t.gurung@warwick.ac.uk 
Contribution: Protocol development, assessment for eligibility, quality assessment of trials, data 
extraction, data entry, data analysis, and report writing 
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Name:  Dr Ngianga-Bakwin Kandala 
Title:  Principal Research Fellow 
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 575054 
Email:  N-B.Kandala@warwick.ac.uk 
Contribution: Data entry, data analysis, and statistical modeller 
 
Name:  Professor Aileen Clarke 
Title:  Director of Warwick Evidence 
Address: Warwick Evidence, Populations, Evidence and Technologies, Division of Health   
  Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL 
Tel:   02476 150189 
Email:  Aileen.Clarke@warwick.ac.uk 
Contribution: Co-ordinate review process, protocol development, data analysis, synthesis of findings 
and report writing 
 
9. Clinical Advisors 
1) Dr Ramesh Arasaradnam: Gastroenterology, University Hospital, Coventry. His clinical and research 
interests are in gut physiology, nutrition, inflammatory and cancer biology. 
 
2) Professor Simon Murch: Professor of Paediatrics, Warwick Medical School, Coventry. His research 
background is in mucosal immunology, and his early work was based on the role of macrophage 
cytokines in intestinal and lung inflammation.  This work contributed to the introduction of anti-TNF 
therapy in Crohn's disease, and also provided the first demonstration of the role of inflammatory 
cytokines in lung disease affecting preterm infants. 
 
Contribution of above clinical advisors include: protocol development, help interpret data, provide a 
methodological, policy and clinical perspective on data and review development of background 
information and clinical effectiveness and review of report drafts.  
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Appendices 
Appendix 1. Draft search strategy details 
Ovid MEDLINE(R) 1946 to May Week 5 2013, searched on 13 June 2013 
1 Crohn Disease/ 29507 
2 Inflammatory Bowel Diseases/ 12777 
3 crohn*.tw. 29987 
4 Inflammatory bowel disease*.tw. 23863 
5 IBD.tw. 10207 
6 1 or 2 or 3 or 4 or 5 53451 
7 remission*.tw. 83291 
8 inactiv*.tw. 227468 
9 quiescen*.tw. 20271 
10 disease-free survival/ 41204 
11 relaps*.tw. 111733 
12 recurr*.tw. 348455 
13 maintenance.tw. 175893 
14 7 or 8 or 9 or 10 or 11 or 12 or 13 923305 
15 6 and 14 8307 
16 ((enteral or elemental or chemically defined) and (nutrition* or diet* or 
feed*)).tw. 
13181 
17 Enteral Nutrition/ 15194 
18 Food, Formulated/ 5229 
19 16 or 17 or 18 24823 
20 15 and 19 324 
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Appendix 2. PRISMA study flow diagram 
 
  # of records identified 
through database searching 
# of additional records 
identified through other sources 
# of records after duplicates removed 
# of records screened # of records excluded at 
title and abstract level 
# of full‐text articles 
assessed for eligibility 
Full-text articles 
excluded, with reasons 
# of studies included in 
quantitative synthesis 
(meta‐analysis) 
# of studies included in 
qualitative synthesis 
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Appendix 3. Data extraction sheet for included primary study reports 
 
Name of first reviewer:  
Name of second reviewer:  
Study details 
First author surname year of publication:  
Country:  
Study design: 
Study setting (primary care/specialty clinic/other - specify):  
Number of centres:  
Total length of follow up:  
Funding (government/private/manufacturer/other - specify):  
Aim of the study 
Participants 
Recruitment dates:  
Total N of patients who received induction therapy:  
Total N of patients achieving remission after induction therapy:  
Total N of patients failing to achieve remission after induction therapy:  
Total N of patients excluded before start of maintenance therapy (e.g., lost to follow up): 
Total number of patients allocated to maintenance treatment:  
Inclusion criteria:  
Exclusion criteria: 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years):  
Women (n [%]):  
Race/ethnicity (n [%]):  
Diagnostic criteria for CD:  
Mean Crohn’s Disease Activity Index (CDAI) (range or SD):  
CD location:  
Type of induction therapy (n [%]): 
Intervention 
Elemental diet group:  
Intervention 2 group:  
Intervention 3 group:  
Outcomes (study-based) 
Primary outcomes (list):  
Measure of disease activity (clinical, endoscopic): 
Definition of remission (clinical, endoscopic): 
Definition of relapse/recurrence (clinical, endoscopic): 
Definition of mucosal healing (clinical, endoscopic):  
Post-baseline timings of primary outcome assessment:  
Number of patients 
 Total Elemental 
diet group 
Intervention 2 group Intervention 3 group 
Allocated to 
treatment 
    
Analysed  
(If more than one 
follow-up, choose 
and specify the last 
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one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose 
and specify the last 
one) 
    
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of 
administration) 
Diet Co-intervention 
Elemental diet group   
Intervention 2 group    
Intervention 3 group   
Patient baseline characteristics  
 Elemental diet group Intervention 2 group Intervention 3 
group 
Age (years) 
Mean (SD)  
   
Sex –female n/N 
(%) 
   
Weight (kg)  
Mean (SD)  
   
BMI (kg/m
2
) 
Mean (SD) 
   
Smoking n/N (%)     
Previous bowel 
resection n/N (%) 
   
Duration of CD 
(months)  
Mean (SD) 
   
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
   
Crohn’s Disease 
Endoscopic Index 
of Severity 
(CDEIS) 
Mean (SD) 
   
Disease activity 
other than CDAI 
(specify) 
   
Mucosal ulceration 
n/N (%) 
    
Other 
complications n/N 
(%) 
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Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-procedural follow-up assessment timing (Specify):  
 Elemental diet 
group 
Intervention 2 
group 
Intervention 3 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N 
(%)  
    
Duration of 
remission (months)  
Mean (SD) or 95% 
CI 
    
Risk of relapse or 
recurrence n/N (%) 
    
Time to relapse 
(months)  
Mean (SD) or 95% 
CI 
    
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% 
CI) 
    
Patients achieving 
mucosal healing 
n/N (%) 
    
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
    
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
    
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
    
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
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Other HQOL 
(specify) Mean (SD)  
95% CI 
     
Weight (kg)  
Mean (SD)  
95% CI 
    
Weight gain (kg)  
Mean change (SD)  
95% CI 
    
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
    
Height gain (cm) 
Mean (SD)  
95% CI 
    
Linear growth rate 
(mean height-for-
age Z-score)  
     
Adherence n/N (%)     
Need for surgery 
n/N (%) 
    
Steroid dose 
tapering n/N (%) 
    
Withdrawal from 
steroids n/N (%) 
    
Adverse events due 
to treatment n/N 
(%) 
    
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental diet 
group 
Intervention 2 
group 
Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
    
Delay in pubertal 
development 
 n/N (%) 
    
Bowel obstruction     
Fistulae      
Abscess      
Colon/bowel 
cancer 
    
Intestinal infection     
Others (Specify)      
Authors conclusion 
Reviewer’s conclusion 
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* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from 
baseline; or between mean final end-point values) 
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Appendix 4. The risk of bias assessment of included randomised controlled trials (adapted from 
Higgins et al. 2011)
15
 
 
Name of first reviewer:  
Name of second reviewer:  
First author surname year of publication:  
Bias 
domain 
Source of bias Support for 
judgment
*
 
Authors’ 
judgment
**
 
Selection 
bias 
Random sequence generation   
Allocation concealment   
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported)   
Objective (e.g., radiography, 
endoscopy) 
  
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported)   
Objective (e.g., radiography, 
endoscopy) 
  
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
  
Objective outcomes (e.g., 
radiography, endoscopy) 
  
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
  
Other bias 
Funding source, adequacy of statistical methods 
used, type of analysis [ITT/PP], baseline imbalance 
in important characteristics 
  
ITT=intention to treat; PP=per protocol; NA=not applicable; ROB=risk of bias 
 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Appendix 5. The risk of bias assessment of included non-randomised controlled trials (adapted 
from Higgins et al. 2011)
15
  
 
Name of first reviewer:  
Name of second reviewer:  
First author surname year of publication:  
Bias 
domain 
Source of bias Support for 
judgment
*
 
Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, 
duration of CD, location of CD, complications 
during induction therapy, type of induction 
therapy, pre-study compliance, co-intervention, 
and/or smoking)  
  
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported)   
Objective (e.g., radiography, 
endoscopy) 
  
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported)   
Objective (e.g., radiography, 
endoscopy) 
  
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
  
Objective outcomes (e.g., 
radiography, endoscopy) 
  
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
  
Other bias 
Funding source, adequacy of statistical methods 
used, type of analysis [ITT/PP] 
  
ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; 
ROB=risk of bias 
 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Appendix 6. Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission 
(e.g., CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides 
clinical), occurrence of relapse/recurrence (includes 
additional objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective 
parameters besides clinical), mucosal healing (endoscopic 
remission), weight gain, linear growth rate, complications, 
adverse events, adherence 
 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias 
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Appendix 7. Methodological quality of economic evaluations in included studies (The Drummond Checklist
16
) 
 
 
 
Item#* 
Study #1 Study #2 Study #3 Study #4 Study #5 Study #6 Study #7 Proportion 
of studies 
with ‘Yes’ 
(%) 
Item 1         
Item 2         
Item 3         
Item 4         
Item 5         
Item 6         
Item 7         
Item 8         
Item 9         
Item 10         
 
*Responses to items: Yes, No, Can’t Tell 
 
Item 1: Was a well-defined question posed in answerable form?  
Item 2: Was a comprehensive description of the competing alternatives given?  
Item 3: Was the effectiveness of the programmes or services established? 
Item 4: Were all the important and relevant costs and consequences for each alternative identified?  
Item 5: Were costs and consequences measured accurately in appropriate physical units (e.g. number of physician visits, lost work-days, gained 
life-years)?  
Item 6: Were costs and consequences valued credibly? 
Item 7: Were costs and consequences adjusted for differential timing? 
Item 8: Was an incremental analysis of costs and consequences of alternatives performed? 
Item 9: Was allowance made for uncertainty in the estimates of costs and consequences?  
Item 10: Did the presentation and discussion of study results include all issues of concern to users?  
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Appendix 8. GRADE evidence profile for gradable outcomes (adapted from Guyatt et al., 2011
20
) 
 
 
Outcome  
[follow-up timing]  
N of studies 
reporting 
outcome 
(participants) 
Pooled effect estimate 
 [95% CI] and 
conclusion  
SROB 
across 
studies 
Consistency Directness Precision Outcome 
reporting 
bias 
Quality of the 
evidence 
(GRADE)* 
Treatment 1 vs. Treatment 2 (n studies) 
Outcome 1          
Outcome 2          
Outcome 3          
Outcome 4          
Treatment 1 vs. Treatment 3 (n studies) 
Outcome 1          
Outcome 2          
Outcome 3          
Outcome 4          
GRADE= Grading of Recommendations, Assessment, Development, and Evaluation; CI=confidence interval; SROB=summary risk of bias; NA=not applicable 
*GRADE categories: high, moderate, low, very low, NA (no evidence)
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8.2 Appendix II: Search strategies 
 
Ovid MEDLINE 1946 to August 2013 (searched on 29/08/2013) 
1.  Crohn Disease/  
2. Inflammatory Bowel Diseases/  
3.  crohn*.tw.  
4. Inflammatory bowel disease*.tw.  
5.  1 or 2 or 3 or 4  
6. ((Enteral or elemental or chemically defined) and (Nutrition$ or diet$ or therap$ or feed$ or 
formula$)).tw.  
7. Enteral Nutrition/  
8.  Food, Formulated/  
9.  6 or 7 or 8  
10.  (remission* or inactiv* or quiescen* or relaps* or recurr* or maintenan*).tw  
11. disease-free survival/  
12.  10 or 11  
13. 5 and 9 and 12  
14.  limit 13 to english language  
 
EMBASE 1947 to August 2013 (searched on 29/08/2013)  
1. Crohn disease/  
2. crohn*.tw.  
3. Inflammatory bowel disease*.tw.  
4. 1 or 2 or 3  
5. ((Enteral or elemental or chemically defined) and (nutrition$ or diet$ or therap$ or feed$ or 
formula$)).tw.  
6. enteric feeding/  
7. elemental diet/  
8. 5 or 6 or 7  
9. (remission* or inactiv* or quiescen* or relaps* or recurr* or maintenan*).tw.  
10. disease free survival/  
11. 9 or 10  
12. 4 and 8 and 11  
13. limit 12 to english language  
 
Ovid MEDLINE In-Process & Other Non-Indexed Citations August 2013 (searched on 
29/08/2013 
1. crohn*.tw.  
2. Inflammatory bowel disease*.tw.  
3. 1 or 2  
4. ((Enteral or elemental or chemically defined) and (Nutrition$ or diet$ or therap$ or feed$ or 
formula$)).tw.  
5. Enteral Nutrition.tw.  
6. Food, Formulated.tw.  
7. 4 or 5 or 6  
8. (remission* or inactiv* or quiescen* or relaps* or recurr* or maintenan*).tw.  
9. disease-free survival.tw.  
10. 8 or 9  
11. 3 and 7 and 10  
12. limit 11 to english language
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Science Citation Index and Conference Proceedings via the Web of Science (searched on 
29/08/2013) 
Topic= (crohn*  or Inflammatory bowel disease or Crohn Disease) and (Enteral or elemental or chemically 
defined or Nutrition* or diet* or therap* or feed* or formula* or Enteral Nutrition or  Food, Formulated) and 
(remission* or inactiv* or quiescen* or relaps* or recurr* or maintenan* or disease-free survival) 
 
Cochrane Library, searched on 04/09/13 
#1 MeSH descriptor: [Crohn Disease] this term only  
#2 MeSH descriptor: [Inflammatory Bowel Diseases] this term only  
#3 (crohn*):ti,ab,kw  
#4 (Inflammatory bowel disease*):ti,ab,kw   
#5 (#1 or #2 or #3 or #4)   
#6 (#1 or #2)   
#7 ((Enteral or elemental or chemically defined) and (Nutrition$ or diet$ or therap$ or feed$ or 
formula$)):ti,ab,kw   
#8 MeSH descriptor: [Enteral Nutrition] this term only  
#9 MeSH descriptor: [Food, Formulated] this term only  
#10 (#7 or #8 or #9)   
#11 (remission* or inactiv* or quiescen* or relaps* or recurr* or maintenan*):ti,ab,kw   
#12 MeSH descriptor: [Disease-Free Survival] this term only  
#13 (#11 or #12)   
#14 (#5 and #10 and #13)  
 
All Results (61) 
Cochrane Reviews (4) 
All 
Review 
Protocol 
Other Reviews (5) 
Trials (52) 
Methods Studies (0) 
Technology Assessments (0) 
Economic Evaluations (0) 
Cochrane Groups (0) 
 
Trial database 
 
WHO ICTRP, searched on 20/09/20138 
 
8 records for 8 trials found for: crohn* and element* 
3 records for 3 trials found for: inflammatory bowel disease* and element* 
13 records for 12 trials found for: crohn* and enteral* 
2 records for 2 trials found for: inflammatory bowel disease* and enteral* 
Total: 25 
Total after duplicates removed: 21 
Total after initial sifting by RC: 3 
Total after check by AT and TG: 0 
 
UKCRN Study Portfolio 
 
Topic: All  
 
AND 
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Research summary:  inflammatory bowel diseases elemental (All terms) 
OR 
Research summary:  inflammatory bowel disease elemental (All terms) 
OR 
Research summary:  inflammatory bowel diseases enteral (All terms) 
OR 
Research summary:  inflammatory bowel disease enteral (All terms) 
OR 
Research summary:  crohn elemental (All terms) 
OR 
Research summary:  crohn enteral (All terms) 
OR 
Research summary:  crohn’s elemental (All terms) 
OR 
Research summary:  crohn’s enteral (All terms) 
 
 
Total: 1 
Total after sifting by RC: 0  
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8.3 Appendix III: Full data extraction of included primary study reports 
 
RCTs 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Hanai 2012
50
 
Country: Japan 
Study design: RCT 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: one 
Total length of follow up: 24 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To evaluate the efficacy of elemental nutrition versus 6-mercaptopurine as maintenance therapy in Crohn’s disease 
Participants 
Recruitment dates: NR 
Total N of patients who received induction therapy: NR 
Total N of patients achieving remission after induction therapy: 105 
Total N of patients unable to achieve remission after induction therapy: NR 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): 10 
Total number of patients allocated to maintenance treatment: 95 
Inclusion criteria: age ≥18 years who achieved remission (CDAI < 150) within 30 days of entry to this trial  
Exclusion criteria: patients with abdominal abscess, stricture (B1 of Vienna and Montreal classification), pregnant 
women, patients with cardiovascular disorders and history of intolerance to 6-MP  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean range 29.8-32.5 
Women (n [%]): 25/95 [26.3] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: NR 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): mean range 89.9-103.4 
CD location (n [%]): Ilio-colic type (59/95 [62.2]), Ileal type (27/95 [28.4]), Colic type (8/95 [8.4]) 
Type of induction therapy (e.g., medical, surgical): parenteral nutrition (70/95 [73.7]), central venous feeding (25/95 
[26.3]), prednisolone (9/95 [9.5]), infliximab (4/95 [4.2]), 6-MP (14/95 [14.7]) 
Previous surgery (n [%]): 19/95 [20.0] 
Intervention 
Elemental nutrition group: elemental nutrition 
Intervention 2 group: 6-mercaptopurine (MP) 
Intervention 3 group: no intervention 
Outcomes (study-based) 
Primary outcomes (list): remission maintenance rate, risk of relapse 
Measure of disease activity (clinical, endoscopic): CDAI score 
Definition of remission (clinical, endoscopic): CDAI < 150 
Definition of relapse/recurrence (clinical, endoscopic): clinical (CDAI ≥200 or the need for an additional medication 
to suppress worsening symptoms) 
Definition of mucosal healing (clinical, endoscopic): NR  
Post-baseline timings of primary outcome assessment: 6, 12, 18, 24 mo 
Number of patients 
 Total Elemental 
nutrition 
group 
6-MP group No intervention 
group 
Allocated to 
treatment 
95 32 30 33 
Analysed (specify 
ITT and/or per 
protocol) 
 
95 
(ITT) 
32 30 33 
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(If more than one 
follow-up, choose and 
specify the last one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose and 
specify the last one) 
11 5 2 4 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of administration) 
Diet Co-intervention 
Elemental nutrition 
group 
Elental (Ajinomoto, Tokyo) at ≥900 kcal/day, 
taken via self-inserted feeding tube (2 pts) or 
by oral intake (32 pts).  
 
Restricted diet: patients were allowed an 
intake of 3.5–4.0 kcal/kg/day from food as 
recommended by a qualified dietician. 
 
Duration: 24 mo 
5-aminosalicylic acid (n=NR; 5-ASA, 2250–
3000 mg/day) 
 
Sulphasalazine 
(n=NR; 3000 mg/day) 
 
Duration: 24 mo 
6-MP group Starting dose 20 mg/day (weight<45 kg) 
starting dose 30 mg/day (weight ≥45 kg) 
 
Within 8–12 weeks of the initial dosing, if 6-
TGN level ≤200 pmol/8×108 RBC, the dose 
of 6-MP could be increased by 10mg 
increments up to a maximum of 80 mg/day.  
 
When 6-TGN level reached 450 pmol/8×10
8
 
RBC, but the patient had not responded, a 5 
mg/day increase could be made and the 
patient was monitored every 2 weeks for 
efficacy and toxicity or until white blood cell 
count (WBC) started to decrease. 
5-aminosalicylic acid (n=NR; 5-ASA, 2250–
3000 mg/day) 
 
Sulphasalazine 
(n=NR; 3000 mg/day) 
 
Duration: 24 mo 
No intervention group - 5-aminosalicylic acid (n=NR; 5-ASA, 2250–
3000 mg/day) 
 
Sulphasalazine 
(n=NR; 3000 mg/day) 
 
Duration: 24 mo 
Patient baseline characteristics  
 Elemental nutrition 
group 
6-MP group No intervention group 
Age (years) 
Mean (SD)  
30.1 (7.7)  32.5 (8.9) 29.8 (10.3) 
Sex –female n/N (%) 10/32 (31.2) 7/30 (23.3) 8/33 (24.2) 
Weight (kg)  
Mean (SD)  
NR NR NR 
BMI (kg/m
2
) 
Mean (SD) 
NR NR NR 
Smoking n/N (%)  18/32 (56.2) 15/30 (50.0) 18/33 (54.5) 
Previous bowel 
resection n/N (%) 
NR NR NR 
Duration of CD 
(months)  
Mean (SD) 
73.2 (69.6)  67.2 (80.4) 58.8 (75.6) 
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Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
103.4 (21.4)  93.2 (27.8) 89.9 (30.1) 
Crohn’s Disease 
Endoscopic Index of 
Severity (CDEIS) 
Mean (SD) 
NR NR NR 
Disease activity other 
than CDAI (specify) 
NR NR NR 
Mucosal ulceration 
n/N (%) 
NR NR NR 
Other complications 
n/N (%) 
NR NR NR 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 6, 12, 18, 24 mo 
 Elemental nutrition 
group 
6-MP group No intervention 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining in 
remission n/N (%)  
27/32 (84.4) at 6 mo 
20/32 (62.5) at 12 mo 
14/32 (46.9) at 24 mo 
24/30 (80.0) at 6 mo 
20/30 (66.7) at 12 
mo 
17/30 (56.7) at 24 
mo 
23/33 (69.6) at 6 mo 
15/33 (45.5) at 12 mo 
7/33 (21.2) at 24 mo 
(1 vs. 2) 
RR=1.05 (0.83, 1.33) 
at 6 mo; calculated  
 
RR=0.93 (0.64, 1.35) 
at 12 mo; calculated 
 
RR=0.77 (0.46, 1.27) 
at 24 mo; calculated 
 
(1 vs. 3) 
RR=1.21 (0.92, 1.58) 
at 6 mo; calculated 
 
RR=1.37 (0.86, 2.17) 
at 12 mo; calculated 
 
RR=2.06 (1.00, 4.43) 
at 24 mo; calculated  
Duration of 
remission (months)  
Mean (SD) or 95% CI 
NR NR NR NA 
Risk of relapse or 
recurrence n/N (%) 
12/32 (37.5) at 24 mo 7/30 (23.3) at 24 mo 21/33 (63.6) at 24 mo (1 vs. 2) 
RR=1.61 (0.73, 3.53) 
at 24 mo; calculated 
(1 vs. 3) 
RR=0.58 (0.35, 0.98) 
at 24 mo; calculated 
Time to relapse 
(months)  
Mean (SD) or 95% CI 
NR NR NR NA 
Survival rate (% 
patients in remission 
who have not relapsed) 
(Kaplan-Meier 
estimate and 95% CI) 
NR NR NR (1 vs. 2) 
p=0.83 [NS] at 6 mo  
p=0.54 [NS] at 12 
mo  
p=0.41 [NS] at 18 
mo  
p=0.31 [NS] at 24 
135 
 
mo  
 
(1 vs. 3) 
p=0.19 [NS] at 6 mo  
p=0.17 [NS] at 12 
mo 
p=0.04 [SS] at 18 mo 
p=0.03 [SS] at 24 mo 
Patients achieving 
mucosal healing n/N 
(%) 
NR NR NR NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NR NA 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NR NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NR NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NR NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NR NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NR NA 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NR NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NR NA 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NR NA 
Linear growth rate 
(mean height-for-age 
Z-score)  
NR NR NR NA 
Adherence n/N (%) NR NR NR NA 
Need for surgery 
n/N (%) 
1/32 (3.1) 1/30 (3.1) 1/33 (3.0) 1 vs. 2 
p>0.99 [NS] Fisher’s 
exact test; RR=0.93 
(0.06, 14.32) 
calculated 
 
1 vs. 3 
p>0.99 [NS] Fisher’s 
exact test; RR=1.03 
(0.06, 15.79) 
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calculated 
Steroid dose tapering 
n/N (%) 
NR NR NR NA 
Withdrawal from 
steroids n/N (%) 
NR NR NR NA 
Adverse events due to 
treatment n/N (%) 
0/32 (0.0) 2/30 (6.6) [elevated 
AST] 
1/30 (3.1) [hair loss] 
1/33 (3.0) [elevated 
amylase] 
- 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
6-MP group No intervention 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth n/N 
(%) 
NR NR NR NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NR NA 
Bowel obstruction NR NR NR NA 
Fistulae  NR NR NR NA 
Abscess  0/32 (0.0) 1/30 (3.1) 0/33 (0.0) - 
Colon/bowel cancer NR NR NR NA 
Intestinal infection NR NR NR NA 
Others (Specify)  NR NR NR NA 
Authors conclusion 
Elemental nutrition as maintenance therapy in Crohn’s disease patients was as effective as 6-mercaptopurine. Elental 
should be useful for long-term maintenance therapy in Crohn’s disease 
Reviewer’s conclusion 
At all follow up points (6, 12, and 24 mo), pts on elemental nutrition and 6-MP experienced similar rates of remission 
maintenance and relapse; at 6 and 12 mo of follow-up, the rates for remission maintenance and relapse were not different 
between the elemental nutrition and the control (no intervention) groups. However, at 24 mo of follow up, the elemental 
nutrition group had significantly greater remission maintenance rates and reduced risk of relapse compared to the control 
(no intervention) group 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
AST; Serum Aspartate transaminase, 6-TGN level; 6-Thioguanine nucleotide 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Takagi 2006,
52
Takagi 2009,
54
 Takagi 2006,
53
 
Country: Japan 
Study design: RCT 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: two 
Total length of follow up: 24 mo 
Funding (government/private/manufacturer/other - specify): no external funding received 
Aim of the study 
To compare relapse rates in pts with inactive CD receiving half elemental nutrition (elemental nutrition + 
unrestricted diet) vs. no intervention (unrestricted diet)  
Participants 
Recruitment dates: December 2002-June 2005 
Total N of patients who received induction therapy: 82 
Total N of patients achieving remission after induction therapy: 56 
Total N of patients unable to achieve remission after induction therapy: 26 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): 31 
Total number of patients allocated to maintenance treatment: 51 
Inclusion criteria: CD pts if they had just undergone induction of remission  
Exclusion criteria: NR 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean range 28.9-30.8 
Women (n [%]): 14/51 [27.4] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: clinically, endoscopically, radiologically and/or histologically (diagnostic criteria as 
defined by the Ministry of Health, Labour and Welfare of Japan) 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): mean range 86.4-101.8 
CD location (n [%]): small bowel only (15/51 [29.4]), colon only (9/51 [17.6]), small bowel and colon (27/51 
[53.0]) 
Type of induction therapy (e.g., medical, surgical): elemental enteral nutrition 22/51 [43.1] (1800–2100 kcal/day) 
for 6–8 weeks; total parenteral nutrition 25/51 [49.0] (1500–2100 kcal/day) for 6–8 weeks; oral/IV prednisolone 
1/51 [2.0] (40 mg/day, then tapered down every 2 weeks by 5–10 mg); 5 mg/kg IV infliximab 3/51 [5.9], and/or 
surgery (5/51 [7.9]) 
Previous surgery (n [%]): 22/51 [43.1] 
Intervention 
Elemental nutrition group: half elemental nutrition (i.e., elemental nutrition + unrestricted diet) 
Intervention 2 group: free (unrestricted) diet [no intervention] 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): cumulative rate of relapse 
Measure of disease activity (clinical, endoscopic): CDAI 
Definition of remission (clinical, endoscopic): CDAI<150 
Definition of relapse/recurrence (clinical, endoscopic): CDAI > 200, or the need for therapy to induce remission 
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: 6, 12, 18, 24 mo 
Number of patients 
 Total Elemental 
nutrition 
group 
Free/unrestricted diet group (no 
intervention) 
Intervention 3 
group 
Allocated to 
treatment 
51 26 25 NA 
Analysed (specify 
ITT and/or per 
protocol) 
 
(If more than one 
follow-up, choose 
and specify the last 
51 
(ITT) 
26 25 NA 
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one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose 
and specify the last 
one) 
11 6 (non-
adherent; 
discontinuation 
of elemental 
nutrition) 
5 (non-adherent; cross-intervention) NA 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of 
administration) 
Diet Co-intervention 
Elemental nutrition 
group 
Pts had to take half the amount of their daily 
allowance of calories by elemental nutrition and the 
remaining half by usual unrestricted meals.  
 
Elental (AJINOMOTO PHARMA Co., Tokyo, 
Japan) through a self-inserted tube and/or by oral 
intake. Total energy content of 375 kcal 100 g. The 
dosage was 900–1200 kcal/d (240–320 g as 
powder, 900–1200 mL as solution in water, 3–4 
sachets) 
 
Unrestricted diet 
 
Duration: NR 
Mesalazine 2250–3000 mg/day/p.o. 
(26/26 [100]) 
 
Azathioprine 50 mg/day/p.o.  
(2/26 [7.6]) 
Free/unrestricted 
diet group (no 
intervention) 
Unrestricted diet; pts took all nutrients via their 
usual un-restricted meals. The energy requirements 
of individual patients were 35–40 kcal/kg ideal 
body weight/day. 
Mesalazine 2250–3000 mg/day/p.o. 
(25/25 [100]) 
 
Azathioprine 50 mg/day/p.o. (4/25 
[16.0]) 
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition 
group 
Free/unrestricted diet group  
(no intervention) 
Intervention 3 
group 
Age (years) 
Mean (SD)  
30.8 (11.1)  28.9 (8.1) NA 
Sex –female n/N 
(%) 
6/26 (23.1) 8/25 (32.0) NA 
Weight (kg)  
Mean (SD)  
NR NR NA 
BMI (kg/m
2
) 
Mean (SD) 
20.1 (3.1)  20.0 (3.6) NA 
Smoking n/N (%)  NR NR NA 
Previous bowel 
resection n/N (%) 
11/26 (42.3)  11/25 (44.0) NA 
Duration of CD 
(months)  
Mean (SD) 
49.2 (50.4)  67.2 (78.0) NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
101.8 (34.1)  86.4 (31.3) NA 
Crohn’s Disease 
Endoscopic Index 
of Severity 
(CDEIS) 
Mean (SD) 
NR NR NA 
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Disease activity 
other than CDAI 
(specify) 
NR NR NA 
Mucosal ulceration 
n/N (%) 
Perianal lesions 
12/26 (46.1) 
Perianal lesions 
10/25 (40.0) 
NA 
Other 
complications n/N 
(%) 
NR NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 12 mo 
 Elemental nutrition 
group 
Free/unrestricted diet 
group  
(no intervention) 
Intervention 
3 group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N 
(%)  
NR NR NA NA 
Duration of 
remission (months)  
Mean (SD) or 95% 
CI 
NR NR NA NA 
Risk of relapse or 
recurrence n/N (%) 
9/26 (34.6) 16/25 (64.0) NA HR (adjusted)=0.40 
(0.16, 0.98) study 
reported; in favour 
of elemental 
nutrition group 
 
RR=0.54 (0.29, 
0.99) calculated; in 
favour of elemental 
nutrition group 
Time to relapse 
(months)  
Mean (SD) or 95% 
CI 
NR NR NA NA 
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% 
CI) 
NR NR NA NA 
Patients achieving 
mucosal healing 
n/N (%) 
NR NR NA NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA NA 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
NR NR NA NA 
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Mean (SD)  
95% CI 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(Inflammatory 
Bowel Disease 
Questionnaire) 
Mean (SD)  
95% CI 
Adjusted mean IBDQ 
score at 13 mo 
 
171.9 (126.4, 217.3) 
Adjusted mean IBDQ 
score at 13 mo  
 
176.7 (142.5, 211.0) 
NA Adjusted mean 
IBDQ score 
difference at 13 mo  
p>0.05 (NS) 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NA 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA p=NR (NS) study 
reported 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NA NA 
Linear growth rate 
(mean height-for-
age Z-score)  
NR NR NA NA 
Adherence n/N (%) 20/26 (77.0) 20/25 (80.0) NA RR=0.96 (0.72, 
1.28) calculated  
Need for surgery 
n/N (%) 
NR NR NA NA 
Steroid dose 
tapering n/N (%) 
NR NR NA NA 
Withdrawal from 
steroids n/N (%) 
NR NR NA NA 
Adverse events due 
to treatment n/N 
(%) 
0/26 (0.0) 0/25 (0.0) NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
Free/unrestricted diet 
group  
(no intervention) 
Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
0/26 0/25  NA NA 
Delay in pubertal 
development 
 n/N (%) 
0/26 0/25  NA NA 
Bowel obstruction 0/26 0/25  NA NA 
Fistulae  0/26 0/25  NA NA 
Abscess  0/26 0/25  NA NA 
Colon/bowel 
cancer 
0/26 0/25  NA NA 
Intestinal infection 0/26 0/25  NA NA 
Others (Specify)  0/26 0/25  NA NA 
Authors conclusion 
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At 24 mo, pts receiving elemental nutrition experienced significantly reduced risk of relapse compared to those on 
free diet. No differences were detected in quality of life or cost of treatment between the two groups  
Reviewer’s conclusion 
At 24 mo, pts receiving elemental nutrition experienced significantly reduced risk of relapse compared to those on 
free diet. No differences were detected in quality of life or cost of treatment between the two groups; no adverse 
events; adherence was similar between the treatment groups; trial terminated at 24 mo for ethical reasons 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
 
 
Cost table (mean per patient monthly in yen)
54
  
 
 Elemental nutrition 
group 
Free diet group Between-group 
difference  
p value 
(or 95% CI) 
Crude costs  109,160  
(95% CI: 63,240 - 155,090)  
68,970  
(95% CI: 22,140–115,800) 
NR 
Age-/sex-adjusted costs 111,540  
(95% CI: 66,850–156,240) 
66,490  
(95% CI: 20,900–112,080) 
NR 
Multivariate costs* 105,860  
(95% CI: 57,380 - 154,340)  
About $880.00 US 
72,400  
(95% CI: 22,810–122,000) 
About $600.00 US 
p>0.05 (NS) 
Adjusted for age, sex, duration of disease, site, perianal lesions, previous gut operation, frequency of relapse, 
administration of azathioprine, inductive therapy (+surgery), and mean CDAI at baseline 
 
 
.
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Verma 2001
55
 
Country: UK 
Study design: RCT 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: one 
Total length of follow up: 24 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To compare safety and efficacy of elemental and polymeric nutrition in terms of the maintenance of remission, 
relapse, and intolerance 
Participants 
Recruitment dates:  
Total N of patients who received induction therapy: NR  
Total N of patients achieving remission after induction therapy: NR 
Total N of patients unable to achieve remission after induction therapy: NR 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): 4 
Total number of patients allocated to maintenance treatment: 33  
Inclusion criteria: pts with inactive CD and documented previously steroid dependency for maintaining clinical 
remission and two previous unsuccessful attempts to withdraw steroid that prompted recurrence during or after 30 
d of withdrawal 
Exclusion criteria: recurrent small-bowel obstruction due to Crohn strictures, significant sepsis including 
perianal disease, previous intolerance to enteral feeding or unwilling to give formal written consent 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 40.8 (SD: 2.7), range: 17-76 
Women (n [%]): 23/33 [70.7] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: standard clinical, radiological, endoscopic and histological criteria 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): mean range 90.4-106.4 
CD location (n [%]): small bowel (11/33 [33.3]), colon (10/33 [30.3]), mixed cites (10/33 [30.3]), anastomotic 
(2/33 [6.0]) 
Type of induction therapy (e.g., medical, surgical): medical (prednisolone; mean dose 7.0 (0.5) mg/d) 
Previous surgery (n [%]): NR 
Intervention 
Elemental nutrition group: elemental nutrition (EO28) 
Intervention 2 group: polymeric nutrition (Fortisip) 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): remission maintenance rate, time to relapse 
Measure of disease activity (clinical, endoscopic): clinical (CDAI) 
Definition of remission (clinical, endoscopic): clinical (absence of diarrhoea and abdominal pain, CDAI≤150 in 
the 2 weeks preceding the study, and ESR<20 mm/h) 
Definition of relapse/recurrence (clinical, endoscopic): clinical (CDAI ≥200 or increased by 100 points from 
baseline) 
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: 12 mo 
Number of patients 
 Total Elemental 
nutrition 
group 
Polymeric nutrition group Intervention 3 group 
Allocated to 
treatment 
33 19 14 NA 
Analysed (specify 
ITT and/or per 
protocol) 
 
(If more than one 
follow-up, choose and 
33 
(ITT) 
 
27 
(PP) 
19 (ITT) 
 
 
13 (PP) 
14 (ITT) 
 
 
14 (PP) 
NA 
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specify the last one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose and 
specify the last one) 
6 6 0 NA 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of 
administration) 
Diet Co-intervention 
Elemental nutrition 
group 
Orally taken (EO28, Scientific Hospital 
Supplies Ltd, Liverpool, UK); sachets 
containing powdered feed mixed with tap 
water (20 g/100 ml); energy content 76 
Kcal per 20g/100 ml; the mean daily intake 
730 (range 600–1017) Kcal 
 
Unrestricted normal diet 
 
Duration: 12 mo 
Steroids/prednisolone (n=19; 6.5 (0.8) mg) 
Azathioprine (n=6; dose: NR) 
5ASA (n=3; dose: NR) 
 
Duration: 12 mo 
Polymeric nutrition 
group 
Orally taken (Fortisip, Nutricia, UK); 
ready-to-drink cartons (200 ml); energy 
content 150 Kcal per 100 ml; the mean 
daily intake 730 (range 600–1017) Kcal 
 
Unrestricted normal diet 
 
Duration: 12 mo 
Steroids/prednisolone (n=14; 7.1 (0.9) mg) 
Azathioprine (n=8; dose: NR) 
5ASA (n=2; dose: NR)  
 
Duration: 12 mo  
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition 
group 
Polymeric nutrition group Intervention 3 group 
Age (years) 
Mean (SD)  
41.7 (5.4)  44.1 (3.2) NA 
Sex –female n/N (%) 13/19 (68.4) 9/14 (64.3) NA 
Weight (kg)  
Mean (SD)  
62.4 (3.4) 
 
71.4 (7.7) NA 
BMI (kg/m
2
) 
Mean (SD) 
21.8 (1.2) 24.4 (1.6) NA 
Smoking n/N (%)  NR NR NA 
Previous bowel 
resection n/N (%) 
NR NR NA 
Duration of CD 
(months)  
Mean (SD) 
154.4 (37.2) 123.6 (26.4) NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
106.4 (14.9) 90.4 (17.8) NA  
Crohn’s Disease 
Endoscopic Index of 
Severity (CDEIS) 
Mean (SD) 
NR NR NA 
Disease activity 
other than CDAI 
(specify) 
NR NR NA 
Mucosal ulceration NR NR NA 
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n/N (%) 
Other complications 
n/N (%) 
NR NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 12 mo 
 Elemental 
nutrition group 
Polymeric 
nutrition group 
Intervention 3 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N (%)  
8/19 (42.1) 6/14 (42.8) NA p=NR (NS) study 
reported 
RR=0.98 (0.44, 2.19) 
calculated  
Duration of 
remission (months)  
Mean (SD) or 95% CI 
NR NR NA NA 
Risk of relapse or 
recurrence n/N (%) 
8/19 (42.1) 5/14 (35.7) NA p=NR (NS) study 
reported 
RR=1.18 (0.48, 2.83) 
calculated 
Time to relapse 
(months)  
Mean (SD) or 95% CI 
NR  NR NA NA 
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% CI) 
NR NR NA NA 
Patients achieving 
mucosal healing n/N 
(%) 
NR NR NA NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA NA 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NA NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NA 
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Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NA NA 
Linear growth rate 
(mean height-for-age 
Z-score)  
NR NR NA NA 
Adherence n/N (%) 13/19 (68.4) 14/14 (100.0)  RR=0.68 (0.50, 0.92) 
calculated; in favour of 
polymeric nutrition 
group 
Need for surgery 
n/N (%) 
NR NR NA NA 
Steroid dose 
tapering n/N (%) 
NR NR NA NA 
Withdrawal from 
steroids n/N (%) 
8/19 (42.1) 6/14 (42.8)  p=NR (NS) study 
reported 
RR=0.98 (0.44, 2.19) 
calculated 
Adverse events due 
to treatment n/N (%) 
NR NR NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
Polymeric 
nutrition group 
Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
NR NR NA NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NA NA 
Bowel obstruction NR NR NA NA 
Fistulae  NR NR NA NA 
Abscess  NR NR NA NA 
Colon/bowel cancer NR NR NA NA 
Intestinal infection NR NR NA NA 
Others (Specify)  NR NR NA NA 
Authors conclusion  
The two formulas are similar in maintaining remission rate and risk of relapse, or withdrawal from steroids use 
Reviewer’s conclusion 
The two formulas are similar in maintaining remission rate, risk of relapse, or withdrawal from steroids use 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
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Non-RCTs 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Hirakawa 1993
51
 
Country: Japan 
Study design: non randomised controlled trial 
Study setting (primary care/specialty clinic/other - specify): primary care 
Number of centres: one  
Total length of follow up: 48 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To compare the effects of elemental nutrition alone, combination of elemental nutrition and drugs, drugs alone, and no 
intervention on maintenance of remission in CD pts  
Participants 
Recruitment dates: NR 
Total N of patients who received induction therapy: 84 
Total N of patients achieving remission after induction therapy: 67 
Total N of patients unable to achieve remission after induction therapy: NR 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): NR 
Total number of patients allocated to maintenance treatment: 61 
Inclusion criteria: pts with CD in remission 
Exclusion criteria: pts with active CD 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean 21.9-27.0  
Women (n [%]): 14/53 [26.4] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: Criteria of the Japanese Society Gastroenterology  
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): mean 61.6-69.3 
CD location (n [%]): small bowel (5/53 [9.4]), large bowel (6/53 [11.3]), small and large bowels (42/53 [79.2]) 
Type of induction therapy (e.g., medical, surgical): elemental nutrition (25/53 [47.1]), elemental nutrition and drugs 
(23/53 [43.4]), drugs alone (5/53 [9.4]) 
Previous surgery (n [%]): NR 
Intervention 
Elemental nutrition group: elemental nutrition 
Intervention 2 group: elemental nutrition + drugs (sulfasalazine 3g/d or prednisolone 10mg/d) 
Intervention 3 group: drugs (sulfasalazine 3g/d or prednisolone 10mg/d) 
Intervention 4 group: No intervention  
Outcomes (study-based) 
Primary outcomes (list): cumulative continuous remission rate 
Measure of disease activity (clinical, endoscopic): CDAI and International Organization for the Study of Inflammatory 
Bowel Disease (IOIBD) scores 
Definition of remission (clinical, endoscopic): IOIBD score (value: NR) and normal values of ESR and CRP 
Definition of relapse/recurrence (clinical, endoscopic): recurrence of subjective/objective symptoms (increase of the 
IOIBD score by ≥2, enhanced ESR, and positive CRP) 
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: 12, 24, 36, and 48 mo 
Number of patients 
 Total Elemental 
nutrition 
group 
Elemental 
nutrition + drugs 
group 
Drugs group No intervention group 
Allocated to 
treatment 
61 25 22 8 6 
Analysed 
(specify ITT 
and/or per 
protocol) 
 
(If more than 
(n=53) 
Per 
protocol 
22 17 8 6 
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one follow-up, 
choose and 
specify the 
last one) 
Losses to 
follow-
up/drop 
out/sample 
attrition  
(If more than 
one follow-up, 
choose and 
specify the 
last one) 
8 3 5 0 0 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of administration) 
Diet Co-intervention 
Elemental 
nutrition 
group 
>30 kcal/kg IBW/d through nasoenteral tube 
as home elemental enteral hyperalimentation 
Actual consumption: 35.2 (SD=4.8) kcal/kg 
IBW/d 
Brand: NR 
Duration of EN: NR 
Restricted diet additionally 
- 
Elemental 
nutrition + 
drugs group 
>30 kcal/kg IBW/d through nasoenteral tube 
as home elemental enteral hyperalimentation 
Actual consumption: 31.8 (SD=4.4) kcal/kg 
IBW/d 
Brand: NR 
Duration of EN: NR 
 
Sulfasalazine 3g/d (n=10)  
prednisolone 10mg/d (n=7) 
Duration: NR  
 
Restricted diet additionally 
 
NR 
Drugs group  Sulfasalazine 3g/d (n=10)  
prednisolone 10mg/d (n=7) 
Duration: NR  
 
Restricted diet 
NR 
No 
intervention 
group 
Restricted diet  - 
Patient baseline characteristics  
 Elemental nutrition 
group 
Elemental 
nutrition + drugs 
group 
Drugs group No intervention group 
Age (years) 
Mean (SD)  
27.0 (7.4) 26.6 (2.4) 21.9 (2.6) 25.7 (5.0) 
Sex –female 
n/N (%) 
3/22 (13.6) 6/17 (35.3) 3/8 (37.5) 2/6 (33.3) 
Weight (kg)  
Mean (SD)  
NR NR NR NR 
BMI (kg/m
2
) 
Mean (SD) 
NR NR NR NR 
Smoking n/N NR NR NR NR 
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(%)  
Previous 
bowel 
resection n/N 
(%) 
NR NR NR NR 
Duration of 
CD (months)  
Mean (SD) 
NR NR NR NR 
Crohn’s 
Disease 
Activity 
Index 
(CDAI) 
Mean (SD) 
61.6 (29.2) 56.0 (26.6) 68.5 (30.2) 69.3 (52.1) 
Crohn’s 
Disease 
Endoscopic 
Index of 
Severity 
(CDEIS) 
Mean (SD) 
NR NR NR NR 
Disease 
activity other 
than CDAI 
(IOIBD) 
0.2 (0.5) 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 
Mucosal 
ulceration 
n/N (%) 
NR NR NR NR 
Other 
complications 
n/N (%) 
Fistula 
8/22 (36.4) 
Fistula 
9/17 (53.0) 
Fistula 
3/8 (37.5) 
Fistula 
1/6 (16.6) 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 12, 24, and 48 mo 
 Elemental nutrition 
group 
Elemental 
nutrition + drugs 
group 
Drugs group No 
intervention 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients 
remaining in 
remission n/N 
(%)  
NR NR NR NR NA 
Duration of 
remission 
(months)  
Mean (SD) or 
95% CI 
NR NR NR NR NA 
Risk of 
relapse or 
recurrence 
n/N (%) 
NR NR NR NR NA 
Time to 
relapse 
(months)  
Mean (SD) or 
95% CI 
NR NR NR NR NA 
Survival rate 
(% patients in 
12 mo: 94% (NR) 
24 mo: 63% (NR) 
75% (NR) 
66% (NR) 
63% (NR) 
42% (NR) 
50% (NR) 
33% (NR) 
At 48 mo 
p<0.05 (1 vs. 3) 
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remission who 
have not 
relapsed) 
(Kaplan-
Meier 
estimate and 
95% CI) 
48 mo: 63% (NR) 66% (NR) 0% (NR) 0% (NR) SS 
p<0.01 (1 vs. 4) 
SS 
p<0.05 (2 vs. 4) 
SS 
 
p≥0.05 (2 vs. 3) 
NS 
p≥0.05 (1 vs. 2) 
NS 
Patients 
achieving 
mucosal 
healing n/N 
(%) 
NR NR NR NR NA 
Crohn’s 
Disease 
Activity 
Index 
(CDAI) 
Mean (SD) 
NR NR NR NR NA 
The Short 
Form Health 
Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NR NR NA 
The Short 
Form Health 
Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NR NR NA 
The Euro-
Qol 
questionnaire 
(EQ-5D) 
Mean (SD)  
95% CI 
NR NR NR NR NA 
Other HQOL 
(specify) 
Mean (SD)  
95% CI 
NR NR NR NR NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NR NR NA 
Weight gain 
(kg)  
Mean change 
(SD)  
95% CI 
NR NR NR NR NA 
Body mass 
index (kg/m
2
)  
Mean change 
(SD)  
95% CI 
NR NR NR NR NA 
Height gain 
(cm) Mean 
(SD)  
95% CI 
NR NR NR NR NA 
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Linear 
growth rate 
(mean 
height-for-
age Z-score)  
NR NR NR NR NA 
Adherence 
n/N (%) 
22/25 (88.0) 17/22 (77.3) 8/8 (100.0) 6/6 (100.0) Fisher’s exact test  
p=0.55 [1 vs. 2] 
NS 
p=0.84 [1 vs. 3] 
NS 
p>0.99 [1 vs. 4] 
NS 
p=0.37 [2 vs. 3] 
NS 
p=0.53 [2 vs. 4] 
NS 
calculated 
Need for 
surgery 
n/N (%) 
NR NR NR NR NA 
Steroid dose 
tapering n/N 
(%) 
NR NR NR NR NA 
Withdrawal 
from steroids 
n/N (%) 
NR NR NR NR NA 
Adverse 
events due to 
treatment 
n/N (%) 
NR NR NR NR NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
Elemental 
nutrition + drugs 
group 
Drugs group No 
intervention 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired 
growth n/N 
(%) 
NR NR NR NR NA 
Delay in 
pubertal 
development 
 n/N (%) 
NR NR NR NR NA 
Bowel 
obstruction 
NR NR NR NR NA 
Fistulae  NR NR NR NR NA 
Abscess  NR NR NR NR NA 
Colon/bowel 
cancer 
NR NR NR NR NA 
Intestinal 
infection 
NR NR NR NR NA 
Others 
(Specify)  
NR NR NR NR NA 
Authors conclusion 
At 1, 2, and 4 yrs of follow-up, both groups of elemental nutrition (with/without drugs) experienced significantly greater 
rates of remission maintenance compared to no intervention; elemental nutrition alone (but not elemental nutrition + 
drug) was more effective than drug alone 
Reviewer’s conclusion 
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Long term administration of elemental nutrition with or without drugs in pts with CD resulted in improved rates of 
maintenance of remission compared with no intervention; there was no significant difference in rates of remission 
maintenance between the two elemental nutrition or two drug groups  
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values)
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Name of first reviewer: alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Verma 2000
56
 
Country: UK 
Study design: non-randomised controlled trial 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: one 
Total length of follow up: 24 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To evaluate clinical effectiveness of adding an elemental nutrition taken orally to normal food for maintaining remission in 
patients with quiescent CD over 12 months 
Participants 
Recruitment dates: NR 
Total N of patients who received induction therapy: 46 
Total N of patients achieving remission after induction therapy: 39 
Total N of patients unable to achieve remission after induction therapy: 7 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): 7 
Total number of patients allocated to maintenance treatment: 39 
Inclusion criteria: pts with quiescent disease defined by the absence of bowel symptoms and CDAI<150 who had been 
treated with either elemental nutrition or prednisolone as an induction therapy within preceding 12 months 
Exclusion criteria: CDAI>150, sepsis, bowel strictures leading to recurrent attacks of small bowel obstruction or previous 
intolerance to enteral feeding 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean 39.2 – 42.0 yrs 
Women (n [%]): 27 [69.2] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: standard clinical, endoscopic, radiological, and when possible, histological criteria 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): mean 94.6 – 112.8 
CD location (n [%]): small bowel (17[43.6]), large bowel (n=10[25.6]), mixed (n=9[23.0]), anastomatic (n=3[7.6]) 
Type of induction therapy (e.g., medical, surgical): medical (prednisolone, azathioprine, 5-ASA)  
Previous surgery (n [%]): 12 [100] 
Intervention 
Elemental nutrition group: elemental nutrition “EO28 Extra” (with normal unrestricted diet) 
Intervention 2 group: no intervention (i.e., normal unrestricted diet) 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): maintenance of clinical remission at 12 mo, withdrawal from steroids, and duration of remission at 
24 mo 
Measure of disease activity (clinical, endoscopic): CDAI 
Definition of remission (clinical, endoscopic): CDAI<150 
Definition of relapse/recurrence (clinical, endoscopic): increase in CDAI by >100 points since baseline or final CDAI 
>150 points; need of surgery; increased doses of steroids  
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: 1, 3, 6, 9, 12, and 24 mo 
Number of patients 
 Total Elemental 
nutrition group 
No intervention group Intervention 3 group 
Allocated to 
treatment 
39 21 18 NA 
Analysed (specify 
ITT and/or per 
protocol) 
(If more than one 
follow-up, choose 
and specify the last 
one) 
35 17 (per 
protocol) 
21 (ITT) 
18 NA 
Losses to follow-  4 0 NA 
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up/drop out/sample 
attrition  
(If more than one 
follow-up, choose 
and specify the last 
one) 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of administration) 
Diet Co-intervention 
Elemental nutrition 
group 
EO28 Extra powder containing 443 kcal 
energy, mixed with water and taken orally 
in three separate portions daily; mean 
intake (768.5, SD: 50.6 kcal/d) 
Duration: 12 mo  
In addition to normal diet 
Prednisolone (mean range: 10.5-17.5 mg/d) 
azathioprine (dose: NR) 
5-ASA (dose: NR) 
Duration: 12 mo 
Intervention 2 group No intervention (i.e., normal diet) 
Duration: 12 mo 
Prednisolone (mean: 13.4 mg/d) azathioprine (dose: 
NR) 
5-ASA (dose: NR) 
Duration: 12 mo 
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition 
group 
No intervention group (i.e., normal diet) Intervention 3 group 
Age (years) 
Mean (SD)  
39.2 (3.9) 42.0 (3.3)  NA 
Sex –female n/N (%) 14/21 (66.6) 13/18 (72.2) NA 
Weight (kg)  
Mean (SD)  
59.4 (2.9) 62.7 (2.8) NA 
BMI (kg/m
2
) 
Mean (SD) 
20.0 (2.2) 22.9 (0.9) NA 
Smoking n/N (%)  NR NR NA 
Previous bowel 
resection n/N (%) 
NR NR NA 
Duration of CD 
(months)  
Mean (SD) 
60.3 (18.4) 91.0 (14.8) NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
112.8 (11.5) 94.6 (7.1) NA 
Crohn’s Disease 
Endoscopic Index 
of Severity (CDEIS) 
Mean (SD) 
NR NR NA 
Disease activity 
other than CDAI 
(specify) 
NR NR NA 
Mucosal ulceration 
n/N (%) 
NR NR NA 
Other 
complications n/N 
(%) 
NR NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 12 mo 
 Elemental nutrition 
group 
No intervention group 
(i.e., normal diet) 
Intervention 3 
group 
Between-group 
difference  
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p value 
(or 95% CI)* 
Patients remaining 
in remission n/N 
(%)  
10/21 (47.6) 4/18 (22.2) NA p=0.0003 (SS) 
RR=2.14 (0.81, 5.67), 
p=0.18 (NS) calculated 
Duration of 
remission (months)  
Mean (SD) or 95% 
CI 
NR  NR  NA NA 
Risk of relapse or 
recurrence n/N (%) 
7/21 (33.3) 14/18 (77.7) NA p<0.00001 (SS) 
RR=0.50 (0.25, 0.98) 
calculated 
Time to relapse 
(months)  
Mean (SD) or 95% 
CI 
7.4 (0.9) 6.2 (0.4) NA  NR (study report) 
MD=1.2 (0.35, 2.04), 
p=0.012 (SS) 
calculated 
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% 
CI) 
NR NR NA NA 
Patients achieving 
mucosal healing 
n/N (%) 
NR NR NA NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA NA 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NA NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NA 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Height gain (cm) NR NR NA NA 
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Mean (SD)  
95% CI 
Linear growth rate 
(mean height-for-
age Z-score)  
NR NR NA NA  
Adherence n/N (%) 17/21 (80.9) 18/18 (100.0) NA NR (study report) 
RR=0.81 (0.65, 0.99) 
calculated; in favour of 
No intervention group 
Need for surgery 
n/N (%) 
NR NR NA NA 
Steroid dose 
tapering n/N (%) 
10/21 (47.6) 4/18 (22.2)  NA NR (study report) 
RR=2.14 (0.80, 5.67) 
(NS) calculated 
Withdrawal from 
steroids n/N (%) 
4/21 (19.0) 0/18 (0.0) NA NR 
Adverse events due 
to treatment n/N 
(%) 
NR NR NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
No intervention group Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
NR NR NA NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NA NA 
Bowel obstruction NR NR NA NA 
Fistulae  NR NR NA NA 
Abscess  NR NR NA NA 
Colon/bowel cancer NR NR NA NA 
Intestinal infection NR NR NA NA 
Others (Specify)  NR NR NA NA 
Authors conclusion 
Over 12 mo, the EN group had higher maintenance remission rate vs. no intervention (usual diet) group 
Reviewer’s conclusion 
Pts receiving EN experienced greater remission rates, longer time to relapse, reduced rates of replace, but similar CDAI, 
BMI, or weight compared to the control group at 12 mo of FU; results for steroid tapering/withdrawals, adherence, and 
intolerance are inconclusive due to small sample number of events or sample size 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Yamamoto 2007a,
30
; Yamamoto 2013,
59
;Yamamoto 2013,
60
 
Country: Japan 
Study design: non-randomised controlled trial 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: one 
Total length of follow up: 12 mo 
Funding (government/private/manufacturer/other - specify): other (no external funding received) 
Aim of the study 
To examine if long-term elemental nutrition infusion along with low fat diet is useful in reducing clinical and 
endoscopic recurrence rates after resection for CD 
Participants 
Recruitment dates: NR 
Total N of patients who received induction therapy: NR  
Total N of patients achieving remission after induction therapy: NR  
Total N of patients unable to achieve remission after induction therapy: NR 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): NR 
Total number of patients allocated to maintenance treatment: 40 
Inclusion criteria: patients with endoscopic and histological diagnosis of CD, aged 15-75 yrs who had resection 
for ileal and ileocolonic (including ileocaecal) CD; received EN therapy including elemental nutrition infusion at 
least once before operation; agreed to continue assigned treatment (with or without enteral nutrition) for more than 
1 year after operation 
Exclusion criteria: Patients with colonic Crohn’s disease alone or with diffuse small bowel Crohn’s disease  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 32.0 (17.0) 
Women (n [%]): 14/40 [35.0] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: endoscopic and histological (no specific criteria reported) 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): NR 
CD location (n [%]): Terminal ileum (12/40 [30.0]), terminal ileum and colon (20/40 [50.0]), Ileocolonic 
anastomosis (8/40 [20.0]) 
Type of induction therapy (e.g., medical, surgical): bowel resection (40/40 [100.0]), corticosteroids (37/40 [92.5]), 
pentasa (32/40 [77.5]) 
Previous surgery (n [%]): 8/40 [20.0] 
Intervention 
Elemental nutrition group: elemental nutrition (with restricted food diet) 
Intervention 2 group: no intervention (i.e., normal unrestricted diet) 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): clinical and endoscopic recurrence 
Measure of disease activity (clinical, endoscopic): clinical (CDAI score), endoscopic (Rutgeerts score) 
Definition of remission (clinical, endoscopic): CDAI<150 (clinical), Rutgeerts score<2 (endoscopic) 
Definition of relapse/recurrence (clinical, endoscopic): clinical (at 6, 12 mo: CDAI≥150; at 60 mo: CDAI≥200), 
endoscopic (Rutgeerts score≥2) 
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: 6 and 12 mo 
Number of patients 
 Total Elemental 
nutrition 
group 
No intervention group Intervention 3 group 
Allocated to 
treatment 
40 20 20 NA 
Analysed (specify 
ITT and/or per 
protocol) 
 
(If more than one 
follow-up, choose and 
40 
(ITT) 
20 20 NA 
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specify the last one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose and 
specify the last one) 
0 0 0 NA 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of 
administration) 
Diet Co-intervention 
Elemental nutrition 
group 
Elental (Ajinomoto, Tokyo, Japan) with the 
calorie density of 1 kcal/mL with an 
osmolarity of 760 mOsm/L. Infused at 
home nasogastrically via self-intubated 
tube in the night-time 1 week after 
operation. The concentration of the 
elemental nutrition was gradually increased 
from one-third to the full strength over 10 
days (adaptation phase) to reduce side 
effects, such as diarrhoea and abdominal 
colic. After the adaptation phase, a 
maintenance dose at the full strength was 
administered in the night-time (for 6–10 h). 
The volume of the elemental nutrition 
infused per night was 1200–1800 mL 
 
Restricted food diet: in the daytime, low fat 
foods (20–30 g/day) were taken according 
to the instructions of their dieticians. The 
daily calorie intake: 35–40 kcal/kg body 
weight; about half of the calorie was 
obtained from the elemental nutrition 
therapy 
 
Duration at least 12 mos 
Pentasa 3000 mg/day as a prophylactic 
medication 
 
No corticosteroid, immunosuppressive 
drugs, or infliximab except patients who 
relapsed 
No intervention group  No elemental nutrition, only normal 
unrestricted diet 
 
Duration > 12 mos  
Pentasa 3000 mg/day as a prophylactic 
medication 
 
No corticosteroid, immunosuppressive 
drugs, or infliximab except patients who 
relapsed 
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition 
group 
No Intervention group Intervention 3 group 
Age (years) 
Mean (SD)  
31.0 (16.5) 33.0 (17.4) NA 
Sex –female n/N (%) 8/20 (40.0) 6/20 (30.0) NA 
Weight (kg)  
Mean (SD)  
NR NR NA 
BMI (kg/m
2
) 
Mean (SD) 
NR NR NA 
Smoking n/N (%)  2/20 (10.0) 2/20 (10.0) NA 
Previous bowel 
resection n/N (%) 
20/20 (100.0) 20/20 (100.0) NA 
Duration of CD 
(months)  
37.0 (31.7) 39.0 (36.7) NA 
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Mean (SD) 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA 
Crohn’s Disease 
Endoscopic Index of 
Severity (CDEIS) 
Mean (SD) 
NR NR NA 
Disease activity 
other than CDAI 
(specify) 
NR NR NA 
Mucosal ulceration 
n/N (%) 
NR NR NA 
Other complications 
n/N (%) 
Diarrhoea, abdominal 
distension or 
colic in most pts (n/N: 
NR) 
NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 6, 12, 60 mo 
 Elemental nutrition 
group 
No Intervention 
group 
Intervention 3 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N (%)  
12 mo: 19/20 (95.0) 12 mo: 13/20 (65.0) NA p=NR 
RR=1.46 (1.04, 2.05) 
calculated; in favour of 
elemental group 
Duration of 
remission (months)  
Mean (SD) or 95% CI 
NR NR NA NA 
Risk of relapse or 
recurrence n/N (%) 
Clinical  
12 mo: 1/20 (5.0) 
60 mo: 6/20 (30.0) 
 
Endoscopic  
6 mo: 5/20 (25.0) 
12 mo: 6/20 (30.0) 
60 mo: 9/16 (56.2) 
Clinical  
12 mo: 7/20 (35.0) 
60 mo: 12/20 (60.0) 
 
Endoscopic 
6 mo: 8/20 (40.0) 
12 mo: 14/20 (70.0) 
60 mo: 14/17 (82.3) 
 Clinical at 12 mo 
p=0.048 (SS) study 
reported; RR=0.14 
(0.02, 1.00) calculated; 
in favour of elemental 
group  
 
Clinical at 60 mo 
p=0.11 (NS) study 
reported; RR=0.50 
(0.23, 1.07) calculated 
 
Endoscopic at 6 mo 
p=0.50 (NS) study 
reported; RR=0.62 
(0.24, 1.58) calculated 
 
Endoscopic at 12 mo 
p=0.027 (SS) study 
reported; RR=0.42 
(0.20, 0.88) calculated; 
in favour of elemental 
group  
 
Endoscopic at 60 mo 
p=0.21 (NS) study 
reported; RR=0.68 
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(0.42, 1.11) calculated 
Time to relapse 
(months)  
Mean (SD) or 95% CI 
NR NR NA NA 
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% CI) 
NR NR NA NA 
Patients achieving 
mucosal healing n/N 
(%) 
NR NR NA NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA NA 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NA NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NA 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NA NA 
Linear growth rate 
(mean height-for-age 
Z-score)  
NR NR NA NA 
Adherence n/N (%) 20/20 (100.0) 
[12 mo] 
 
16/20 (80.0)  
[60 mo] 
20/20 (100.0)  
[12 mo] 
 
20/20 (100.0)  
[60 mo] 
NA - [12 mo] 
 
 
RR=0.80 (0.64, 0.99) 
calculated; in favour of 
the control group [60 
mo] 
Need for surgery 1/20 (5.0)  5/20 (25.0)  NA p=0.18 (NS) study 
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n/N (%) [60 mo] [60 mo]  reported; RR=0.20 
(0.02, 1.56) calculated 
[60 mo] 
Steroid dose 
tapering n/N (%) 
NR NR NA NA 
Withdrawal from 
steroids n/N (%) 
NR NR NA NA 
Adverse events due 
to treatment n/N (%) 
NR NR NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
No Intervention 
group 
Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
NR NR NA NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NA NA 
Bowel obstruction NR NR NA NA 
Fistulae  NR NR NA NA 
Abscess  NR NR NA NA 
Colon/bowel cancer NR NR NA NA 
Intestinal infection NR NR NA NA 
Others (Specify)  NR NR NA NA 
Authors conclusion 
The long-term enteral nutritional therapy significantly reduced clinical and endoscopic recurrence after resection 
for Crohn’s disease 
Reviewer’s conclusion 
Assignment depended on compliance, i.e., pts with good compliance were assigned to elemental nutrition group 
and those with low compliance to control group.  The long-term enteral nutritional therapy significantly reduced 
clinical and endoscopic recurrence at 12 mo after resection for Crohn’s disease; however, at 60 mo the rates of 
clinical/endoscopic recurrences as well as the need for operation were not significantly different between the two 
treatment groups; compliance rates were better in the control group   
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values)
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Yamamoto 2007b
57
 
Country: Japan 
Study design: non-randomised controlled trial 
Study setting (primary care/specialty clinic/other - specify): NR 
Number of centres: one 
Total length of follow up: 12 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To investigate if long-term enteral nutrition (vs. no intervention) is effective in reducing clinical and endoscopic 
relapse rates and inhibiting mucosal cytokine production in patients with quiescent CD 
Participants 
Recruitment dates: NR 
Total N of patients who received induction therapy: NR  
Total N of patients achieving remission after induction therapy: NR  
Total N of patients unable to achieve remission after induction therapy: NR  
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): NR 
Total number of patients allocated to maintenance treatment: 40 
Inclusion criteria: patient with endoscopic/histological diagnosis of CD in the terminal ileum and/or the colon; 
age: 15-75 years; clinical remission (CDAI<150) after medical treatment; the duration from the induction of 
remission to 
entry<8 weeks; patient had experienced enteral nutrition therapy including elemental nutrition infusion at least 1 
time before entry; patient agreed to continue with assigned treatment (with or without enteral nutrition) for >1 
year; and patient agreed to have ileocolonoscopy with multiple mucosal biopsies even if they did not have any 
clinical symptoms 
Exclusion criteria: diffuse jejunoileal or gastroduodenal; severe anorectal stricture or sepsis; tight bowel strictures 
or enteric fistulae even though clinical symptoms were quiescent; patient had received corticosteroids, 
immunosuppressive drugs, or infliximab at entry 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean 29.0-31.0 
Women (n [%]): 13/40 [32.5] 
Race/ethnicity (n [%]): NR 
Diagnostic criteria for CD: endoscopic and histological (not specified) 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): 97 (56-139) 
CD location (n [%]): terminal ileum (15/40 [37.5]), colon (4/40 [10]), terminal ileum and colon (21/40 [52.5]) 
Type of induction therapy (e.g., medical, surgical): 4 pts (5 mg/kg x 1 or x 3 prednisolone, infliximab), 6 pts 
(prednisolone with enteral nutrition), 10 pts (prednisolone alone), 20 pts (enteral nutrition alone), 36 pts (Pentasa, 
750–3000 mg/day), and the majority of pts required parenteral nutrition at the start of the treatment.  
Previous surgery (n [%]): 8/40 [20] 
Intervention 
Elemental nutrition group: elemental nutrition (with restricted food diet) 
Intervention 2 group: no intervention (i.e., normal unrestricted diet) 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): CDAI score, cumulative proportion of pts maintaining clinical remission (CDAI<150), 
endoscopic severity of disease activity/mucosal inflammation, mucosal cytokine assays 
Measure of disease activity (clinical, endoscopic): CDAI (clinical), mucosal inflammation grade by Wardle et al. 
1992 [0=macroscopically normal, 1= granular mucosa and contact bleeding, 2= erythematous and edematous 
mucosa, aphtoid or superficial ulcers, and 3=deep ulcers with slough and inflammatory pseudo polyps] 
(endoscopic) 
Definition of remission (clinical, endoscopic): CDAI<150 (clinical), NR (endoscopic; specific threshold for the 
mucosal inflammation grade NR) 
Definition of relapse/recurrence (clinical, endoscopic): CDAI≥150 (clinical), NR (endoscopic; specific 
threshold for the mucosal inflammation grade NR) 
Definition of mucosal healing (clinical, endoscopic): endoscopic (specific threshold for the mucosal 
inflammation grade NR) 
Post-baseline timings of primary outcome assessment: 0, 6, and 12 mo 
Number of patients 
162 
 
 Total Elemental 
nutrition group 
No intervention group Intervention 3 group 
Allocated to 
treatment 
40 20 20 NA 
Analysed (specify 
ITT and/or per 
protocol) 
 
(If more than one 
follow-up, choose 
and specify the last 
one) 
40 
(ITT) 
20 20 NA 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose 
and specify the last 
one) 
0 0 0 NA 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of 
administration) 
Diet Co-intervention 
Elemental nutrition 
group 
Elemental nutrition: Elental (Ajinomoto, 
Tokyo); one pack contains 80 g of powdered 
elemental nutrition, dissolved in warm water 
to give 300 mL of solution; 1200–1800 
mL/night infused via self-intubated 
nasogastric tube every night; patients were 
advised to take 35–40 kcal/kg ideal 
body weight daily, and to take 
approximately half of the calorie from the 
enteral nutrition 
 
Restricted food diet: in the daytime, a low-
fat diet (20–30 g/day) was taken in accord 
with dieticians instructions  
 
Duration > 12 mo 
Pentasa 3000 mg/day as a prophylactic 
medication.  
 
No corticosteroid, immunosuppressive 
drugs, or infliximab except patients who 
relapsed 
No intervention 
group 
 No elemental nutrition, only normal 
unrestricted diet 
 
Duration > 12 mo 
Pentasa 3000 mg/day as a prophylactic 
medication.  
 
No corticosteroid, immunosuppressive 
drugs, or infliximab except patients who 
relapsed 
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition 
group 
No Intervention group Intervention 3 
group 
Age (years) 
Mean (SD)  
29.0 (17.4)  31.0 (20.1)  NA 
Sex –female n/N (%) 6/20 (30.0) 7/20 (35.0) NA 
Weight (kg)  
Mean (SD)  
51.1 (8.5)  48.9 (7.6)  NA 
BMI (kg/m
2
) 
Mean (SD) 
19.2 (1.3)  19.1 (1.8)  NA 
Smoking n/N (%)  2/20 (10.0) 4/20 (20.0) NA 
Previous bowel 4/20 (20.0) 4/20 (20.0) NA 
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resection n/N (%) 
Duration of CD 
(months)  
Mean (SD) 
32.0 (35.3)  36.0 (38.9)  NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
101.0 (28.2)  92.0 (21.5)  NA 
Crohn’s Disease 
Endoscopic Index of 
Severity (CDEIS) 
Mean (SD) 
NR NR NA 
Disease activity 
other than CDAI 
(endoscopic mucosal 
inflammation grade 
0-3) 
Grade 0: 8/20 (40.0) 
Grade 1: 7/20 (35.0) 
Grade 2: 3/20 (15.0) 
Grade 3: 2/20 (10.0) 
Grade 0: 9/20 (45.0) 
Grade 1: 7/20 (35.0) 
Grade 2: 2/20 (10.0) 
Grade 3: 2/20 (10.0) 
NA 
Mucosal ulceration 
n/N (%) 
 NR (see above 
endoscopic mucosal 
inflammation grade) 
NR (see above endoscopic mucosal 
inflammation grade) 
NA 
Other complications 
n/N (%) 
Diarrhea, abdominal 
distention, or colic in 
most pts (n/N: NR) 
NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 12 mo 
 Elemental nutrition 
group 
No 
Intervention 
group 
Intervention 
3 group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N (%)  
15/20 (75.0) 7/20 (35.0) NA P=0.01 study reported 
SS  
 
RR=2.14 (1.12, 4.10) 
SS calculated; in favour 
of elemental nutrition 
group 
Duration of 
remission (months)  
Mean (SD) or 95% 
CI 
NR NR NA NA 
Risk of relapse or 
recurrence n/N (%) 
5/20 (25.0) 
 
 
13/20 (65.0) NA OR=0.20  
p=0.03 (study reported) 
95% CI (0.04, 0.70) 
calculated 
 
RR=0.38 (0.16, 0.87) 
calculated  
 
(SS) in favour of 
elemental nutrition 
group 
Time to relapse 
(months)  
Mean (SD) or 95% 
CI 
NR NR NA NA  
Survival rate (% 
patients in remission 
NR NR NA p=0.01 (SS) in favour 
of elemental nutrition 
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who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% CI) 
group 
Patients achieving 
mucosal healing n/N 
(%) 
Grade 0: 6/20 (30.0) 
 
Grade 0: 2/18 
(11.1) 
 
NA RR=2.70 (0.62, 11.72) 
NS calculated 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA p=0.04 (SS) in favour 
of elemental nutrition 
group 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NA NA 
Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NS (p>0.05) 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA SS (p<0.05) in favour 
of elemental nutrition 
group 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NA NA 
Linear growth rate 
(mean height-for-
age Z-score)  
NR NR NA NA 
Adherence n/N (%) 18/20 (90.0) 20/20 (100.0) NA p=0.48 Fisher test (NS) 
Need for surgery 
n/N (%) 
0/20 (0.0)  2/20 (10.0) NA NR 
Steroid dose 
tapering n/N (%) 
NA NA NA NA 
Withdrawal from 
steroids n/N (%) 
NA NA NA NA 
Adverse events due 
to treatment n/N (%) 
NR NR NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition 
group 
No 
Intervention 
group 
Intervention 3  
group 
Between-group 
difference  
p value 
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(or 95% CI)* 
Impaired growth 
n/N (%) 
NR NR NA NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NA NA 
Bowel obstruction NR NR NA NA 
Fistulae  NR NR NA NA 
Abscess  NR NR NA NA 
Colon/bowel cancer NR NR NA NA 
Intestinal infection NR NR NA NA 
Others (Specify)  NR NR NA NA 
Authors conclusion 
Long-term enteral nutrition in patients with quiescent CD has a clear suppressive effect on clinical and endoscopic 
disease activities and the mucosal inflammatory cytokine levels 
Reviewer’s conclusion 
Assignment depended on compliance, i.e., pts with good compliance were assigned to elemental nutrition group 
and those with low compliance to control group.  The maintenance rates of clinical remission, relapse rates, and 
CDAI scores were significantly better in the elemental nutrition vs. control group after 12 mos of follow-up 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Tara Gurung 
Study details 
First author surname year of publication: Yamamoto 2010
58
 
Country: Japan 
Study design: non-randomised controlled trial 
Study setting (primary care/specialty clinic/other - specify): specialty clinic 
Number of centres: one 
Total length of follow up: 14 mo 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To assess the efficacy of EN on the maintenance rate of clinical remission in patients with quiescent CD receiving 
infliximab as maintenance therapy 
Participants 
Recruitment dates: NR  
Total N of patients who received induction therapy: NR 
Total N of patients achieving remission after induction therapy: 56 
Total N of patients unable to achieve remission after induction therapy: NR 
Total N of patients excluded before start of maintenance therapy (e.g., in relapse, lost to follow up): NR 
Total number of patients allocated to maintenance treatment: 56 
Inclusion criteria: patients diagnosed with CD who had achieved clinical remission (CDAI<150 after infliximab 
induction therapy) with time from the induction of remission to entry ≤2 weeks; patients who had experienced EN 
therapy including elemental nutrition infusion at least one time before entry; and patients who agreed to continue with 
the assigned treatment (with or without concomitant enteral nutrition) for 56 weeks.  
Exclusion criteria: patients who had severe anorectal involvement; patients who had tight bowel strictures or enteric 
fistulae even if clinical symptoms were quiescent 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 32 (NR) 
Women (n [%]): 20/56 [35.7] 
Race/ethnicity (n [%]): NR  
Diagnostic criteria for CD: NR 
Mean Crohn’s Disease Activity Index (CDAI) (range or SD): 102.2 (NR) 
CD location (n [%]): small bowel (22/56 [39.3]), small bowel and colon (34/56 [60.7]) 
Type of induction therapy (e.g., medical, surgical): medical (infliximab 5 mg/kg) 
Previous surgery (n [%]): bowel resection (19/56 [34.0%]) 
Intervention 
Elemental nutrition group: elemental nutrition + infliximab 5 mg/kg + restricted low fat diet 
Intervention 2 group: Infliximab 5 mg/kg + unrestricted low fat diet 
Intervention 3 group: NA 
Outcomes (study-based) 
Primary outcomes (list): cumulative proportion of pts maintaining clinical remission, CDAI score 
Measure of disease activity (clinical, endoscopic): CDAI 
Definition of remission (clinical, endoscopic): CDAI < 150 
Definition of relapse/recurrence (clinical, endoscopic): CDAI > 150 
Definition of mucosal healing (clinical, endoscopic): NR 
Post-baseline timings of primary outcome assessment: baseline, 8, 16, 24, 32, 40, 48, and 56 wks 
Number of patients 
 Total Elemental 
nutrition + 
infliximab 
group 
Infliximab group Intervention 3 group 
Allocated to 
treatment 
56 32 24 NA 
Analysed (specify 
ITT and/or per 
protocol) 
 
(If more than one 
follow-up, choose 
and specify the last 
56 (ITT) 32 24 NA 
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one) 
Losses to follow-
up/drop out/sample 
attrition  
(If more than one 
follow-up, choose 
and specify the last 
one) 
0 0 0 NA 
Interventions 
 Description  
(e.g., formula manufacturer, calorie content, type, mode, dose, and duration of administration) 
Diet Co-intervention 
Elemental nutrition 
+ infliximab group 
Elemental nutrition (1200–1500 mL) nasogastric 
tube infusion during night-time; Brand: Elental 
(Ajinomoto, Tokyo); One Elental pack 
contained 80 g of powdered ED, which is to be 
dissolved in warm water to give 300 mL of 
solution before administration. The calorie 
density 1 kcal/mL 
 
Duration: 56 wks (14 mo)  
 
Restricted diet - low fat (20–30 g/day) diet 
during daytime according to instructions to take 
35–40 kcal/kg ideal body weight daily 
 
Infliximab (5 mg/kg, every 8 weeks) 
Mesalazine (Pentasa 3 g/day), Azathioprine 
(Imuran 50–100 mg/day) 
Infliximab group  Infliximab (5 mg/kg, every 8 weeks) 
Unrestricted diet 
Mesalazine (Pentasa 3 g/day), Azathioprine 
(Imuran 50–100 mg/day)  
Intervention 3 group NA NA 
Patient baseline characteristics  
 Elemental nutrition + 
infliximab group 
Infliximab group Intervention 3 group 
Age (years) 
Mean (SD)  
31.0 (9.0) 33.0 (7.8) NA 
Sex –female n/N (%) 12/32 (37.5) 8/24 (33.3) NA 
Weight (kg)  
Mean (SD)  
NR NR NA 
BMI (kg/m
2
) 
Mean (SD) 
NR NR NA 
Smoking n/N (%)  4/32 (12.5) 4/24 (16.6) NA 
Previous bowel 
resection n/N (%) 
11/32 (34.4) 8/24 (33.3) NA 
Duration of CD 
(months)  
Mean (SD) 
33.0 (24.8) 35.0 (19.6) NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
102.1 (18.1) 102.3 (22.5) NA 
Crohn’s Disease 
Endoscopic Index 
of Severity (CDEIS) 
Mean (SD) 
NR NR NA 
Disease activity 
other than CDAI 
(specify) 
NR NR NA 
Mucosal ulceration 
n/N (%) 
NR NR NA 
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Other 
complications n/N 
(%) 
NR NR NA 
Efficacy outcomes  
For each timing of assessment please provide a separate table 
For scores, extract only total scores 
Post-baseline follow-up assessment timing (Specify): 56 wks (14 mo) 
 Elemental nutrition +  
infliximab group 
Infliximab group Intervention 3 
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Patients remaining 
in remission n/N 
(%)  
25/32 (78.1) 16/24 (66.6) NA p=0.51 (NS) study 
reported 
RR=1.17 (0.83, 1.64) 
calculated 
Duration of 
remission (months)  
Mean (SD) or 95% 
CI 
NR NR NA NA 
Risk of relapse or 
recurrence n/N (%) 
7/32 (21.8) 8/24 (33.3) NA p=0.51 (NS) study 
reported 
RR=0.65 (0.27, 1.56) 
calculated  
Time to relapse 
(months)  
Mean (SD) or 95% 
CI 
NR NR NA NA 
Survival rate (% 
patients in remission 
who have not 
relapsed) 
(Kaplan-Meier 
estimate and 95% 
CI) 
NR NR NA p=0.32 (NS) 
Patients achieving 
mucosal healing n/N 
(%) 
NR NR NA NA 
Crohn’s Disease 
Activity Index 
(CDAI) 
Mean (SD) 
NR NR NA p>0.05 (NS) 
The Short Form 
Health Survey (SF-
36)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Short Form 
Health Survey (SF-
12)  
Mean (SD)  
95% CI 
NR NR NA NA 
The Euro-Qol 
questionnaire (EQ-
5D) 
Mean (SD)  
95% CI 
NR NR NA NA 
Other HQOL 
(specify) Mean (SD)  
95% CI 
NR NR NA NA 
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Weight (kg)  
Mean (SD)  
95% CI 
NR NR NA NA 
Weight gain (kg)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Body mass index 
(kg/m
2
)  
Mean change (SD)  
95% CI 
NR NR NA NA 
Height gain (cm) 
Mean (SD)  
95% CI 
NR NR NA NA 
Linear growth rate 
(mean height-for-
age Z-score)  
NR NR NA NA 
Adherence n/N (%) 25/32 (78.1) NR NA NA 
Need for surgery 
n/N (%) 
NR NR NA NA 
Steroid dose 
tapering n/N (%) 
NR NR NA NA 
Withdrawal from 
steroids n/N (%) 
NR NR NA NA 
Adverse events due 
to treatment n/N 
(%) 
NR NR NA NA 
Complications - Number (%) of patients with an event  
[if more than one follow-up, choose and specify the last follow up] 
 Elemental nutrition +  
infliximab group 
Infliximab group Intervention 3  
group 
Between-group 
difference  
p value 
(or 95% CI)* 
Impaired growth 
n/N (%) 
NR NR NA NA 
Delay in pubertal 
development 
 n/N (%) 
NR NR NA NA 
Bowel obstruction NR NR NA NA 
Fistulae  NR NR NA NA 
Abscess  NR NR NA NA 
Colon/bowel cancer NR NR NA NA 
Intestinal infection NR NR NA NA 
Others (Specify)  NR NR NA NA 
Authors conclusion 
After 56 wks of follow-up, the effect of addition of elemental nutrition to infliximab was not statistically significant for 
the maintenance of remission rate and CDAI scores 
Reviewer’s conclusion 
Assignment depended on compliance, i.e., pts with good compliance were assigned to elemental nutrition group and 
those with low compliance to infliximab alone group. The maintenance rates of clinical remission and CDAI scores 
were not significantly different between the elemental nutrition and control groups after 56 weeks of follow-up; age 
and gender did not significantly modify the observed effect of elemental nutrition on the maintenance of remission 
rates 
* Risk ratio, risk difference, or mean difference (specify if it is between mean change values from baseline; or 
between mean final end-point values) 
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8.4 Appendix IV: The risk of bias assessment of included primary study reports 
 
RCTs 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Hanai 2012
50
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
Random sequence generation Group assignment was 
done by a random process 
Low ROB 
Allocation concealment No information provided Unclear ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) No information provided, 
but probably not blinded; 
their knowledge of the 
treatment likely to 
influence the outcome 
reporting  
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Although participants and 
personnel not blinded, 
their knowledge of the 
treatment unlikely to 
influence the outcome 
reporting  
Low ROB  
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) No information provided, 
but even if blinded, the 
reporting of subjective 
outcomes may have 
already been influenced 
High ROB  
Objective (e.g., radiography, 
endoscopy) 
Even if not blinded, the 
assessment of objective 
outcomes unlikely to be 
influenced 
Low ROB 
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
 Although there were 11 
withdrawals, the assessed 
data was complete (no 
missing outcomes) 
Low ROB 
Objective outcomes (e.g., radiography, 
endoscopy) 
 Although there were 11 
withdrawals, the assessed 
data was complete (no 
missing outcomes) 
Low ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
Cumulative probability 
(survival) of maintaining 
remission incompletely 
reported (only p values) 
High ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP], baseline imbalance in 
important characteristics 
 No serious issues detected 
(funding source not 
reported, statistical 
methods adequate, no 
major baseline imbalance 
across the study groups 
Low ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; ROB=risk of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission 
(e.g., CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Maintenance of remission (CDAI<150):  
 
High ROB  
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Occurrence of relapse/recurrence (CDAI ≥200 or 
the need for an additional medication to suppress 
worsening symptoms), need for surgery, adverse 
events:  
 
Low ROB  
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias  
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Takagi 2006,
52, 53
Takagi2009
54
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
Random sequence generation A block randomisation 
(block size of 10) was 
made with a random 
number table 
Low ROB 
Allocation concealment Randomised allocation 
done independently of 
the two clinical centres 
by the randomisation 
centre. 
Low ROB  
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) Participants and 
personnel not blinded; 
their knowledge of the 
treatment likely to 
influence the reporting 
of outcome 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Although participants 
and personnel not 
blinded, their knowledge 
of the treatment unlikely 
to influence the 
reporting of outcome  
Low ROB  
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) Blinded (see below), but 
subjective outcomes 
may have been already 
influenced since patients 
and personnel were not 
blinded 
High ROB  
Objective (e.g., radiography, 
endoscopy) 
To blind the principal 
investigators at each 
site, the results (lab 
tests, CDAI) were 
reviewed by co-
investigators who had no 
contact with patients, 
and these results were 
reported in a separate 
case report form 
Low ROB  
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
No missing outcome 
data 
Low ROB  
Objective outcomes (e.g., radiography, 
endoscopy) 
No missing outcome 
data 
Low ROB  
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
Remission rates not 
reported 
High ROB  
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP], baseline imbalance in 
important characteristics 
No serious issues 
detected (i.e., no 
external funding 
received, statistical 
methods adequate, ITT 
analysis, no major 
baseline imbalance 
between the study 
groups) 
Low ROB  
ITT=intention to treat; PP=per protocol; NA=not applicable; ROB=risk of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission 
(e.g., CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Quality of life measure (IBDQ):  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Occurrence of relapse/recurrence (CDAI > 200, 
or the need for therapy to induce remission), 
adherence, adverse events:  
 
Low ROB 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias; IBDQ= Inflammatory Bowel 
Disease Questionnaire 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Verma 2001
55
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
Random sequence generation No information provided  Unclear ROB 
Allocation concealment No information provided  Unclear ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) No information 
provided, but probably 
not blinded; their 
knowledge of the 
treatment likely to 
influence the outcome 
reporting 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Although participants 
and personnel not 
blinded, their knowledge 
of the treatment would 
not influence the 
outcome reporting 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) No information 
provided, but even if 
blinded, the reporting of 
subjective outcomes 
may have already been 
influenced 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
No information 
provided, but even if not 
blinded the assessment 
of objective outcomes 
unlikely to be influenced 
Low ROB  
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
Although there were 6 
(18%) withdrawals, the 
analysed data was 
complete (no missing 
outcome) 
Low ROB 
Objective outcomes (e.g., radiography, 
endoscopy) 
Although there were 6 
(18%) withdrawals, the 
analysed data was 
complete (no missing 
outcome) 
Low ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
Outcomes were not pre-
specified in Methods 
section, only in the 
abstract; need for 
surgery was not reported 
in Results section; 
selective reporting likely 
High ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP], baseline imbalance in 
important characteristics 
No funding reported; 
statistical analyses 
adequate; there was 
some imbalance in the 
elemental nutrition 
group being on steroids 
for shorter period, higher 
CDAI, and lower weight 
than the control group 
Unclear ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; ROB=risk of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias
175 
 
Summary assessment of the within-study risk of bias for an outcome across domains 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission 
(e.g., CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Occurrence of relapse/recurrence (CDAI ≥200 or 
increased by 100 points from baseline):  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence  
Maintenance of remission (absence of diarrhoea 
and abdominal pain, CDAI≤150 in the 2 weeks 
preceding the study, and ESR<20 mm/h), 
withdrawal from steroids, adherence: 
 
Unclear ROB 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias  
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Non-RCTs 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe 
First author surname year of publication: Hirakawa 1993
51
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, duration 
of CD, location of CD, complications during induction 
therapy, type of induction therapy, pre-study 
compliance, co-intervention, and/or smoking)  
There was some 
imbalance in induction 
therapy and distribution 
of lesion across the 
study groups 
High ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) Pure subjective 
outcomes: NR 
No information on 
blinding but probably 
not blinded 
NA 
Objective (e.g., radiography, 
endoscopy) 
No information on 
blinding but probably 
not blinded. However, 
given the objective 
outcomes their 
knowledge of the 
treatment would not 
influence the outcome 
reporting 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) Pure subjective 
outcomes: NR 
No information on 
blinding but probably 
not blinded 
NA 
Objective (e.g., radiography, 
endoscopy) 
No information on 
blinding but probably 
not blinded. However, 
given the objective 
outcomes their 
knowledge of the 
treatment would not 
influence the outcome 
reporting 
Low ROB 
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
Pure subjective 
outcomes: NR 
NA 
Objective outcomes (e.g., radiography, 
endoscopy) 
8 patients were excluded 
from the analyses 
(incomplete outcome 
data) 
High ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
The analyses for 
survival of remission, 
remission maintenance 
rates, and relapse rates 
were incompletely 
reported (no or partial 
numerical data) 
High ROB  
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP] 
Funding source not 
stated, PP analysis 
instead of ITT, possible 
imbalance in 
unmeasured prognostic 
factors 
High ROB  
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ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; ROB=risk 
of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
 
Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission (e.g., 
CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
NR (see below): NA 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Maintenance of remission (cumulative 
survival): High ROB 
 
Adherence: Low ROB 
 
 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias; IOIBD= International 
Organization for the Study of Inflammatory Bowel Disease: ESR=erythrocyte sedimentation rate; CRP=C-
reactive protein 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Verma 2000
56
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, duration 
of CD, location of CD, complications during induction 
therapy, type of induction therapy, pre-study 
compliance, co-intervention, and/or smoking)  
The elemental nutrition 
group had shorter 
disease duration (60.3 
vs. 91.0 months), greater 
ESR, and longer steroid 
use compared to control 
group  
High ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) No information on 
blinding but probably 
not blinded; their 
knowledge of the 
treatment likely to 
influence the outcome 
reporting 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
No information on 
blinding but probably 
not blinded. However, 
given the objective 
outcomes their 
knowledge of the 
treatment would not 
influence the outcome 
reporting 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) No information on 
blinding; the reporting 
of subjective outcomes 
may have already been 
influenced 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
No information on 
blinding; however, given 
the objective outcomes 
their knowledge of the 
treatment would not 
influence the outcome 
reporting 
Low ROB  
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
Complete data analysed  Low ROB  
Objective outcomes (e.g., radiography, 
endoscopy) 
Complete data analysed Low ROB  
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
No pre-specification of 
outcomes (Methods 
section) 
High ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP] 
No funder reported; 
statistical analyses 
adequate; ITT used 
Low ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; ROB=risk 
of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission (e.g., 
CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Maintenance of remission (CDAI<150), CDAI 
score:  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Occurrence of relapse/recurrence (increase in 
CDAI by >100 points since baseline or final 
CDAI >150 points; need of surgery; increased 
doses of steroids), time to relapse, adherence, 
steroid dose tapering, withdrawal from steroids, 
adverse events:  
 
Unclear ROB 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Yamamoto 2007a
30, 59, 60
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, duration 
of CD, location of CD, complications during induction 
therapy, type of induction therapy, pre-study 
compliance, co-intervention, and/or smoking)  
No major imbalance 
between the study 
groups in the pre-
specified important 
prognostic factors. 
However, patients with 
good compliance were 
assigned to elemental 
nutrition group and 
those with low 
compliance to no 
treatment group; this 
selective assignment 
may have generated 
differences between the 
groups in not otherwise 
pre-specified factors 
Unclear 
ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) Not blinded; subjective, 
i.e., patient-reported 
outcomes reporting 
likely influenced 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Not blinded; objective 
outcomes reporting 
unlikely to be influenced 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) No information; 
regardless of blinding 
status, subjective, i.e., 
patient-reported 
outcomes reporting 
likely influenced 
High ROB  
Objective (e.g., radiography, 
endoscopy) 
Endoscopic investigators 
were blind to patient 
status; objective 
outcomes assessment 
unlikely to be influenced 
Low ROB 
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
Outcomes for all 
patients available 
(complete data analysed) 
Low ROB 
Objective outcomes (e.g., radiography, 
endoscopy) 
Outcomes for all 
patients 
available (complete data 
analysed) 
Low ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
Main outcomes pre-
specified (Methods 
section) and reported 
Low ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP] 
No external funding 
received; statistical 
methods adequate; ITT 
analysis done 
Low ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; ROB=risk 
of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission (e.g., 
CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Maintenance of remission (CDAI<150), 
occurrence of relapse/recurrence (CDAI≥150, 
CDAI≥200):  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Occurrence of relapse/recurrence (Rutgeerts 
score≥2), adherence, need for surgery:  
 
Low ROB 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Yamamoto 2007b
57
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, duration 
of CD, location of CD, complications during induction 
therapy, type of induction therapy, pre-study 
compliance, co-intervention, and/or smoking)  
No major imbalance 
between the study 
groups in the pre-
specified important 
prognostic factors. 
However, patients with 
good compliance were 
assigned to elemental 
nutrition group and 
those with low 
compliance to no 
treatment group; this 
selective assignment 
may have generated 
differences between the 
groups in not otherwise 
pre-specified factors 
Unclear 
ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) Not blinded; the 
knowledge of the 
treatment could have 
influenced the outcome 
recording 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Not blinded; the 
knowledge of the 
treatment would not 
have influenced the 
outcome recording 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) Lab investigators were 
blinded to the clinical 
data; however the 
collected patient-
reported outcome data 
may have already been 
influenced 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Lab investigators were 
blinded to the clinical 
data; the blinding status 
unlikely to influence the 
outcome assessment 
Low ROB 
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
Outcome data for all 
patients was available  
Low ROB 
Objective outcomes (e.g., radiography, 
endoscopy) 
Outcome data for all 
patients was available  
Low ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
All pre-specified 
outcome (Methods) 
were reported (Results) 
Low ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP] 
No funding reported; 
analyses were adequate; 
ITT analysis done 
Low ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; ROB=risk 
of bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
 
Summary assessment of the within-study risk of bias for an outcome across domains 
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Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission (e.g., 
CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Maintenance of remission (CDAI<150), 
occurrence of relapse/recurrence (CDAI≥150), 
CDAI score:  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Mucosal healing (endoscopic remission), 
weight, BMI, adherence, need for surgery: 
 
Low ROB 
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Paul Sutcliffe  
First author surname year of publication: Yamamoto 2010
58
 
Bias 
domain 
Source of bias Support for judgment
*
 Authors’ 
judgment
**
 
Selection 
bias 
The presence/absence of baseline between-group 
imbalance in important prognostic 
characteristics/factors (e.g., age, sex, CDAI, duration 
of CD, location of CD, complications during induction 
therapy, type of induction therapy, pre-study 
compliance, co-intervention, and/or smoking)  
No major imbalance 
between the study groups 
in the pre-specified 
important prognostic 
factors. However, patients 
with good compliance 
were assigned to elemental 
nutrition group and those 
with low compliance to 
infliximab alone group; 
this selective assignment 
may have generated 
differences between the 
groups in not otherwise 
pre-specified factors 
Unclear 
ROB 
Performance 
bias 
Blinding of 
participants 
and 
Personnel  
Subjective (e.g., patient-reported) No information provided, 
but probably not blinded; 
their knowledge of the 
treatment likely to 
influence the outcome 
reporting 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
Although participants and 
personnel not blinded, 
their knowledge of the 
treatment would not 
influence the outcome 
reporting 
Low ROB 
Detection 
bias 
Blinding of 
outcome 
assessors  
Subjective (e.g., patient-reported) No information provided, 
but even if blinded, the 
reporting of subjective 
outcomes may have 
already been influenced 
High ROB 
Objective (e.g., radiography, 
endoscopy) 
No information provided, 
but even if not blinded the 
assessment of objective 
outcomes unlikely to be 
influenced 
Low ROB 
Attrition 
bias 
Incomplete 
outcome 
data 
Subjective outcomes (e.g., patient-
reported)  
The analysed data was 
complete (no missing 
outcome) 
Low ROB 
Objective outcomes (e.g., radiography, 
endoscopy) 
The analysed data was 
complete (no missing 
outcome) 
Low ROB 
Reporting 
bias 
Selective reporting of the outcome, subgroups, or 
analysis 
All pre-specified (in 
Methods section) 
outcomes were reported (in 
Results section) 
Low ROB 
Other bias 
Funding source, adequacy of statistical methods used, 
type of analysis [ITT/PP] 
No funding reported; 
statistical analyses 
adequate; ITT analysis 
reported 
Low ROB 
ITT=intention to treat; PP=per protocol; NA=not applicable; CDAI=Crohn’s disease activity index; ROB=risk of 
bias 
*
 Statement, description or quote supporting the judgment  
**
 Low risk of bias, high risk of bias, or unclear risk of bias 
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Summary assessment of the within-study risk of bias for an outcome across domains 
 
Outcome measure Summary risk of bias across all domains 
within a study 
Subjective (list of outcomes): Maintenance of remission (e.g., 
CDAI<150), occurrence of relapse/recurrence (e.g., 
CDAI≥150), time to relapse/recurrence (e.g., CDAI≥150), 
quality of life measures, clinical scores of severity (e.g., 
CDAI) 
Maintenance of remission (CDAI<150), 
occurrence of relapse/recurrence (e.g., 
CDAI≥150), clinical scores of severity (CDAI):  
 
High ROB 
Objective (list of outcomes): Maintenance of remission 
(includes additional objective parameters besides clinical), 
occurrence of relapse/recurrence (includes additional 
objective parameters besides clinical), time to 
relapse/recurrence (includes additional objective parameters 
besides clinical), mucosal healing (endoscopic remission), 
weight gain, linear growth rate, complications, adverse 
events, adherence 
Adherence: Low ROB  
CD=Crohn’s Disease; CDAI= Crohn’s Disease Activity Index; ROB=risk of bias 
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8.5 Appendix V: Studies excluded with reasons 
N Study  Reason for exclusion 
1 Belli DC, Seidman E, Bouthillier L, Weber AM, Roy CC, Pletincx M, et al. Chronic 
intermittent elemental diet improves growth failure in children with Crohn's disease. 
Gastroenterology. 1988;94(3):603-10 
<80% participants in 
remission 
2 Cucchiara S, Guandalini S, Staiano A, Ferola A, Romaniello G, Latte F, et al. Remission of 
colonic crohns-disease induced by elemental diet. Italian Journal of Gastroenterology. 
1984;16(4):302-4 
Case report 
3 Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, et al. Preventive effect of 
nutritional therapy against postoperative recurrence of Crohn disease, with reference to 
findings determined by intra-operative enteroscopy. Scandinavian Journal of 
Gastroenterology. 2005;40(12):1431-7 
Unclear control 
group 
4 Fukuda Y, Okui M, Tamura K, Shimoyama T. Serum fatty acid and disease activity in 
Crohn's disease patients during maintenance therapy with elemental diet. 1999 [cited; 
Available from: http://0-
onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/o/cochrane/clcentral/articles/882/CN-
00382882/frame.html] 
Irrelevant 
treatment/outcome 
5 Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel M, 
Stockbrugger RW, et al. Nutritional supplementation with n-3 fatty acids and antioxidants 
in patients with Crohn's disease in remission: Effects on antioxidant status and fatty acid 
profile. Inflammatory Bowel Diseases. 2000;6(2):77-84 
Irrelevant 
treatment/outcome 
6 Gorard DA, Hunt JB, Paynejames JJ, Palmer KR, Kumar PJ, Clark ML, et al. Relapse rates 
in Crohns-disease after initial treatment with elemental diet or prednisolone. Gut. 
1991;32(5):A582 
Abstract 
7 Harries AD, Jones LA, Danis V, Fifield R, Heatley RV, Newcombe RG, et al. Controlled 
trial of supplemented oral nutrition in Crohn's disease. Lancet. 1983;1(8330):887-90 
Participants with 
active CD 
8 Herzog D, Deslandres C, Martin S, Rasquin A, Alvarez F, Bouthillier L, et al. Cyclical 
exclusive semi-elemental diet therapy normalizes growth and decreases relapse rate in 
pediatric Crohn's disease. Gastroenterology. 1997;112(4):A995 
Abstract 
9 Hunt JB, Payne-James JJ. A randomised controlled trial of elemental diet versus 
prednisolone in treatment of new and recurrent Crohn's disease. 1989 [cited; Available 
from: http://0-
onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/o/cochrane/clcentral/articles/761/CN-
00258761/frame.html] 
Abstract 
10 Hunt JB, Payne-James JJ, Palmer KR, Kumar PK, Clark ML, Farthing MJ, et al. A Abstract 
187 
 
randomised controlled trial of elemental diet versus prednisolone in the treatment of new & 
recurrent Crohns disease. 1989 [cited; Available from: http://0-
onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/o/cochrane/clcentral/articles/382/CN-
00281382/frame.html] 
11 Imes S, Pinchbeck B, Dinwoodie A, Walker K, Thomson AB. Effect of Ensure, a defined 
formula diet, in patients with Crohn's disease. Digestion. 1986;35(3):158-69. 
Participants with 
active CD 
12 Kamata N, Watanabe K, Tsukahara T, Hagihara Y, Morimoto K, Noguchi A, et al. 
Concomitant elemental diet therapy is effective in sustaining infliximab scheduled 
maintenance therapy in patients with crohn's disease to prevent loss of response. 
Gastroenterology. 2013;1:S433 
Abstract 
13 Matsui T, Ueki M, Yamada M, Sakurai T, Yao T. Indications and options of nutritional 
treatment for Crohn's disease. A comparison of elemental and polymeric diets. 1995 [cited; 
Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/053/CN-
00123053/frame.html] 
Abstracts of 3 
studies 
14 Otley AR, Murray A, Christensen B, Williams T, Ste-Marie M, Rashid M. Primary enteral 
nutrition therapy induces and maintains remission, and reduces steroid exposure in a 
pediatric Crohn's disease population. Gastroenterology. 2005;128(4):A584 
Abstract 
15 Papadopoulou A, Rawashdeh MO, Brown GA, McNeish AS, Booth IW. Remission 
following an elemental diet or prednisolone in Crohn's disease. Acta Paediatrica, 
International Journal of Paediatrics. 1995;84(1):79-83 
Retrospective 
(cohort) study 
16 Roggero P, Santus F, Barabino A, Canani RB, Cucchiara S, Guariso G, et al. A prospective 
pediatric multicenter trial of enteral nutrition and azathioprine in preventing relapses of 
Crohn disease: preliminary results. 2003 [cited; Available from: http://0-
onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/o/cochrane/clcentral/articles/329/CN-
00593329/frame.html] 
Abstract 
17 Shoda R, Yamato S. Comparison of therapeutic efficacy of elemental and polymeric 
enteral numition in the patients with quiescent Crohn's disease: A pilot cross-over trial. 
Gastroenterology. 2007;132(4):A523 
Abstract 
18 Takahashi S, Takagi S, Shiga H, Umemura K, Endo K, Kakuta Y, et al. Scheduled 
maintenance therapy with infliximab improves the prognosis of Crohn's disease: a single 
center prospective cohort study in Japan. Tohoku Journal of Experimental Medicine. 
2010;220(3):207-15 
Retrospective 
(cohort) study 
19 Vaisman N, Griffiths A, Pencharz PB. Comparison of nitrogen utilization of two elemental 
diets in patients with Crohn's disease. J Pediatr Gastroenterol Nutr. 1988;7(1):84-8 
Unclear 
population/control 
group 
20 Watanabe O, Ando T, Ishiguro K, Takahashi H, Ishikawa D, Miyake N, et al. Enteral Retrospective 
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nutrition decreases hospitalization rate in patients with Crohn's disease. Journal of 
Gastroenterology and Hepatology. 2010;25(SUPPL. 1):S134-S7 
(cohort) study 
21 Wierdsma NJ, Van Bodegraven AA, Uitdehaag BMJ, Arjaans W, Savelkoul PHM, 
Kruizenga HM, et al. Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial 
influence on microbiota and gastrointestinal quality of life. Scandinavian Journal of 
Gastroenterology. 2009;44(7):804-12 
Head and neck 
cancer pts 
22 Woolner JT, Parker TJ, Kirby GA, Hunter JO. The development and evaluation of a diet 
for maintaining remission in Crohn's disease. Journal of Human Nutrition and Dietetics. 
1998;11(1):1-11 
Irrelevant 
treatment/outcome 
23 Yamamoto T, Shiraki M. Efficacy of enteral nutrition during infliximab maintenance 
therapy in patients with Crohn's disease. Digestive Diseases and Sciences. 
2013;58(6):1802-3 
Comment 
24 Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Yokoyama Y, Hida N, et al. 
Infliximab mono-therapy prevented post operative recurrence of Crohn's disease after 
intestinal resection: A prospective randomized open trial in Japanese population. 
Gastroenterology. 2010;1:S691 
Abstract 
